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PCI      Percutaneous Coronary Intervention 
POSSUM  Physiological and Operative Severity Score for enUmeration 
of Mortality 
PPV  Positive Predictive Value 
PRS of E-PASS  Preoperative Risk Score of the Estimation of Physiological 
Ability and Surgical Stress Score 
RCRI      Revised Cardiac Risk Index (Lee‘s) 
RNV      RadioNuclide Ventriculography 
ROC      Receiver-Operator Characteristics 
SD      Standard Deviation 
SSS      Surgical Stress Score 
TI      Thallium Imaging 
V-POSSUM  Vascular Physiological and Operative Severity Score for 
enUmeration of Mortality 
V(p)-POSSUM  Vascular (physiology only) Physiological and Operative 
Severity Score for enUmeration of Mortality 
VBHOM    Vascular Biochemical and Haematological Outcome Model 
WHO      World Health Organisation 
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Summary 
 
Major vascular surgery is associated with a substantial risk of cardiovascular 
events and death. This risk is of increased importance in prophylactic elective 
open Abdominal Aortic Aneurysm (AAA) repair, where a balance of risk of 
rupture and postoperative outcome is assessed prior to management decisions. 
Further, the UK Small Aneurysm Trial has shown that prophylactic repair of an 
AAA has no survival benefit for the first three years due to the major adverse 
cardiac event (MACE) rate of 5-15%. There is however no ideal method of 
predicting this risk.  
Cardiac Troponin I (cTnI) is a contractile protein that is a highly sensitive and 
specific marker of myocardial necrosis. A few case reports have commented on 
the finding of preoperative asymptomatic elevated cTnI levels and poor outcome 
in a small number of patients undergoing major vascular surgery. There are 
however no studies looking at its incidence in the vascular surgical population or 
its utility as a preoperative marker. 
Several studies have noted that B-type natriuretic peptide (BNP), a diagnostic 
and prognostic marker of heart failure, may have a role in predicting MACE in 
settings including major vascular surgery. There are no studies that have 
investigated this role in AAA repair alone. 
The aim of this thesis is to investigate the incidence of, and to determine a 
possible role for, preoperative elevated cTnI in major vascular surgery. The 
further aim is to determine if a single preoperative BNP level correlated with 
MACE and all-cause mortality in elective open AAA repair in both the short and 
long-term. Comparisons to current accepted risk indices in AAA, and a possible 
role for BNP in EndoVascular Aneurysm Repair (EVAR) will also be investigated. 
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Patients were recruited in two cohorts: 
Firstly, a prospective, 2 year observational single centre cohort study of all 
patients undergoing a vascular procedure, with an expected cardiac event rate 
>5%, recruited patients who had no clinical or ECG evidence of myocardial 
ischaemia. Preoperative cTnI was performed in all and postoperative screening 
(clinical assessment, ECG and cTnI) for cardiac events was performed at days 2, 
5 and 30. 
213 patient were recruited, of whom 11 (5.2%) had an asymptomatic elevated 
preoperative cTnI (>0.02 ng/ml). Eight of these patients proceeded directly to 
theatre, and 2 were delayed but later underwent surgery with a persistently 
elevated cTnI. Of these 10 patients, 5 (50%) died and 4 (40%) suffered MACE. The 
remaining patient was delayed due to the poor outcome of the preceding 
patients, and later underwent an uncomplicated aortic bifurcation graft with a 
normal cTnI level which had been preceded by coronary intervention. 
Secondly, a prospective, 2 year observational multi-centre cohort study in the 3 
largest vascular units in Glasgow (Gartnavel General Hospital, Glasgow Royal 
Infirmary and Southern General Hospital) was performed between August 2005 
and August 2007, recruiting all patients who were admitted for both elective 
open AAA repair and EVAR. Preoperative BNP levels were performed and batch 
analysed at the end of the study. Postoperative screening for cardiac events was 
performed as described above. Data was collected to allow calculation of risk 
indices associated with outcome in AAA repair (Glasgow Aneurysm Score [GAS], 
Vascular physiology only Physiological and Operative Severity Score for 
enUmeration of Mortality [V{p}-POSSUM], Vascular Biochemical and 
Haematological Outcome Model [VBHOM], Revised Cardiac Risk Index [RCRI] and 
Preoperative Risk Score of the Estimation of Physiological Ability and Surgical 
Stress Score [PRS of E-PASS]). Follow-up was continued to a minimum of 3 years, 
where possible, with cause of death recorded.  
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106 of 111 patients were recruited. The median [interquartile range] BNP 
concentrations in the 16 patients (15%) who suffered immediate postoperative 
MACE was 206 [118-454] vs 35 [17-61] pg/ml in the remainder (p=0.001). ROC 
analysis indicated a BNP concentration of 99.5 pg/ml best predicted MACE (area 
under the curve 0.927), with sensitivity of 88% and specificity of 89%. The BNP in 
patients who suffered cardiac death was significantly higher than in those that 
did not (median BNP 496 [280-881] vs 38 [18-84] pg/ml, p=0.043). ROC analysis 
revealed a cut-off of 448 pg/ml (AUC 0.963), with sensitivity 80%, specificity 
100%, positive predictive value 100% and negative predictive value 99%. 
Not only did higher values of BNP predict MACE, but it was also found to predict 
all-cause mortality in the immediate (median BNP 100 [84-521] vs 35 [17-81], 
p=0.028), intermediate (median BNP 201 [97-496] vs 35 [17-73], p<0.001) and 
long-term (median BNP 98.5 [58-285] vs 32 [17-71.5], p<0.001) postoperative 
periods. ROC analysis revealed decreasing BNP levels to predict outcome over 
time, with a BNP of >60.5 pg/ml (AUC 0.761) found to best predict death at 3 
years. 
Whilst BNP was found to predict outcome, most risk indices performed poorly. 
The GAS, VBHOM and RCRI performed poorly and did not predict any outcome 
measure. V(p)-POSSUM was, however, found to predict all outcome measures 
(p=0.028, p=0.030, p=0.038 for MACE, cardiac death and all-cause mortality 
respectively). The PRS component of E-PASS was found to predict MACE 
(p=0.019) and cardiac death (p=0.017). BNP performed better than any risk 
index. 
During the study period only 40 of 42 patients admitted for elective EVAR were 
recruited. Of these 40, only 3 suffered a non-fatal MI and 1 died of respiratory 
failure. BNP was not found to predict MACE or death in this cohort, and due to 
the small number of patients, and events, no strong conclusions could be drawn. 
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Whilst preoperative elevated cTnI was found to identify patients that were at an 
increased risk of both postoperative MACE and death following their major 
vascular surgical procedure, its use in elective open AAA repair is limited due to 
infrequent occurrence. Preoperative serum BNP concentration, however, 
predicted postoperative MACE, cardiac death and all-cause mortality in patients 
undergoing elective open AAA repair on immediate, intermediate and long term 
follow-up. Further, BNP performed better than any current risk index for 
elective open AAA surgery. This simple blood test, therefore, offers valuable 
information regarding risk stratification of prospective surgical patients and 
should be considered a part of routine preoperative assessment in this 
prophylactic procedure. 
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Chapter 1 
 
Introduction 
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1.1 Perioperative Cardiac Events – the Extent of the 
Problem 
Patients undergoing major non-cardiac surgery are at significant risk of 
cardiovascular morbidity and mortality. It is estimated that in Europe 40 million 
surgical procedures are performed annually with a postoperative myocardial 
infarction (MI) rate of 1% (400,000) and a cardiovascular mortality rate of 0.3% 
(133,000).
1 The true extent of the problem is likely to be considerably worse 
with further pooled analysis of several large studies finding a 30-day incidence of 
cardiac events (perioperative MI or cardiac death) of 2.5% in unselected patients 
over the age of 40 years.
2 These complications were highest in vascular surgery 
patients, who had an incidence of 6.2% for cardiac events.
3 The high frequency 
of perioperative cardiac complications reflects the high prevalence of underlying 
coronary artery disease, present in severe form in 28% of patients undergoing 
infrainguinal arterial reconstruction and 36% of patients undergoing abdominal 
aortic aneurysm repair 
. Screening asymptomatic individuals for perioperative cardiac events following 
high risk vascular procedures can further amplify these figures, with abdominal 
aortic aneurysm (AAA) repair resulting in cardiac event rates of up to 25%.
4 
In Scotland the problem is exacerbated by the high incidence of coronary artery 
disease due in part to the high levels of obesity, hypertension and cigarette 
smoking, making Scotland a high risk population. The impact on those that suffer 
a perioperative cardiac event is considerable with hospital mortality rates of 15-
25% following non-fatal MI
5,6 and 65% following a cardiac arrest.
7 For those that 
survive, the length of hospital stay increases and health costs swell. In addition 
the risk of further non-fatal MI and cardiac death in both the short and long term 
following surgery is greater than before.
8,9 Perioperative cardiac risk should 
therefore be a serious consideration prior to planning any surgical procedure.  
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1.2 Abdominal Aortic Aneurysm Repair – A Unique 
Problem 
An abdominal aortic aneurysm is defined as an abnormal dilatation of the 
abdominal aorta with a maximal diameter ≥30mm.
10  AAAs are a common disease 
in the elderly affecting some 4-10% of males and 0.5-1.5% females aged 65-79 
years old.
11,12 Over time, despite the vast majority remaining asymptomatic, 
AAAs expand in size. The risk of rupture of an AAA increases with size with an 
estimated 25% per year rupture rate for aneurysms ≥6 cm and a 25% 5-year 
rupture rate for those >5.5 cm [Figure 1.1].
13 
The mortality after AAA rupture is high at approximately 80% for those who 
reach hospital and 50% for those undergoing emergency surgery for ruptured 
aortic aneurysm.
15,16  This is reflected in that 1.5% (7000) of all UK male deaths 
are attributable to AAA mortality.
15 
The rationale for elective surgical treatment of AAAs is based on the natural 
history of aneurysms, progressive expansion leading to rupture, and in the 
absence of established effective medical therapy. Symptomatic AAAs require 
surgical repair to relieve symptoms and to reduce the risk of impending rupture. 
Asymptomatic aneurysm management is dependent on size. The risk of rupture 
of an AAA <4 cm is in the order of 2%/year which makes elective open repair 
with its perioperative mortality of around 5-6% an unattractive option.
17, 18 Large 
AAAs with a maximal diameter of >6 cm are generally considered for repair as 
the risk of rupture outweighs the surgical risk.  
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Figure 1.1 Survival without abdominal aortic aneurysm (AAA) rupture by size category of 
last measured aortic diameter. 
 
 
 
The above graph shows survival without AAA rupture from the last measurement of aortic 
diameter up to the time of aneurysm repair, death, AAA rupture, or cessation of follow-up. This 
analysis does not provide an estimate of rupture rates but allows assessment of how the risk of 
rupture varies with the last known AAA diameter. The much-higher risk of rupture in patients 
with aneurysms ≥6.0 cm is shown clearly. The number of ruptures per 100 patient-years 
increased from 0.3 for AAA ≤3.9 cm to 1.5 and 6.5 for patients with AAAs in the diameter ranges 
4.0 to 4.9 cm and 5.0 to 5.9 cm, respectively. The person-years of follow-up for patients with 
AAAs ≥6.0 cm was so restricted by censorship at surgery that no estimate of rupture rate was 
calculated, although the rate of rupture appeared very high. Figure adapted from 
14. 
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The decision on whether to repair AAAs with a diameter of between 4 and 5.5 
cm (the ‗small‘ aneurysm) is a more difficult one. The only appropriate 
randomised controlled trial that has been designed to address this question is 
‗The UK Small Aneurysm Trial‘.
18 This study recruited greater numbers than 
originally powered for and obtained 100% follow-up. The trial included 1090 men 
and women aged 60-76 years with asymptomatic AAAs of anteroposterior 
diameter 4.0-5.5cm. Patients were identified in centres throughout the UK and 
were randomised (using computerised allocation) to open elective surgery or 
routine ultrasound surveillance every 6 months (3 months if diameter 5.0-
5.5cm). This high operative mortality (5.8%), primarily cardiac in origin
19, meant 
that there was a greater risk of death from surgery than from any other cause in 
the observation group for the first three years of follow-up. Survival was 
subsequently worse in the surveillance group so that the survival curves crossed 
at about 3 years, although this has never reached statistical significance even 
after 12 years of follow-up [Figure 1.2].
20 Thus, the evidence to date does not 
support the routine surgical repair of aneurysms <5.5cm in diameter.
 
Attempts to reduce the high level of cardiac postoperative mortality associated 
with open elective AAA repair led to the development of endovascular aneurysm 
repair (EVAR), where stenting of the aneurysm using similar interventional 
techniques to that of angiography is performed. Major trials of EVAR have shown 
that whilst perioperative mortality is lower (1.7% 30-day mortality in EVAR 1 
trial)
21, there is a constant level of device failure which requires regular 
surveillance with consequent increased cost (postoperative complications at 4 
years 41% EVAR group vs 9% open group).
22 In addition the all cause mortality at 
4 years was found to be similar in both groups. This led to the realisation that 
EVAR would not be the first choice for all patients given the lower morbidity and 
greater long term survival after open elective repair, especially in the young fit 
patient. 
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Figure 1.2 Overall survival by treatment group. 
 
 
 
At 3 years mortality after early surgery was less than that of ultrasound surveillance, however 
this difference did not reach statistical significance. After 12 years, mortality in the surgery and 
surveillance groups was 63.9 and 67.3 per cent respectively, unadjusted hazard ratio 0·90 
(p=0.139). Figure adapted from 
20. 
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In view of the findings of the ‗UK Small Aneurysm Trial‘ and EVAR 1 trial, any 
development that would allow the identification of those at high risk of 
perioperative cardiac morbidity or mortality would greatly improve 
management. Low risk patients could be offered open elective repair of even 
small aneurysms, leading to longer survival and the avoidance of the long-term 
morbidity associated with EVAR use. Equally, identification of high risk patients 
who would not survive an open procedure could lead to them being offered an 
endovascular repair or of delaying surgery altogether until the risk of rupture 
was felt to outweigh that of prophylactic repair.  
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1.3 The Pathophysiology of the Perioperative MI 
1.3.1 Non-Cardiac Surgery 
The pathophysiology of perioperative cardiac events is not entirely clear with 
little data on the topic; however, it is believed that in the perioperative period 
around half of all cardiac complications are caused by coronary plaque rupture 
with subsequent thrombus formation and coronary artery occlusion
23 and the 
remainder by prolonged myocardial ischaemia.
24  This distinction occurs as a 
result of histopathological autopsy analyses of coronary arteries and the 
myocardium of patients who suffered perioperative fatal MIs, revealing direct 
evidence of plaque disruption (fissure or rupture of plaque and haemorrhage into 
the plaque cavity) in 55% of cases, with the site of infarction commonly 
correlating with the affected vessel.
24 Similar autopsy results were found in 
further histological analyses of 1841 autopsy records with 26 cases of 
postoperative MI of whom 46% had plaque rupture with confirmed transmural 
infarctions within their territory.
25 
The evidence for severe or prolonged myocardial ischaemia is based on a number 
of findings. The presence of a circumferential distribution of infarction on 
pathological specimens is consistent with myocardial supply/demand mismatch 
as the trigger of myocardial injury.
25 Further, most perioperative MIs are 
asymptomatic and are characterised by ST-segment depression, reflecting 
subendocardial ischaemia.
26  In addition, almost all perioperative MIs are non-Q-
wave rather than Q-wave with complete reversal of ECG changes to baseline in 
nearly all patients with ischaemia (including those with infarction).
27 The 
likelihood however is that myocardial ischaemia and plaque rupture are not 
mutually exclusive and that MIs can develop by different mechanisms at 
different locations in the same patient. For this reason it is the triggers of 
perioperative MIs that are the key to these cardiac events. 
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Surgery, with its associated trauma, anaesthesia and analgesia, intubation and 
extubation, pain, hypothermia, bleeding and anaemia, and fasting, is analogous 
to an extreme stress test. Increasing grades of surgical trauma and general 
anaesthesia can initiate inflammatory and hypercoagluable states which may 
have a role in plaque fissuring and acute coronary thrombosis.
28, 29 The stress 
state involves increased levels of catecholamines and cortisol resulting in 
increases of blood pressure, heart rate and coronary artery sheer stress.
30 
Coronary artery sheer stress may trigger plaque fissuring and coronary 
thrombosis, while the haemodynamic changes may be responsible for increased 
myocardial oxygen demand resulting in perioperative myocardial ischaemia. 
Further to this a hypoxic state can be initiated by anaemia, hypothermia 
(through shivering) and analgesia (through respiratory depression).
31-33 
Perioperative hypoxia can result in further myocardial ischaemia in the setting 
of haemodynamically significant coronary artery stenosis. Further research is 
awaited to determine which triggers are most important in preventing 
perioperative MIs [Figure 1.3]. 
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Figure 1.3 Potential triggers of states associated with perioperative elevations in troponin 
levels, arterial thrombosis and fatal myocardial infarction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The numerous potential triggers of a perioperative myocardial infarction impact in different 
ways when considering the pathophysiology of a cardiac event. It remains unknown which 
factor/trigger is most important. TNF-α = tumour necrosis factor-α, IL = interleukin, CRP = C-
reactive protein, PAI-1 = plasminogen activator inhibitor-1, BP = blood pressure, HR = heart rate, 
FFAs = free fatty acids. Figure adapted from 
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1.3.2 Abdominal Aortic Aneurysm Repair 
Surgical repair of an AAA provides further haemodynamic changes that further 
risk the myocardium. The basic surgical procedure in open repair of an AAA 
includes clamping the aorta, opening the aortic sac, suturing in a prosthetic 
graft to replace the aneurysmal artery and then unclamping the aorta. The 
initial response to clamping the aorta is arterial hypertension due to impedance 
of aortic flow and left ventricular ejection producing increased afterload, with 
no significant effect on heart rate. The more proximal the clamp placement the 
greater the rise in blood pressure. Infrarenal clamping can increase blood 
pressure 7-10% with an increase in afterload. The systemic vascular resistance 
can increase up to 40% and the effect on cardiac filling pressures, further 
exacerbated by reduced preload due to a decreased venous return, is variable 
resulting in a reduction of cardiac output by 9-33%.
35 Infrarenal clamping is often 
well tolerated in patients with preserved ventricular function, but in the 
presence of significant dysfunction it can precipitate ischaemia and heart 
failure.
36  
Unclamping the aorta after repair causes a reduction in blood pressure due to an 
abrupt decrease in systemic vascular resistance, and central hypovolaemia 
secondary to sequestration of blood into reperfused tissues. There is also a 
reperfusion injury with mild acidaemia, and circulation of released vasodilators 
and myocardial depressants. This all contributes to hypotension and myocardial 
dysfunction. To counteract this surgeons and anaesthetists frequently ensure 
that their patients are volume-loaded prior to releasing the cross-clamp, and 
that cross clamping times are kept to a minimum.
37  
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The effects of cross-clamping and unclamping with regards to myocardial 
function and coronary blood flow are well documented. Increased preload and 
afterload associated with aortic cross-clamping lead to an increase in myocardial 
oxygen demand. In patients without coronary artery disease, the myocardial 
oxygen supply is usually adequately increased by increased coronary blood flow 
and preservation of myocardial autoregulation and endocardial-epicardial flow 
rates, thereby avoiding severe myocardial ischaemia and maintaining myocardial 
contractility.
38 However, in patients with atherosclerotic coronary artery 
disease, both left and right filling pressures increase, and ECG evidence of 
myocardial ischaemia can be demonstrated
39-41 indicating an inability to increase 
subendocardial blood flow in response to an increase in intra-ventricular 
pressure. Echocardiography and ventriculography findings in post-myocardial 
infarction patients after cross-clamping reveal that those with pre-existing 
impaired myocardial contractility or increased left ventricular end-diastolic 
volumes cannot further mobilise the Frank-Starling mechanism. A decrease in 
the velocity and contraction of myocardial fibres can then occur and they then 
proceed to develop left ventricular failure in response to myocardial ischaemia 
and release of myocardial depressant factors from ischaemic tissue.
42 It is clear 
therefore that open AAA surgery provides a substantial threat to cardiac 
outcome in patients who are often already high risk candidates. 
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1.4 Diagnosing Perioperative Cardiac Events 
1.4.1 The Difficulty in Detection 
It is already known that MIs occur unnoticed outwith the operative setting. A 
review of eight large cohort studies with samples over 100 evaluating the 
frequency of unrecognised MIs (based on the appearance of new diagnostic Q 
waves) revealed that of 65,000 people 3,237 MIs occurred, of which 945 (29%, 
95% CI 28-31%) were not detected at the time of the event.
43 In addition patients 
experiencing an unrecognised MI were shown to have a prognosis similar to that 
of patients with a recognised MI.
44  
The scale of the problem of perioperative clinically unrecognised MI is 
demonstrated by three large prospective cohort studies of non cardiac surgery. 
The studies, all with sample sizes greater than 300 and unrestricted surgery 
type, with at least one postoperative measurement of cardiac 
enzyme/biomarker and accountability of signs/symptoms revealed that only 14% 
(95% CI 3-25%) of patients complained of chest pain and 53% (95% CI 38-68%) had 
clinical signs or symptoms recognised by medical staff to imply an MI.
5,6,45 
Although the total number of events was small (38/1309, 3%), the large 
proportion of these events which were clinically unrecognised is concerning. This 
can however be reasoned as most perioperative MIs occur during the first 3 days 
after surgery
6,46 during which time most patients receive analgesics blunting 
cardiac pain perception. Further, patients experiencing potential signs 
(tachycardia, hypotension etc.) may have these mistaken for other more 
common postoperative explanations such as hypovolaemia, epidural anaesthesia, 
bleeding, medication effects, atelectasis or sepsis. Some patients may remain 
intubated and sedated in this high risk period leading to difficulty in 
communicating the development of an event. 
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1.4.2 Methods of Diagnosis 
Currently there are no standard agreed diagnostic criteria for perioperative MI in 
patients undergoing noncardiac surgery. For MI in general the World Health 
Organisation (WHO) definition, described in the mid-80s, requires at least two of 
three criteria to be met including 1) ischaemic type chest pain lasting greater 
than 20mins, 2) change in serial ECG tracings including the development of 
pathological Q waves and 3) increased concentration of serum creatine kinase-
MB (CK-MB) fraction.
47 The development of assays for the cardiac troponins T 
(cTnT) and I (cTnI) that are highly specific and sensitive to myocardial injury led 
to a revision by the European Society of Cardiology and the American College of 
Cardiology (ESC/ACC) [Table 1.1].  
This gave more prominence to cardiac biomarkers so that the definition of an 
acute, evolving or recent MI required a typical rise and gradual fall of cardiac 
troponin or a rapid rise and fall of creatine kinase isoenzyme MB (CK-MB) 
accompanied by at least one of 1) typical ischaemic symptoms; 2) pathological Q 
waves; 3) ECG changes indicative of ischaemia; 4) coronary intervention 
(including percutaneous intervention or coronary artery bypass graft).
48 Of the 
cardiac biomarkers named, the use of CK-MB in the perioperative setting has 
been avoided as measurements are prone to false-positive and false-negative 
values. This is in part due to surgical trauma resulting in the release of CK-MB 
from skeletal muscle and a false–positive CK-MB value for MI.
49,50  Furthermore, a 
significant proportion of perioperative MIs occur early after surgery, when 
creatine kinase values will be high following surgical trauma. These high values 
of creatine kinase can therefore result in a low ratio of CK-MB to creatine kinase 
levels resulting in false negative measurements.
50,51  
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Table 1.1 Diagnostic criteria for non-perioperative MI of the ESC/ACC. 
 
Definition of MI. 
Criteria for acute, evolving or recent MI - 
Either one of the following criteria satisfies the diagnosis
 for an acute, evolving or recent 
MI: 
1.  Typical rise and gradual
 fall (troponin) or more rapid rise
 and fall (CK-MB) of 
biochemical
 markers of myocardial necrosis
 with at least one of the following: 
- Ischaemic symptoms 
- Development of pathologic Q waves on
 the
 ECG 
- ECG changes indicative of ischaemia (ST segment elevation
 or
 depression) 
- Coronary artery intervention (e.g. coronary
 angioplasty). 
2.  Pathologic findings of an acute MI. 
Criteria for established MI - 
Any one of the following criteria satisfies the diagnosis for
 established MI: 
1.  Development of new pathologic Q waves on serial
 ECGs. The patient
 may or may 
not remember previous symptoms.
 Biochemical markers
 of myocardial necrosis 
may have normalized,
 depending on the
 length of time that has passed since the 
infarct
 developed. 
2.  Pathologic findings of a healed or healing MI. 
 
The redefined definition of an MI published in 2000 highlights the importance of new and 
established cardiac biomarkers. Adapted from 
48. 
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As described, perioperative MI is often silent and clinicians may not be alerted 
to the possibility. In addition, many patients have an uninterpretable ECG due to 
bundle branch block, chronic ST changes and pacing. Some will have infarcts in 
areas where conventional ECG lacks sensitivity (e.g. posterior) and some will 
have significant ST-segment changes that resolve by the time the ECG is 
repeated the following day. In an attempt to reduce the risk of missing MIs use 
of echocardiography has been advocated. The evidence for this is however 
contradictory since echocardiography has been shown to be insensitive due to 
the requirement of a myocardial injury involving >20% of the wall thickness to 
detect a wall motion abnormality.
48 This is challenged by a study revealing a new 
wall-motion abnormality in 8 of 9 patients who suffered a perioperative MI from 
108 noncardiac surgery patients.
50 None of the remaining 99 patients had new 
wall-motion abnormalities although those that were considered to have had a 
perioperative MI were based on criteria of elevated troponin and significant ECG 
changes. This makes it difficult to know if echocardiography would pick up a new 
perioperative MI that was not picked up by conventional criteria. It is not 
unreasonable, however, that when clinicians come across a patient with an 
elevated troponin after surgery without either ischaemic symptoms or a 
diagnostic ECG, they should consider obtaining an echocardiogram. Further 
research is needed to evaluate the diagnostic criteria for a perioperative MI and 
to clear inconsistencies. 
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1.5 Risk Stratification 
For over 40 years researchers have been studying perioperative cardiac risk and 
how best to estimate it. The goal of improved risk stratification is important for 
allowing accurate informed decisions, both by the patient and their physicians. 
Although no research has documented its benefits, risk stratification has taken 
on an important role in clinical decision-making. Accurate risk estimates provide 
guidance for perioperative management, including the choice of surgical 
techniques and the location and intensity of postoperative care. Improved 
accuracy is considered especially critical today with the demands for cost 
containment and the increasing age of the population. 
Preoperative clinical evaluation is an important part of the routine workup to 
any operative procedure. In non-cardiac vascular patients a thorough history, 
physical examination and routine ECG can aid assessment of cardiac risk. 
Patients in this group without a previous MI, angina, diabetes, congestive cardiac 
failure and with a normal resting ECG have been reported to be at very low 
cardiac risk (<1%) for major perioperative cardiac complications.
52,53  This can 
therefore identify a subgroup of low risk patients; however, separating the 
remaining patients into categories based on degree of risk can be more 
complicated. 
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Clinical history can also help estimate functional status in order to calculate 
perioperative risk. Functional capacity can be expressed in metabolic 
equivalents (METs). Multiples of the baseline MET value can be used to express 
aerobic demands for specific activities [Table 1.2].
54  One MET is equivalent to 
the oxygen consumption of a resting 70 kg 40-year-old male, while 10 METs 
would be equivalent to participation in strenuous sports such as swimming or 
singles tennis. A low functional capacity is defined as the inability to perform 
more than 4 METs of activity. A decreased functional capacity (inability to walk 
600m or climb 2 flights of stairs) has been shown to be an independent predictor 
of perioperative cardiac events,
55 with a positive predictive value (PPV) of 89% 
for cardiopulmonary complications.
56 Patients with severe limitations of function, 
such as those who are close to or bedridden, have been shown to have a greater 
risk of cardiac events.
57 With its emphasis on identifying high risk patients this 
system is a poor predictor of complications in patients at intermediate risk. A 
number of risk identification strategies have therefore been developed to help 
further separate these groups. 
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Table 1.2 Estimated energy requirements for various activities.  
 
1 MET    Eating, dressing and using toilet. 
  Walking indoors around the house. 
  Walking around a block or 2 on level ground at 2 to 3 mph 
(3.2 to 8.4 kph). 
  Doing light work around the house such as dusting or 
washing dishes. 
4 METs    Climbing a flight of stairs or walking up a hill. 
  Walking on level ground at 4mph (6.4kph). 
  Running a short distance. 
  Doing heavy work around the house like scrubbing floors or 
lifting or moving heavy furniture. 
  Participating in moderate recreational activity like golfing, 
bowling, dancing or doubles tennis. 
Greater than 
10 METs 
  Participating in strenuous sports like swimming, singles 
tennis, football or skiing. 
 
Calculating metabolic equivalents based on daily activities makes estimation of functional status 
in the clinical situation uncomplicated, although this relies on subjective information. kph - 
kilometres per hour, MET - metabolic equivalent, mph - miles per hour. 
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1.5.1 Risk Index Systems 
The original stratification system for perioperative risk assessment was the 
Dripps Index of the American Society of Anaesthesia (ASA), published in 1961 
[Table 1.3].
58 It remains in clinical use today, classifying patients into 5 physical 
status classes, with class 1 being a completely healthy patient and class 5 being 
patients considered moribund and in whom surgery is undertaken as a last 
resort. Limitations of the ASA physical status are that it is a subjective index and 
that it has been found not to be predictive of cardiac outcome.
59   
The more recent clinical indices can be split into two types – generic and 
Bayesian. The published generic indices (Lee, Goldman, Eagle) estimate a 
patient‘s risk through determination of how many predictors of risk (e.g. 
diabetes, angina, congestive cardiac disease) the patient has. The published 
Bayesian risk indices (Detsky) modify the hospital‘s average cardiac event rate 
for a specific surgery (pretest probability) through use of a patient‘s individual 
index score (likelihood ratio), which is based on how many predictors of risk the 
patient has. This results in an estimate of the patient‘s risk of a perioperative 
cardiac event (post-test probability). 
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Table 1.3 ASA grading and mortality in the anaesthetised general population.
 
 
ASA  Grade Definition  Mortality 
(%) - in 
general 
I  Normal healthy individual  0.05 
II  Mild systemic disease that does not limit activity  0.4 
III  Severe systemic disease that limits activity but is not 
incapacitating 
4.5 
IV  Incapacitating systemic disease which is constantly 
life-threatening 
25 
V  Moribund, not expected to survive 24 hours with or 
without surgery 
50 
 
Postoperative mortality associated with increasing degrees of ASA class, published in 1961 and 
based on subjective information. ASA – American Society of Anaesthesia. Adapted from 
58. 
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The first generic multifactorial risk index for cardiac complications was 
published by Goldman in 1977. 
60 Goldman‘s cardiac risk index based on 1001 
consecutive patients (>40 years of age) was the first validated multivariate 
model to be used in non-cardiac surgery for predicting cardiac morbidity and 
mortality. Nine risk factors were identified and weighted, based on their ability 
to predict postoperative cardiac death or MI, congestive cardiac failure or 
ventricular tachycardia. A history of a previous MI or the presence of an S3-
gallop rhythm were the strongest predictors. A patients cardiac risk score was 
calculated on the basis of the number and corresponding weight of risk factors, 
with scores ranging from 1 to 4 (4 representing the highest risk). The most 
obvious limitation of this cardiac index was the lack of ability to take into 
account the specific risk of any given surgical procedure. 
In order to improve the predictive accuracy in patients undergoing major 
vascular surgery, Detsky produced a modified cardiac risk index in 1986 using a 
Bayesian approach.
61 Surgical risk was incorporated into the index using the 
institution‘s average cardiac event rate for particular surgical procedures (as the 
pretest probability) which was then modified by a number of patient-specific 
risk factors. The presence of significant angina was included and the presence of 
an old or recent MI was differentiated. To simplify further, the number of risk 
classes was decreased from 4 to 3. This modified index fulfilled the 
methodological criteria of a clinical prediction rule study and has shown 
consistent results in a separate setting. This validation however is limited to one 
high-quality single-centre study
62 and the current predictive accuracy of the 
Detsky index is uncertain. This is due in part to the Bayesian approach where the 
defined average surgical risk for a particular hospital for a particular procedure 
at a particular time is used. It is not known at present if the complication rates 
at one institution are transferable to others when using the same defined risk 
factors. The advances in medical therapy for cardiac disease and improvement 
in anaesthetic and surgical techniques also question the applicability in the 
modern age. 
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More recent risk scoring systems have been developed by Eagle
63 and Lee.
64 Both 
systems use multivariate analysis to identify preoperative clinical factors that 
are predictive of perioperative cardiac events. Both arrived at 6 similar risk 
factors although the Eagle score included the findings of myocardial thallium 
scanning in patients presenting for major vascular surgery. Due to limited 
thallium scanning availability and cost the Revised Cardiac Risk Index (RCRI), 
developed in 1999 by Lee et al, has become the most widely used model of risk 
assessment in noncardiac surgery. This risk index assigns one point each for the 
presence of 6 independent risk factors for major cardiac complications in patient 
undergoing major elective surgery [Table 1.4]. The incidence of major adverse 
cardiac events in patients with 0, 1, 2 or 3 risk factors were 0.4%, 0.9%, 7% and 
11% respectively in the validation cohort. Recently it was demonstrated in 
108,593 patients undergoing all types of noncardiac surgery that this RCRI was 
indeed predictive of cardiovascular mortality but could be substantially 
improved by adding age and a more detailed classification of type of surgical 
procedure.
65 This is especially relevant to AAA surgery as open abdominal aortic 
surgery carries a higher risk than either intraperitoneal or intrathoracic 
surgery.
62, 66  
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Table 1.4 Risk factors from the Revised Cardiac Risk Index. 
 
• High-risk surgery 
– Intraperitoneal, intrathoracic or suprainguinal vascular 
procedures 
• Ischaemic heart disease 
• History of congestive heart failure  
• History of cerebrovascular disease 
• Insulin therapy for diabetes mellitus 
• Preoperative creatinine level > 2.0 mg/dl (>176μmol/l) 
 
Ischemic
 heart disease was defined as those with major cardiac
 complications included any of the 
following: history of myocardial
 infarction, history of a positive exercise test, current complaint
 
of chest pain considered to be secondary to myocardial ischaemia,
 use of nitrate therapy, or ECG 
with pathological Q waves. Congestive heart failure was defined as the presence of any
 of the 
following: history of congestive heart failure, pulmonary oedema,
 or paroxysmal nocturnal 
dyspnoea; physical examination showing bilateral
 rales or S3 gallop; or chest radiograph showing 
pulmonary vascular
 redistribution. Cerebrovascular disease was defined
 as a history of transient 
ischemic attack or stroke. 
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1.5.2 ACC/AHA Algorithm 
The American College of Cardiology (ACC) and the American Heart Association 
(AHA) published a consensus statement on the preoperative cardiac evaluation 
of patients presenting for noncardiac surgery in 1996,
67 which was updated in 
2001
68 and again in 2007.
69 This was based on expert opinion to help clarify an 
important step of operative work-up, given that there were few meaningful 
trials existing on the topic. The consensus produced an algorithm that included 
factors about the patient and their medical history whilst also taking into 
account the specific type of surgery [Figure 1.4]. The first step in the algorithm 
was to establish if there was a need to assess cardiac risk based on the urgency 
of surgery. In patients undergoing elective surgery, the need existed and so the 
next stage was to identify those with active unstable cardiac conditions 
including acute or recent MI (<1 month), severe or unstable angina, 
decompensated heart failure, significant arrhythmia or severe valvular heart 
disease. In these conditions, intensive management was recommended with 
surgical delay or cancellation if necessary. 
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Figure 1.4 ACC/AHA 2007 preoperative cardiac evaluation before non-cardiac surgery. 
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In those presenting for low risk surgery, the procedure could take place as 
planned. If however the procedure was of higher risk, then an estimation of 
functional status was made. Only those patients achieving a MET level of ≥4 
would then proceed to surgery. For the remainder, an estimation of patient 
specific clinical risk was required using the Lee RCRI, adapted to exclude the 
type of surgery which was incorporated elsewhere in the algorithm. Patients 
were then divided into groups based on the number of clinical risk factors (those 
of Lee‘s revised cardiac risk index excluding high risk surgery) and the surgical 
risk. The recommendation was for preoperative cardiac testing for elective 
vascular surgery patients with ≥3 clinical risk factors and poor functional 
capacity. Preoperative testing could also be considered in those with 1-2 clinical 
risk factors and poor functional capacity for intermediate risk non-cardiac 
surgery, or good functional capacity undergoing vascular surgery. Preoperative 
testing was not recommended for patients without clinical risk factors 
undergoing intermediate- or low-risk non-cardiac surgery. 
The validity of these guidelines has been evaluated in only a few prospective or 
randomised studies. One prospective evaluation published in 1997 was 
performed using a similar protocol to the ACC/AHA guidelines in 203 patients 
presenting for aortic surgery.
70 In this study patients identified as being at 
intermediate risk (n=79) with an estimated functional capacity of <4 METs and 
all patients at high risk (n=23) underwent non-invasive testing and/or 
subsequent medical care. The results showed that the algorithm predicted 
outcome with total cardiac morbidity in the low, intermediate and high-risk 
categories of 9%, 14% and 24% respectively. In a similar retrospective study the 
use of dobutamine stress echocardiography (DSE) was studied in accordance with 
ACC/AHA guidelines in 85 patients undergoing non-cardiac surgery.
71 This study 
found that the ACC/AHA guidelines had a positive predictive value of 4.7% for 
selecting patients with a positive DSE. During the perioperative period no 
patients had a cardiac complication related to myocardial ischaemia. These 
findings prompted a conclusion that the current ACC/AHA guidelines for non-
invasive testing result in a low frequency of positive tests and were of limited 
value in the clinical setting. 
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1.5.3 Preoperative Non-Invasive Testing 
If indeed it is deemed necessary to perform further non-invasive cardiac stress 
testing there are a number of options available. The exercise ECG is the most 
common method of non-invasively evaluating individuals for the presence of 
coronary artery disease with pooled data from 7 studies indicating a sensitivity 
of 74% and specificity of 69% for predicting a major adverse cardiac event 
(MACE, being a non-fatal MI or cardiac death) in major vascular surgery.
72 
Exercise ECG testing can be safely performed in the outpatient setting and is 
considered the least expensive non-invasive test for detecting myocardial 
ischaemia and providing a good estimate of functional capacity. The limitations 
of this test are inherent in its nature. Those that cannot reach the target heart 
rate for age have an inadequate investigation which is common in patients with 
peripheral vascular disease (claudication), diabetes mellitus (peripheral 
neuropathy), prior cerebrovascular event, or beta-blockade. Up to 40% of 
patients also have pre-existing ECG abnormalities such as ST-segment/T wave 
abnormalities, underlying left-bundle branch blocks or ventricular paced rhythms 
that may preclude reliable ST-segment analysis.
73 In addition, no information 
regarding ventricular function can be obtained.  
As an alternative to exercise induced stress, pharmacological non-invasive 
testing is often required in patients undergoing major vascular surgery. Coronary 
artery vasodilators such as dipyridamole, combined with nuclear imaging or 
echocardiography, or the use of agents that increase myocardial oxygen demand 
such as dobutamine combined with echocardiography have both been advocated. 
The most extensively researched of these is dipyridamole perfusion scintigraphy 
(DiPS) which has been shown in a meta-analysis of 23 studies to have a 
sensitivity of 83% and a specificity of 49% for predicting MACE in major vascular 
surgery.
72 The major limitation of this type of test is the frequent occurrence of 
false-positive results owing to attenuation artefacts (breast tissue, diaphragm 
etc.) that can produce apparent perfusion defects.  
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The most recent recommended non-invasive test is dobutamine stress 
echocardiography (DSE). Review of 6596 stress tests has shown it to be safe, 
revealing a low incidence of side effects with cardiac arrhythmias (8%) and 
hypotension (3%) the most common.
74-76 The feasibility of DSE in patients with 
abdominal aortic aneurysm has also been confirmed in 98 patients in whom 
there was no evidence of aneurysm rupture or haemodynamic instability.
77 The 
sensitivity and specificity on a review of 8 studies of DSE in major vascular 
surgery were 85% and 70% respectively for predicting MACE [Figure 1.5].
72  
There are only a few studies comparing the prognostic accuracy of these tests 
used for preoperative cardiac risk assessment. A meta-analysis of 20 studies by 
Mantha et al
78 comparing the predictive value of DiPS, radionuclide 
ventriculography (RNV), ambulatory ECG and DSE for perioperative MACE showed 
that, with the exception of DSE, each test demonstrated a bias for better 
predictive value in earlier studies. Although DSE appeared to be the best among 
these tests and ambulatory ECG the least predictive, the analysis was not 
sufficient to determine the optimal test.
79 A subsequent meta-analysis studied 
data from 15 papers regarding perioperative screening using DiPS and DSE in 
2439 patients undergoing vascular surgery. The development of MACE with a 
negative DiPS was 3% versus 18% in patients with a reversible defect. The 
positive predictive value (PPV) of DSE for cardiac death and myocardial 
infarction were 17% and 26% respectively, while the negative predictive value 
(NPV) was 99%. 
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Figure 1.5 Results of meta-analysis evaluating ability of non-invasive cardiac tests to 
predict risk of perioperative cardiac events in patients undergoing major vascular surgery. 
 
 
Meta-analysis results of 8119 patients including 8 studies on ambulatory electrocardiography (A-
ECG), 7 on exercise electrocardiography (Ex-ECG), 8 on radionuclide ventriculography (RNV), 23 
on myocardial perfusion scintigraphy (MPS), 8 on dobutamine stress echocardiography (DSE), and 
4 on dipyridamole stress echocardiography (DiSE). Positivity was considered as ST segment 
depression of ≥1 mm or ST elevation ≥2 mm after J point (measured at 60 ms) lasting at least 
one minute in A-ECG, development of exercise induced horizontal or down sloping ST depression 
of 1 mm or more in Ex-ECG, ejection fraction ≤35% in RNV, one or more fixed or reversible 
thallium-201 myocardial defects in MPS, and new or worsening ventricular wall motion 
abnormalities in both DiSE and DSE. DSE showed a positive trend towards better diagnostic 
performance than the other tests, but this was only significant in the comparison with 
myocardial perfusion scintigraphy. The conclusion of the meta-analysis was that DSE may be the 
favoured test in situations where there is valvular or left ventricular dysfunction. Adapted from 
34 and 
72. 
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Recently Kertai et al compared the predictive value of DSE and dipyridamole 
stress echocardiography (DiSE) with DiPS in 2204 patients undergoing major 
vascular surgery.
80 There was no statistically significant difference in the 
predictive value of a positive test result for either DiSE (OR 37.1, 95%CI 8.1-
170.1) or DSE (OR 9.6, 95%CI 4.9-18.4). A positive test result for DiPS however 
had a significantly lower odds ratio and prognostic capability (OR 1.9, 95%CI 1.2-
3.2). In the most recently published meta-analysis by Beattie et al 68 studies 
including over 10,000 patients undergoing non-cardiac surgery were reviewed.
81 
The likelihood of a positive stress echocardiography predicting a cardiac 
complication was twice that of thallium imaging (OR 4.09, 95%CI 3.21-6.56 vs OR 
1.83, 95%CI 1.59-2.10). While one third of all cardiac events occurred in patients 
with negative cardiac testing, the proportion was significantly higher in those 
with a negative thallium scan. In addition, the rate of referral for angiography 
where coronary intervention was not required was twice as high in those that 
received thallium imaging than in the remainder. Despite these findings no 
statistically significant difference between thallium imaging and stress 
echocardiography could be found for either positive or negative tests [Table 
1.5]. 
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Table 1.5 Meta-analytic comparison of stress echocardiography versus thallium imaging as 
a preoperative screening tool. 
 
        Stress Echocardiography    Thallium Imaging 
             
 
Likelihood         Likelihood   
     ratio               ratio         
Variable Analysed    Studies    (95% CI)  Studies        (95% CI)       p-value 
 
All studies      25         4.09(3.21-6.56)  50  1.83(1.59-2.10)    0.0001  
 
Vascular studies only    19         4.75(3.44-6.56)  39  1.83(1.57-2.13)    0.0001 
 
Studies with blinding only  4         5.52(3.45-8.85)  11  1.73(1.11-2.71)    0.0001 
 
Studies completed after 1995  19         3.75(2.89-4.87)  29  1.79(1.45-2.21)    0.001 
 
Studies with routine     12         4.11(2.85-5.93)  10  1.60(1.22-2.08)    0.0001 
screening for MI       
 
Direct comparisons of SE to TI  7         3.78(2.10-6.79)  7  1.73(0.96-3.11)    0.16 
 
Quantitative studies     9         0.80(0.75-0.84)  13  0.75(0.70-0.80)    0.35 
(Comparison of ROC*) 
 
Proportion revascularised†  9         57.5(34.0-81.0)  23  29.0(18.0-30.1)    0.05 
 
 
       
Meta-analysis of 68 studies including 10,049 patients, with 25 of Stress Echocardiography (SE) 
and 50 of Thallium Imaging (TI). Results reveal that positive SE has a likelihood ratio that is 2 
times more predictive than a positive TI. SE was found overall to be superior. Further, 
preoperative SE was shown in this meta-analysis to have a better negative predictive value than 
thallium scintigraphic imaging (not shown above). MI – Myocardial Infarction, TI – Thallium 
Imaging, SE – Stress Echocardiography, * - expressed as receiver operating characteristic curve 
(95% CI), † - expressed as percentage of patients (95% CI). Adapted from 
81. 
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Despite the studies and meta-analyses available there remains a considerable 
number of limitations. Most of the data available is from small studies, many of 
which were retrospective with blinding taking place in less than 20% of patients. 
Screening for MI was not routinely performed and there was no protocol for 
interventions for a positive test in any study. In addition the data spanned 20 
years during which time single-photon computed tomography and magnetic 
resonance imaging has become the current standard rather than thallium 
scanning, and significant advances in perioperative management have taken 
place. As a result there is currently no conclusive evidence to support one 
cardiac stress test over another. It appears that DSE has a better PPV and NPV 
than both exercise ECG and nuclear imaging. The degree of positivity of a test 
also appears important with moderate to large defects on nuclear imaging being 
associated with a nine-fold increase in MI or cardiac death. Patients with weakly 
positive nuclear imaging had no significantly increased risk over those with 
negative tests.
81  
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1.5.4 Preoperative Biochemical Markers of Outcome 
1.5.4.1  B-type Natriuretic Peptide 
Brain (or B-type) natriuretic peptide (BNP) is one of a family of cardiac peptides 
secreted almost exclusively by the myocardium in a non-specific response to 
wall stress in association with ventricular dilatation and pressure overload.
82 The 
physiological effects of BNP include the augmentation of urinary volume 
(diuresis), sodium excretion (natriuresis), aldosterone antagonism through 
inhibition of the renin-angiotensin system, sympathetic autonomic nervous 
system inhibition and direct antiproliferative effects on the cardiac myocytes.
83 
These effects result in relaxation of vascular smooth muscle, counteraction of 
hypertrophy and destruction of the myocyte sarcomere structure.  
  The synthesis of BNP occurs through a preprohormone. Once produced in 
the myocardial cells from preproBNP, proBNP is cleaved into the inactive N-
terminal fragment (NT-proBNP) and the active hormone BNP1-32. Variable 
amounts of BNP1-32, NT-proBNP and proBNP itself are released into the 
circulation. BNP1-32 rapidly undergoes breakdown to form the biologically active 
fragments BNP3-32 and BNP7-32. During periods of cardiac strain, up regulation of 
BNP production occurs with levels of BNP clearly reflecting significant change 
within 2-12 hours.
84  Although NT-proBNP and BNP (or BNP1-32) are secreted in a 
1:1 ratio, serum levels differ due to the longer half life of NT-proBNP. Pre-
analytical factors that need consideration include stability of BNP and renal 
clearance as its parts are cleared by the kidney and thus levels rise as renal 
function deteriorates.
85 Based on early investigations, it has been commonly 
accepted that the plasma clearance of NT-proBNP is more dependent on renal 
function than is that of BNP.
86, 87 More recently however it has been 
demonstrated that BNP and NT-proBNP correlate well when examined across the 
spectrum of renal disease and that no clear difference can be shown in chronic 
renal disease.
85, 88 For each 30 ml/min reduction in creatinine clearance (from 
150-30 ml/min) BNP increased by 9%, 22%, 44% and 89% and NT-proBNP increased 
by 9%, 24%, 46% and 95% respectively.
85 It is recommended that BNP should be 
analysed within 4 hours of collection due to its short half-life. If not, then it 
should be tested within 24 hours when at 2 to 8
oC, or stored at -22
oC. Testing 
recommendations for NT-proBNP include analysis within 2 hours of collection  
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because of possible evaporation effects.
89 Despite these initial 
recommendations, a later study has shown no statistical difference between 
results obtained for NT-proBNP or BNP when EDTA anticoagulated blood was 
aliquoted and stored at room temperature or 4
oC in glass or plastic tubes for 48 
hours.
90 Age is also a variable to take into consideration when interpreting BNP. 
Age-related ventricular changes, subclinical cardiac dysfunction and decreases in 
renal function all contribute to normal values of BNP increasing with age.
91-93 
BNP increases from 40 pg/ml (95
th percentile reference) in age 55-64 years to 86 
pg/ml in patients aged ≥75 years.
93  
The physiological role of BNP is to effect an adaptive response to cardiovascular 
strain through natriuretic peptide receptors A and B.
94 It modulates the 
cardiovascular system by limiting myocardial hypertrophy, causing peripheral 
vasodilatation and increasing endothelial permeability. At a renal level, 
inhibition of renin and aldosterone production occurs, with resulting natriuresis 
and diuresis. In the central nervous system the inhibition of salt and water 
intake, in addition to vasopressin secretion, takes place. Type C receptors and 
neutral endopeptidases act as scavengers and clear the peptides from the 
circulation.
95 Pharmacological reproduction has resulted in natriuretic peptide 
analogues which have been used in the treatment of renal failure and congestive 
cardiac failure with varying degrees of success.
96-98   
The close association of BNP levels with myocardial stress and its expression in 
cardiac failure has resulted in its development as a biomarker of cardiac failure. 
Levels are directly related to left ventricular mass and inversely related to left 
ventricular ejection fraction.
99-101 BNP has also been described as a diagnostic 
tool, for example in the evaluation of acute dyspnoea where it can help to 
differentiate cardiac failure from other causes of dyspnoea: a serum BNP value 
of <100 pg/ml was thought to make congestive cardiac failure unlikely, and a 
value >500 pg/ml made it highly likely [Figure 1.6].
101 
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Figure 1.6 BNP values in evaluation of acute dyspnoea.
 
 
 
 
 
Boxplots from a prospective study of 1586 patients who attended an emergency department with 
acute dyspnoea and whose BNP was measured with a bedside assay. Final diagnosis was dyspnoea 
due to congestive heart failure in 744 patients (47%), dyspnoea due to noncardiac causes in 72 
patients with a history of left ventricular dysfunction (5%), and no finding of congestive heart 
failure in 770 patients (49%). The difference among groups was significant for each pair wise 
comparison (p<0.001). Patients with a diagnosis of acute congestive heart failure had mean (±SD) 
BNP levels of 675±450 pg/ml, whereas those without congestive heart failure had BNP levels of 
110±225 pg/ml. The 72 patients who had base-line ventricular dysfunction without an acute 
exacerbation had a mean BNP 346±390 pg/ml. Adapted from 
101. 
 
 
 
 
 
  
                   
62 
In patients with chronic cardiac failure BNP has been used to monitor disease 
progression and prognosis. A single NT-proBNP level has been shown to 
independently predict both mortality and subsequent hospitalisation.
102 
Response to treatment with diuretic, angiotensin-converting-enzyme inhibitor or 
vasodilator therapy, can be monitored by a decrease in BNP levels, and an 
increase on their withdrawal.
103 A rise in BNP is closely linked to myocardial 
ischaemia and the degree of damage sustained with large amounts of cardiac 
muscle damage resulting in significant rises in BNP levels.
104, 105 In a subset of 
patients presenting with symptoms of acute coronary syndrome (ACS) without 
heart failure, BNP levels were significantly different between acute MI (median 
203.5 pg/ml), unstable angina (77.9 pg/ml) and patients without ACS (27.7 
pg/ml). In the presence of cardiac failure, BNP levels did not discriminate 
between those who had an acute MI or those who did not.
106 Other causes of 
raised BNP are listed below [Table 1.6]. 
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Table 1.6 Non-cardiac failure causes of raised BNP. 
 
 
 
 
  Cardiac      Pulmonary      Other  
                     
  Heart muscle disease  Pneumonia/Bronchitis  Anaemia 
  Acute cardiomyopathy  COPD        GI tract pathology 
    Myocarditis     Lung carcinoma    Cancer 
    Hypertrophic     Pulmonary embolism  Critical illness 
        cardiomyopathy    Pulmonary hypertension  Septic shock 
  Arrhythmias      ARDS        Burns 
    Atrial fibrillation            Ischaemic stroke 
    Atrial flutter            Sleep apnoea 
  Acute coronary syndrome          Hyperthyroidism 
  Pericarditis 
  Valvular heart disease 
 
 
 
BNP levels are a continuous variable, with even mildly elevated levels being associated with 
increased risk of death, heart failure, atrial fibrillation and stroke. Further, even mildly elevated 
levels of serum BNP are associated with an increased mortality risk in comparison to those below 
the cut-off levels, irrespective of the cause of the increase in BNP. The many possible causes of 
an elevated BNP level, other than congestive cardiac failure, are similar to those seen to cause 
elevations of cTnI [Table 3.3]. COPD – Chronic Obstructive Pulmonary Disease, GI – 
Gastrointestinal, ARDS – Acute Respiratory Distress Syndrome. Adapted from 
107. 
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Interest in BNP as a biomarker for risk in non-cardiac surgery has recently 
accelerated. This interest was catalysed by the well-recognised and 
acknowledged finding that preoperative ventricular dysfunction is a strong risk 
factor for perioperative cardiac morbidity and mortality as identified by 
Goldman in 1977.
108 Further to this, risk-adjusted operative mortality and 30-day 
readmission rates have been found to be higher in those with cardiac failure 
than those with known coronary artery disease (11.7% vs 6.6% and 20% vs 14.2% 
respectively, p<0.001).
109, 110 It is therefore being increasingly recognised that 
there is a significant mortality and morbidity associated with the diagnosis of 
cardiac failure. As a result, initial trials, reported in 2005 and 2006, found that 
elevated preoperative NT-proBNP concentrations were associated with cardiac 
events after non-cardiac and major vascular surgery.
111, 112 A further study in 
2006 of 1590 patients undergoing non-cardiac surgery showed that preoperative 
elevated concentrations of BNP were an independent biomarker of postoperative 
cardiac events.
113 BNP levels were also found to be a superior predictor of 
cardiac outcome to the Goldman multifactorial clinical index, with preoperative 
BNP concentrations >189 pg/ml identifying those at highest risk. An additional 
publication this year in the British Journal of Anaesthesia further supported this 
evidence reporting that patients with raised preoperative BNP levels were more 
likely to suffer perioperative cardiac death or myocardial injury during the first 
3 postoperative days.
114 
In Glasgow, a recent prospective single-centre derivation study was performed in 
high-risk patients undergoing major non-cardiac surgery, with a subsequent 
validation study. Forty one patients were recruited to the derivation cohort in 
whom 11 suffered a postoperative cardiac event. The median (interquartile 
range) pre-op BNP in those that had an event was 240 (172-344) pg/ml compared 
with 39 (15-70) pg/ml in those with no cardiac complication (p<0.001) [Figure 
1.7].  
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Figure 1.7 BNP concentrations by cardiac event incidence.
 
 
 
 
The median (interquartile range) plasma BNP concentration in patients who experienced a fatal 
or non‐fatal MI (n  =  11) was 240 (172–344) pg/ml, compared with 39 (15–70) pg/ml in those who 
did not (n  = 30). All patients who experienced an event had a preoperative BNP concentration > 
120 pg/ml. Adapted from 
115. 
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In the validation cohort, the median (interquartile range) BNP concentration in 
the 15 patients who had a cardiac event was 351 (127-1034) pg/ml, compared 
with 30.5 (11-79.5) pg/ml in the remainder (p<0.001). Using an ROC curve 
analysis it was calculated that a BNP concentration of ≥108.5 pg/ml best 
predicted the likelihood of cardiac events, with a sensitivity and specificity of 
87% each. Postoperative BNP concentrations above this value were a significant 
outcome predictor even after adjustment for confounders using multivariate 
analysis. The conclusion, therefore, was that preoperative serum BNP 
concentration predicted postoperative cardiac events in patients undergoing 
major non-cardiac surgery independently of other risk factors.
116 
As a result of the many studies examining the perioperative role of BNP in non-
cardiac surgery [Table 1.7] it is clear that there is a direct association between 
increasing levels of BNP and risk of postoperative events. Clearly, the wildly 
divergent quoted discriminatory thresholds for BNP make interpretation 
difficult. Variations in patient cohorts with respect to age, gender (males have 
consistently lower levels of BNP compared to females), co-morbidity, BMI and 
degree of pre-existing cardiac failure almost certainly account for this. This 
therefore makes the identification of a single universally-applicable BNP 
discriminatory point unlikely, and the optimal discrimination will be influenced 
by the prevalence of cardiac pathology in the population being examined.  
A single preoperative BNP level as part of routine workup in patients presenting 
for major or intermediate risk surgery allows preoperative risk stratification that 
is equal to, or possibly better than, current prognostic tools. There is, however, 
no study to date that looks at elective abdominal aortic aneurysm patients as a 
single group with an emphasis on appropriate sample size and long term 
outcome.  
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Table 1.7 Characteristics of studies examining the perioperative role of BNP in non-cardiac 
surgery. 
 
First author 
[reference] 
Surgery   Urgency of surgery  Study period  Patient 
numbers 
Optimal 
discrimination 
point 
BNP 
  Dernellis [113]  Mixed 
vascular/non-
vascular 
Elective  Short term 
< 30 days 
1590  189 pg/ml 
  Cuthbertson [117]  Mixed 
vascular/non-
vascular 
Emergency   6 months 
(emergency 
surgery) 
  40  170 pg/ml 
  Leibowitz [119]  Non-vascular  Mixed 
Elective/Emergency  
Short term 
< 30 days 
  44  165 pg/ml 
  Gibson [116]  Mixed 
vascular/non-
vascular 
Elective   Short term 
< 30 days 
 190  108.5 pg/ml 
  Cuthbertson[114]  Mixed 
vascular/non-
vascular 
Elective  Short term 
< 30 days 
 204   40 pg/ml 
  Cuthbertson [118]  Mixed 
vascular/non-
vascular 
Elective  Median 
654 days 
 204   35 pg/ml 
NT-proBNP 
  Feringa [112]  Vascular  Elective  Short term 
< 30 days 
 170  533 pg/ml 
  Goei [121]  Vascular  Elective  Short term 
< 30 days 
 356  478 pg/ml 
  Yeh [111]  Mixed 
vascular/non-
vascular 
Elective  Short term 
< 30 days 
 190  450 pg/ml 
  Feringa [120]  Vascular  Elective  14 months   335  319 pg/ml 
  Mahla [122]  Vascular  Elective  Median 
826 days 
 218  280 pg/ml 
 
Most of the studies that have been conducted thus far have looked at determining optimal cut-
off points for predicting postoperative cardiac events including cardiac death, non-fatal 
myocardial infarction, heart failure, acute pulmonary oedema and haemodynamic compromise 
from cardiac arrhythmias, as well as composites of the above. Adapted from 
107. 
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1.5.4.2  Cardiac Troponin-I 
Cardiac troponins are regulatory proteins that control the calcium-mediated 
interaction of the thin actin and myosin filaments of the cardiac muscle. The 
troponin portion of this cardiac contractile apparatus consists of 3 subunits: 
cardiac troponin T (cTnT), cardiac troponin I (cTnI) and cardiac troponin C 
(cTnC).
123  Although troponins are present in skeletal muscle, myocardium 
contains cTnT and cTnI isoforms that are not present in skeletal muscle, allowing 
separation by immunologic techniques.
124 Troponin I has 3 isoforms: cardiac 
muscle (cTnI), and fast-twitch skeletal muscle and slow-twitch skeletal muscle 
(sTnI) each encoded by an individual gene. Located exclusively in the 
mammalian heart, cTnI is never expressed in skeletal muscle.
125  
Many factors determine the rate of appearance in the blood of a marker such as 
cTnI, including molecular weight, charge, binding, degradation and clearance by 
the renal, hepatic or reticulo-endothelial systems.
126 Following an insult 
(ischaemic or other) myocytes can recover, succumb or hibernate. In all cases, 
be it by survivable ischaemia, necrosis or apoptosis, cTnI degradation products 
are released.
127, 128 After acute MI, approximately 50% of patients have a rise in 
their cTnI within 3-4 hours, with a peak at 10-24 hours.
129 Levels remain elevated 
for 4-10 days because of gradual degradation of myofibrils and release of the 
troponin complex.
130, 131  This results in cTnI having a wider diagnostic window 
than CK-MB, which peaks at 18-24 hours.
132  The clinical sensitivity of cTnI for 
detection of myocardial injury has been reported to be as high as 100% at 36 
hours following the onset of symptoms, compared to 81.8% for CK-MB mass at 
the same time point.
133  Debate continues as to the appropriate cut-off values of 
troponin concentrations for defining a clinically relevant MI. Initial cut-off values 
(cTnI >1.5 ng/ml and cTnT >0.1 ng/ml) were derived from titration of troponin 
concentrations to a population of patients with a clinically diagnosed MI. 
However, even small increases in serum concentrations of cardiac troponins are 
associated with adverse cardiac outcome in patients with or without ST-segment 
elevation.
134, 135  Considering the high specificity of cardiac troponins for 
myocardial cell injury, the consensus document of the European Society of 
Cardiology and the American College of Cardiology Committee on the re-
definition of MI states that in the presence of documented myocardial 
ischaemia, even minor increases in troponin serum concentration to >99
th  
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percentile of the normal population should be regarded as indicative of MI. As 
most troponin assays lack adequate precision to allow this at such low 
concentrations, slightly higher cut-off values based on ≤10% imprecision are 
recommended.
48, 136 
In the frequent absence of typical symptoms and ECG changes of acute MI, the 
diagnosis of a perioperative MI is difficult and has to rest heavily on changes in 
biochemical markers. Cardiac troponins appear to be well suited to identifying 
these events and have been shown to be more sensitive than CK-MB.
27, 137, 138  In 
one study of 1175 noncardiac surgery patients, abnormal levels of cTnT were 
detected in 87% of patients with MI and in 16% patients without MI. Among this 
latter group, cTnT was abnormal in 62% of patients with and 15% of those 
without other major cardiac complications, with the highest rates being 
observed in those undergoing AAA repair or other vascular surgery. Although CK-
MB had a similar diagnostic performance with regards MI, cTnT was better in 
detecting other cardiac complications.
137 A further paper also identified 
abnormal postoperative cTnI levels in patients undergoing vascular surgery. In 
total, 18% of 100 patients had elevated cTnI levels, highest in those undergoing 
ruptured AAA repair (67%), elective open AAA repair (20%) and infrainguinal 
bypass surgery (15%). Again CK-MB was less sensitive in detecting cardiac 
complications other than MI.
139 
Whilst cardiac troponins are of use in diagnosing a perioperative MI, the 
difficulty is in defining these cardiac events and therefore identifying their true 
incidence. This can depend not only on the cut-off value, but also on the rigour 
with which perioperative MIs are looked for. In one paper, had biochemical 
monitoring for ischaemic events not taken place, only 3.6% of patients would 
have met criteria for a perioperative MI rather than the 5.6% actually identified. 
Similarly, whereas 12% of patients had increased cTnT concentrations during 
routine postoperative monitoring, only 3% had a perioperative MI by the WHO 
definition.
140 The dilemma remains whether a reported incidence of 
perioperative myocardial injury based on traditional definition underestimates 
the true incidence of clinically relevant myocardial injury, or whether a 
reported incidence based on serum concentrations of cardiac troponins 
overestimates it.  
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The dilemma of defining perioperative MI seems less critical when the 
significance of elevated cardiac troponins is investigated. Several investigations 
have shown that abnormal levels of perioperative cardiac troponins identify 
patients at increased risk of perioperative and long-term cardiac 
complications.
50, 137, 140-142 Indeed, even postoperative cardiac troponin 
elevations below the conventional cut-off levels for the diagnosis of myocardial 
infarction and without clinical complications have been associated with 
significantly worse long-term survival after major vascular surgery.
140-143 One 
study demonstrated that asymptomatic elevation of cTnT in non-cardiac surgery 
was associated with a 4-fold increased in the risk of cardiac events during a 6-
month follow-up.
141 Furthermore, a 6-fold increased risk of 6-month mortality 
has been found in patients with abnormal elevations of cTnI following vascular 
surgery in 229 patients.
140 More recently, a positive association between 
abnormal levels of cTnI after vascular surgery and all-cause mortality over 2.5 
years has been reported.
143 It seems therefore that measurement of 
postoperative cardiac troponin levels provide important short- and long-term 
prognostic information, and perioperative routine cardiac troponin 
measurements in high risk patients can be useful for identifying patients at 
increased risk of perioperative and long-term morbidity and mortality. With 
regard to preoperative cardiac risk stratification, there is no paper published 
that quantifies this risk based on cardiac troponin measurements, although 
preoperative elevations have been reported.  
1.5.4.3  C-reactive Protein and D-dimers 
C-reactive protein (CRP), in particular when measured using high-sensitivity 
assays (hs-CRP), has been suggested as a potentially useful prognostic marker for 
cardiovascular disease. Atherosclerosis is an inflammatory disease,
144 and 
patients with elevated inflammatory markers (such as CRP) have a worse 
prognosis following acute coronary events.
144, 145 A number of publications have 
suggested that this link may extend to predicting adverse cardiac events 
following vascular surgery. To investigate this association further and to 
compare its usefulness with that of DSE and BNP, a meta-analysis of 10 
prospective patient cohort studies was published looking at CRP as a predictive 
test in early, intermediate and long term cardiac outcomes in vascular 
surgery.
146 Unfortunately due to small sample size it was not possible to  
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determine the prognostic value of preoperative CRP for early cardiac outcome. 
It was also not possible to compare CRP to BNP or DSE due to differing cardiac 
risk profiles and to the inclusion of patients undergoing surgical procedures with 
low or intermediate risk (carotid endarterectomy, peripheral angioplasty or 
EVAR). The same held for intermediate outcomes. A CRP >3 mg/l was, however, 
associated with a significantly increased risk of late all-cause mortality, cardiac 
death and MACE (OR 2.4, 5.65 and 2.76 respectively). Only one study reported 
on short-term MACE after AAA surgery.
147 Of the 34 patients included, 3 suffered 
a non-fatal MI or cardiac death, only one of whom had an elevated CRP 
(although the cut off level was not recorded). This led to an OR of 1.22 (95% CI 
0.1-15.23). However, the wide 95% CI exposes the true impact of this result, 
with little being added by this paper.  
As CRP levels are affected by local or systemic infection, due to its role as an 
acute phase protein, there is doubt about its ability to predict cardiac 
outcome.
148 This is certainly the case in vascular surgery where patients often 
have infectious pathologies, such as infected ischaemic ulcers. Further, there is 
a published link between aortic aneurysm diameter and CRP levels, where CRP is 
elevated compared to controls when AAA is present and the levels rise with 
increasing aortic diameter.
149, 150  With this and the limited data it is not possible 
to make positive conclusions on CRP as a preoperative marker, especially in the 
setting of AAA surgery. 
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Hypercoagulability has also been suggested as an important factor in 
perioperative myocardial infarction. This is supported by the association 
between raised preoperative fibrin D-dimer levels and a higher risk of 
perioperative cardiac events found in 110 patients undergoing peripheral 
vascular surgery.
151 In both univariate and multivariate analysis, D-dimer levels 
were found to be predictors of MACE, cardiac failure, unstable angina and 
arrhythmias combined. When the study was limited to MACE alone, although 
there was a significant difference in D-dimer levels (2.75 vs 2.47, p=0.003), this 
did not hold in regression analysis. There were also a number of limitations in 
the study including only a 49% inclusion (297/647) with 106 patients excluded 
due to ‗logistics preventing work-up‘. Although one other published paper found 
fibrinogen, von Willebrand factor and fibrin D-dimer levels to strongly predict 
poor outcome after infrainguinal bypass in 184 consecutive patients,
152 another 
small study of 42 patients undergoing vascular surgery found no correlation.
153 
More importantly neither commented specifically on cardiac outcome and there 
is no published data at this time in relation to AAA surgery.     
1.5.5 Risk Scores in AAA Repair 
There are a number of mathematical models available to aid risk prediction in 
elective abdominal aortic aneurysm repair in both the open and EVAR setting. 
There is however no consensus as to which scoring system should be considered 
the most predictive whilst questions about validity and transference between 
populations remain. Of the scoring systems available only three are frequently 
used to predict risk in the abdominal aortic population. These are the Glasgow 
Aneurysm Score (GAS), the Physiological and Operative Severity Score for 
enumeration of Mortality (POSSUM) and the Vascular Biochemical and 
Haematological Outcome Model (VBHOM). A number of other scoring systems 
have been published including the Estimation of Physiological Ability and 
Surgical Stress (E-PASS), Leiden score, Vanzetto score, the Australian Audit Risk 
Model for EVAR and the Society of Vascular Surgeons co-morbidity score.  
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In 1994 the Glasgow Aneurysm Score (GAS) was constructed by Samy et al 
following retrospective analysis of 500 patients undergoing AAA repair in 
Glasgow between 1980 and 1990. Logistic regression was used and identified 
preoperative shock, myocardial dysfunction, renal impairment and 
cerebrovascular disease as significant factors in determining postoperative 
outcome.
154 The GAS comprised a weighted score for each of these risk factors in 
addition to age and was validated by the author after its conception, confirming 
the accuracy of the method in both the elective and emergency settings for 
open surgery.
155 Further validation was carried out in the Scandinavian 
population in 2003 on two separate occasions, including use of the Finnvasc 
registry (a national registry of vascular surgery in Finland).
156, 157 Analysis of the 
Finnvasc registry demonstrated that the predictive power for mortality was 
lower than previously suggested with an area under the curve (AUC) of only 
0.668 (p<0.001) suggesting that the GAS was inaccurate in this context. 
Subsequently the GAS has been shown to be accurate in predicting mortality 
(AUC>0.80) by teams in the UK and the Netherlands.
158,159  
The GAS is a relatively easy score to collate and its simplicity makes it user 
friendly. It has also been validated successfully numerous times and predicts in-
hospital mortality with acceptable accuracy in open AAA repair. A definite 
drawback is that the GAS does not reliably identify individual high-risk patients 
due to a low-positive predictive value
160 and is consistently inaccurate when 
used to predict morbidity, and specifically cardiac morbidity. Further to this it 
has been found to perform relatively poorly compared to more recent models 
despite an acceptable AUC of 0.749 (p=0.01).
161   
The Physiological and Operative Severity Score for enUmeration of Mortality 
(POSSUM) prediction models score, created in 1991 as an audit tool, contains 
both physiological and operative components, and can only be used to predict 
mortality preoperatively if the physiological component is used alone.
162-164 This 
score has been applied to a number of surgical groups including orthopaedic 
patients, head and neck surgery, GI/Colorectal surgery and vascular surgery. The 
original POSSUM score using exponential analysis was evaluated and an early 
report claimed that POSSUM over-predicted death in their group of patients 
especially in low-risk patients. In an effort to counteract this effect the original 
POSSUM equation was modified leading to the Portsmouth predictor equation for  
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mortality (P-POSSUM) utilising the same physiological and operative variables, 
but using linear analysis. Modifications were subsequently suggested to improve 
the predictive accuracy of POSSUM for vascular surgical procedures including 
AAA repair (V-POSSUM). This score was developed following a meeting of the 
Vascular Surgical Society of Great Britain and Ireland where additional factors 
that were potentially of use were added to the standard P-POSSUM database. 
This new model was validated using data from the UK national vascular database 
and was shown to be predictive of outcome when physiological data were used 
alone or in combination with operative details, although this only applied to 
elective aneurysm repair.
165 
The various POSSUM-based scores have produced variable results when 
undergoing validation as preoperative scores, which raises the point that the 
score was intended as an audit tool. Use of the physiology-only scores yielded 
inconsistent results when used to predict outcome in AAA repair. The true 
validity may also be clouded by the complexity of the system where unknown 
scores are recorded as normal, potentially underestimating risk, and where 
potential observer bias may result in subjectivity. 
As an alternative score to the POSSUM score, a logistic regression model based 
on a minimal dataset derived from the UK national vascular dataset haematology 
and biochemistry results was described called the Vascular Biochemical and 
Haematological Outcome Model (VBHOM).
166 This VBHOM was also initially 
designed as an audit tool but was validated using a population of patients 
undergoing both elective and emergency AAA repair, and appeared to have a 
good predictive value, failing nevertheless to show statistical ―goodness-of-fit‖, 
indicating poor calibration.
167 In response, a new VBHOM model was constructed 
using two years of data from the vascular dataset as opposed to 1 year as in the 
original, amounting to 2718 patients.
168 
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External validation suggested a high degree of accuracy when used to predict 
death using entirely objective data, suggesting that any model based on a single 
preoperative blood sample could accurately predict outcome. However, once 
again the results of validation studies have not been consistent. Validation of the 
revised VBHOM as yet is not available. 
The use of risk scores to predict outcome in AAA surgery is clearly in its infancy. 
Those that are available are not user friendly enough for clinical use and lack 
sufficient validation. There are no further cardiac risk prediction models for AAA 
surgery other than those mentioned in previous chapters. 
1.5.6 Cardiopulmonary Exercise Testing 
Cardiopulmonary exercise testing (CPX) is a non-invasive, integrated assessment 
of cardiovascular and pulmonary function both at rest and under stress. During 
the test patients are exposed to incremental physical exercise up to their 
maximally tolerated level, dictated either by exhaustion or symptom related 
cessation (i.e. shortness of breath or angina). A number of physiological 
variables are recorded during the test including blood pressure, ECG, ventilatory 
parameters and inspiratory/expiratory gases from which the body‘s maximum 
oxygen uptake (VO2 max) and the point at which metabolism exceeds aerobic 
capacity (Ventilatory Anaerobic Threshold or VAT) are derived. Together these 
broadly indicate the ability of the cardiovascular system to deliver oxygen to the 
peripheral tissues and the ability of the tissues to utilise that oxygen. CPX should 
therefore be able to determine a patient‘s physiological capacity to cope with 
the metabolic demands created by the trauma of major surgery. 
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CPX has been widely researched in cardiac and pulmonary medicine and surgery, 
including in lung resection and cardiac transplantation.
169, 170 However, few 
studies have investigated the role of CPX in the preoperative assessment of 
patients undergoing non-cardiopulmonary thoraco-abdominal surgery. In 
particular, despite increasing interest, its use in AAA repair or vascular surgery is 
limited to only a few papers. Of those, the 2 better conducted studies showed 
only a weak relationship between VO2 max and postoperative morbidity and 
mortality in patients undergoing open elective AAA repair.
171, 172 One study 
investigated the role of anaerobic threshold in elective AAA repair and found it 
to be a strong predictor
171, however there was no comment on cardiac morbidity 
or its ability to predict MACE, and for the purposes of this thesis, despite its 
increasing popularity as a research tool CPX did not appear to have research or 
clinical benefits in predicting postoperative cardiac outcome. 
1.5.7 Preoperative Cardiac Assessment in Glasgow 
In Glasgow, at the time of writing, there is no standardised assessment of 
cardiac risk. There are no published papers or other forms of literature that help 
shed light on what is currently practised locally. From personal experience and 
from discussions with consultant vascular surgeons throughout Glasgow, it is 
apparent that in almost all surgical cases there is a clinical assessment made in 
the outpatient clinic at the time of discussing surgical options and making the 
decision to proceed to surgery. This takes the form of case note review, with 
special attention to past medical history and drug history, and focused 
questioning regarding functional status and metabolic equivalents. An 
experience- and knowledge-based assessment is then made of the patients‘ 
likely risk of surgery. This will often prompt an anaesthetic review and 
sometimes lead to a cardiology opinion, where risk of surgery is estimated and 
attempts to optimise cardiac status may be made. No documented attempts at 
risk scoring are made, although RCRI scores are often mentally estimated. No 
other form of risk scoring is attempted. 
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Although all patients undergo a preoperative ECG, it is unlikely that any other 
form of cardiac investigation will be directed by surgical staff other than the 
transthoracic echocardiogram which is increasingly requested. Anaesthetic or 
cardiology opinion may rarely result in preoperative non-invasive cardiac 
imaging. In the present studies, this author has found that of 106 patients 
proceeding to theatre only 3 had a DSE performed and 2 had thallium scanning. 
Despite these low numbers, it was noted that 12 patients had had a preoperative 
coronary angiogram, with or without intervention, in the preceding year. Four of 
these resulted in percutaneous intervention and 3 in coronary artery bypass 
grafting. Undoubtedly, modification of cardiac medication and commencement 
of beta-blocker therapy occurred, however what medication changes were made 
and for what reason is outwith the scope of this research.  
As discussed there is no set preoperative pathway for assessing cardiac risk. The 
most likely reason for this is the complex nature of preoperative cardiac risk 
stratification. There is no simple assessment that can be implemented at the 
time of clinic review, and often those assessments that are made in the surgical 
outpatient setting are the simplest available, such as questioning functional 
capacity and reviewing past medical history. Undoubtedly a quick method of 
accurately assessing that risk would be beneficial in deciding the 
appropriateness of surgery, or what surgical option to employ. The possible 
cardiac interventions aimed at optimising cardiac status when surgery is deemed 
necessary despite apparent high risk, are discussed in the following section.  
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1.6 Intervention in the High Risk Patient 
The goal of improved cardiac risk stratification is to allow accurate informed 
decisions to be made both by the patient and the surgeon. This important role is 
not only useful in predicting outcome and making a decision about proceeding to 
theatre, but also in guiding the choice of interventions. A range of strategies are 
employed aimed at reducing the incidence of perioperative cardiac 
complications of which the simplest is delaying or cancelling surgery. Other 
interventions include preoperative coronary revascularisation, modification of 
medical therapy or adjustment of anaesthetic technique. Closer perioperative 
monitoring could also aid the detection of cardiac complications. 
1.6.1 Preoperative Coronary Revascularisation. 
The use of coronary revascularisation before noncardiac surgery is based on the 
assumption that perioperative MIs occur primarily in coronary arteries with 
haemodynamically significant stenoses, and that revascularisation will therefore 
prevent infarction. As discussed above, the pathophysiology of a perioperative MI 
may make this assumption false. Controversy therefore is widespread about the 
effectiveness of preoperative revascularisation and it is unsurprising that there 
have been numerous studies looking at the use of percutaneous transluminal 
coronary angioplasty (PTCA) and coronary artery bypass grafting (CABG) in 
patients undergoing major noncardiac surgery. This is especially true in the 
vascular surgical population. A number of early studies collected retrospective 
hospital data of patients who underwent PTCA before surgery in order to relieve 
symptomatic angina or to treat myocardial ischaemia identified by non-invasive 
testing.
173-175 The results of these studies showed that the incidence of 
perioperative cardiac death and myocardial infarction was low, but these studies 
failed to use a comparison group of patients with coronary artery disease not 
treated with PTCA. A follow-up study compared adverse cardiac outcomes after 
noncardiac surgery among patients with prior PTCA, patients with preoperative 
coronary revascularisation and normal control subjects.
176 The findings of the 
study showed that patients treated with PTCA within 90 days of surgery had a 
similar incidence of perioperative events to matched patients with CAD in the 
control group. Patients revascularised more than 90 days before surgery had a  
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lower risk of cardiac events than those revascularised within 90 days. This rate 
however was not as low as that in the control group. Furthermore, the effect of 
revascularisation was limited to a reduction in the incidence of angina and 
congestive heart disease. There was no reduction in MI or cardiac death.  
In 2000 a study was published highlighting the hazards of noncardiac surgery 
following percutaneous coronary stent placement.
177 Perioperative coronary 
thrombosis and major bleeding complications were reported in 40 patients 
treated with PTCA and coronary stenting less than 6 weeks before major 
noncardiac surgery. In the perioperative period 7 nonfatal MIs, 11 major 
bleeding episodes and 8 deaths were observed. All the deaths and MIs, as well as 
8 of the 11 bleeding episodes occurred in those who underwent surgery within 14 
days of stenting. Fatal cardiac events were mostly caused by stent thrombosis, 
which was associated with interruption of antiplatelet medication 1-2 days 
before surgery. In contrast, severe bleeding occurred in patients whose 
antiplatelet medication was continued. These findings were also confirmed in a 
group of 207 patients who underwent noncardiac surgery within 60 days of 
coronary stent placement.
178 Eight of the 207 patients had MACE. Six patients 
died, 2 of whom suffered a periarrest myocardial infarction. The risk of MACE 
therefore persisted for 6 weeks after stent placement. No major complication 
was observed in 39 other patients who had surgery 7-9 weeks after stent 
placement.  
Where former evidence was based on small observational studies and expert 
opinion, a number of recent randomised controlled trials have clarified the 
issue. The Coronary Artery Revascularisation Prophylaxis (CARP) trial was the 
first randomised trial that investigated the benefit of coronary revascularisation 
in patients presenting for AAA repair or lower extremity revascularisation.
179 A 
total of 510 patients with significant coronary artery stenosis were randomised 
to either revascularisation or intensive medical therapy perioperatively. Of the 
316 patients enrolled who had nuclear stress imaging, 72% had moderate-to-
large reversible defects (44.3% of total cohort). The incidence of death or MI 
within 30 days of the vascular procedure was high but similar in the two groups, 
with an incidence of 14.7% in those revascularised and 17.7% with medical 
therapy. Long-term mortality was high but similar between the groups, 
averaging 22.5% [Figure 1.8].   
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Figure 1.8 Prophylactic coronary revascularisation – long-term survival from the CARP trial.
 
 
 
The median follow-up time for mortality was 2.8 years (interquartile range 1.7-3.9) in the 
revascularization group and 2.6 years (1.6-3.8) in the no-revascularisation group. There were 137 
deaths (70 in the revascularisation group and 67 in the no-revascularisation group). At a median 
of 2.7 years after randomization, mortality was 22 percent in the revascularization group and 23 
percent in the no-revascularisation group (relative risk, 0.98, 95% CI 0.70-1.37; P=0.92). Adapted 
from 
175. 
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Although these results appear impressive, there were a number of limitations: 
there was no subgroup analysis investigating the impact of CABG versus PCI; 
patients undergoing CABG had, on average, 3 vessels revascularised versus 1.3 in 
the PCI group, with the completeness of revascularisation reported as 61.9% for 
PCI versus 98% for CABG; acute or sub-acute stent thrombosis posed an 
additional risk with prophylactic PCI compared to CABG; and premature 
termination of antiplatelet therapy may have skewed results as discussed above. 
In 2006 a follow-up study revealed that both short and long-term outcome was 
significantly better in those receiving CABG compared to PCI.
180 This study 
involved 91 patients undergoing prophylactic CABG and 131 patients undergoing 
PCI before major vascular surgery using the same enrolment criteria as the CARP 
trial. In the CABG group, the 30-day mortality and MI rate was 2.2% and 6.6% 
versus 3.8% and 16.8% for PCI. Mortality at 2.7 years was 16% for CABG and 21% 
for PCI. The most significant criticism of the CARP trial relates to the inclusion 
(coronary stenosis of >69% in at least 1 major coronary vessel suitable for 
revascularisation) and exclusion criteria (severe co-existing illness, >50% left 
main coronary stenosis, severe aortic stenosis or LVEF <20%). Therefore the 
optimal preoperative management for patients with the above exclusion criteria 
was not determined. The authors of the CARP trial considered most patients in 
their cohort to be high risk, but only 7.3% had severe perfusion defects and 
multiple risk factors whilst those with triple CAD plus mildly depressed LV 
function represented only 14.5%. In response a subgroup analysis was performed 
and a trend towards improved outcome with revascularisation was seen in 
patients with a large burden of ischaemia and multiple clinical risk factors.
181 
Further evidence of this trend was shown by 3 other studies. The first 
retrospective study involving patients with moderate-severe defects on thallium 
imaging showed improved long-term mortality outcomes in those patients who 
underwent vascular surgery following coronary revascularisation.
182 There was a 
significantly higher incidence of triple vessel and left-main vessel disease in the 
group who underwent revascularisation, suggesting that revascularisation in this 
particular pattern of disease was protective in high risk patients. A follow-up 
retrospective study identified a number of predictors of long-term survival of 
which only prophylactic coronary revascularisation and statin use were positive 
predictors of increased long-term survival.
183 Finally, in a prospective study of  
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patients undergoing major vascular procedures, prophylactic revascularisation in 
those with moderate-severe defects on thallium imaging decreased the 
incidence of low-level troponin release and of elevations consistent with a 
diagnosis of MI from 49% to 22.4% and 23.4% to 6.4% respectively.
184 
While much of the above work by Landesberg has gone against that found in the 
CARP trial, results from the pilot study of the Dutch Echocardiographic Cardiac 
Risk Evaluation Applying Stress Echocardiography Study Group (DECREASE)-V trial 
implied that revascularisation, even in patients with multiple risk factors and 
severe CAD, does not improve outcome as long as best medical therapy is 
instituted preoperatively.
185 Of the 1888 suitable patients, undergoing elective 
open AAA repair, screened prior to thallium imaging or DSE, 430 proceeded to 
cardiac testing and 101 were found to have extensive ischaemia and randomised 
to revascularisation or medical therapy. Of the 49 patients revascularised, 12 
had 2-vessel CAD, 33 had 3-vessel CAD and 4 had left main disease. In addition 
43% had a LVEF <35%. Complete revascularisation was achieved in 86% with 32 
patients receiving PCI and 17 CABG. The 30-day incidence of MI and all-cause 
mortality after their subsequent aneurysm surgery was 42.9% in the 
revascularisation group and 32.7% in the control group. There was no significant 
difference in outcome at 1 year (49% vs 44.2%). There was a ―catch-up‖ effect 
noted by 1 year where the number of cardiac events in the medically managed 
group approached that of the revascularisation group. With or without 
revascularisation the 30-day operative mortality was 33-43% despite medical 
management, leading to the question over the need for revascularisation in AAA 
patients. 
While the argument that revascularisation does not improve outcome is 
compelling, there remains sufficient doubt about this conclusion that, given the 
current literature, it is difficult to advise against prophylactic revascularisation 
in the highest risk patients. There is mounting evidence that the completeness 
of revascularisation is the most important variable
180 and that CABG may confer 
benefit over PCI, particularly in patients with extensive CAD or in those with 
ischaemic cardiomyopathy. In long-term outcome studies, CABG is associated 
with an improved outcome.  
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1.6.2 Pharmacological Treatment 
The beneficial effect of preoperative treatment of a coronary stenosis is limited 
because of the unpredictable behaviour of non-significant coronary lesions with 
regards to plaque rupture, thrombus formation and subsequent coronary 
occlusion. Plaque instability is driven by the stress of surgery and any therapy 
aimed at plaque stabilisation may benefit in both the short and the long-term. 
Perioperative use of beta-blockers, statins and aspirin have all shown promise. 
1.6.2.1  Beta-blocker Therapy 
The benefit from beta-blockade (specifically beta1-selective blockade) is with 
restoration of the oxygen supply/demand mismatch by decreasing myocardial 
contractility, heart rate and arterial pressure. The complexity of the 
interactions between the heart, sympathetic nervous system and inflammation 
also contribute to the beneficial effect of beta-blockade.
186 Furthermore, beta-
blockers decrease the release of intracardiac noradrenaline during ischaemia 
reducing cardiac toxicity, attenuate exercise-induced coronary vasoconstriction 
improving exercise capacity, and have antiarrhythmic properties, increasing the 
threshold for ventricular fibrillation during myocardial ischaemia. 
Despite wide-scale use of beta-blockers perioperatively there has remained  
some debate about their protective effect. This was intensified by the results of 
the PeriOperative ISchaemic Evaluation (POISE) trial in 2007.
187 Prior to this 
publication a number of papers showed clear evidence in favour of the use of 
beta-blockers. These included a randomised controlled trial of 200 patients 
receiving either perioperative (induction and 7 days therapy) atenolol or 
placebo.
188 Over the 2-year follow-up period, overall mortality after hospital 
discharge was significantly lower in the atenolol (10%) than in the placebo group 
(21%) amounting to a relative risk reduction of 55%. Criticism was concentrated 
on the exclusion of a number of in-hospital deaths (n=4) associated with atenolol 
use which, if included, would have negated the significance of the observed 
difference. In addition, the tolerance to beta-blockade therapy was poor, with a 
trend towards a more severe cardiac history in the control group. A subsequent 
study (DECREASE-I), looking at perioperative bisoprol (30 days pre-op and 30  
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days post-op with heart rate titration) in patients with documented CAD 
undergoing major vascular surgery, randomised 112 from 1351 screened 
patients.
189 This paper reported a 10-fold reduction in the rate of perioperative 
cardiac events in the bisoprolol group (3.4% vs 34%). Limitations included a small 
sample size resulting in only 20 events, early termination of the trial due to 
unexpectedly large beneficial effects, lack of blinding, and the lack of 
representation from the broader population. A recent large meta-analysis 
including 15 studies (1,077 patients) showed a significant beneficial effect of 
beta-blockers in non-cardiac surgery [Table 1.8].
190 
The recently presented POISE study showed a benefit of high-dose metoprolol 
controlled-release therapy on the risk of MI but an increased risk of stroke and 
overall mortality. These results have been questioned due to widespread 
criticism relating to the dose and timing of beta-blocker use, the choice of beta-
blocker, criteria for dose adjustment and patient inclusion. The starting dose of 
metoprolol was between 2 and 8 times that commonly prescribed, with initiation 
of therapy immediately before surgery and therefore an extremely narrow 
window for titration. Further, titration was based not only on heart rate control 
but on a single blood pressure measure, with therapy discontinued when levels 
fell below a systolic pressure of 100 mmHg. No consideration was taken to 
preoperative blood pressure or the actual drop, with the potential for patients 
to drop blood pressure from a high systolic pressure down to 105 mmHg and still 
be included in the study. It has therefor been hypothesised that dose-related 
hypotension in patients naïve to beta-blockers, and in whom without prior 
knowledge of their cardiac status could have asymptomatic left ventricular 
dysfunction, could account for much of the adverse outcome associated with this 
trial. Indeed 49 of the 60 strokes in POISE were proven ischaemic in origin. The 
inclusion of emergency patients, those that had signs of preoperative sepsis, and 
the use of ‗individual physician‘s judgement‘ on choosing the type of surgery to 
be included further questions the true clinical impact of these results. 
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Table 1.8 Comparison of patients treated with perioperative beta-blocker therapy versus no 
drug or placebo. 
 
 
Ischaemic event data available from 11 of 15 studies (n=410 treated and n=407 controls). Beta-
blocker use resulted in a 67% relative reduction in the combined endpoint of cardiac death and 
non-fatal MI (1.1% vs 6.1%, OR 0.33, 95% CI 0.17-0.67; p=0.002, NNT = 20). OR - odds ratio, Rx – 
treatment, MI - myocardial infarction, CI – confidence interval, NNT – number needed to treat. 
Adapted from 
190. 
 
 
 
 
 
 
 
 
  
                   
86 
The importance of the initiation time of beta-blocker therapy before surgery can 
be argued based on its physiological effects. The acute effects include reduction 
of myocardial oxygen demand as describe above. Otherwise, the further 
suggested benefits may be related to anti-inflammatory properties possibly 
observed only after prolonged use as seen in acute MI patients who require to be 
on beta-blocker therapy for at least 48 hours before a clear reduction in the 
inflammatory response is seen.
191 It is unclear whether the effect on coronary 
plaque stabilisation can be achieved immediately on commencement of beta-
blocker therapy. As described above, a randomised trial of 200 patients using 
atenolol at anaesthetic induction revealed a long-term benefit. There was, 
however, no difference in perioperative cardiac events.
188 The Metoprolol After 
Vascular Surgery (MAVS) trial randomised 496 patients to metoprolol or placebo 
starting 2 hours before surgery until a maximum of 5 days post-op.
192 No 
significant difference in outcome was observed at 30 days; or at 6 months after 
surgery. The Perioperative Beta-Blockade (POBBLE) trial randomised 103 
patients undergoing vascular surgery to metoprolol or placebo, starting less than 
24 hours prior to surgery and continuing to 7 days.
193 This trial again showed no 
benefit on 30 days outcome with a cardiac event rate of 32% in the metoprolol 
group versus 24% in the placebo group. The Diabetic Postoperative Mortality and 
Morbidity (DIPOM) trial started therapy at the earliest on the evening prior to 
surgery, and again no benefit was seen.
194 The POISE trial randomised patients to 
receive either controlled-release metoprolol or placebo starting 2-4 hours before 
surgery and continued for 30 days.
187 In contrast the DECREASE-I trial started 
bisoprolol at an average of 37 (range 7-89) days before surgery with careful 
titration of therapy and revealed a significant benefit with bisoprolol use in the 
perioperative period.
189 The long-term beneficial effects were recently 
confirmed by a study which demonstrated a decreased progression of coronary 
atherosclerosis in patients receiving beta-blocker therapy using pooled analysis 
from four intravascular ultrasonography trials.
195 The use of beta-blockers was 
significantly associated with a decrease of atheroma volume at follow-up, not 
seen in those without therapy. 
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The different beta-blockers have various plasma half-lives and peak ratios. 
Bisoprolol and atenolol are long-acting agents with half-lives of 10-11 hours and 
6-7 hours respectively, whereas metoprolol has a short duration of action of 
about 3.5 hours. Beta-blockers with short half-lives will increase the risk of a 
cardiovascular event on sudden withdrawal as seen in elderly patients 
undergoing elective surgery where long-acting beta-blockers are associated with 
higher cardioprotective benefits.
196 Additional consideration is required with 
metoprolol and atenolol which are only moderately beta1-adrenoreceptor 
selective. As described, beta1 blockade is beneficial during the perioperative 
period where high adrenaline and noradrenaline levels create increased heart 
rates and blood pressure whilst stimulating an inflammatory process putting 
vulnerable plaques at risk. Blocking beta2-receptors in addition to beta1 leads to 
uncontrolled alpha stimulation and a subsequent adverse rise in blood 
pressure.
197 Therefore the highly beta1-selective bisoprolol is the favoured agent 
in the perioperative setting.  
In addition to initiation time and type of beta-blocker, dose adjustment for 
heart rate control is important. This is based on the fact that cardiovascular and 
sympathetic suppression is required to produce cardiac protection. As the extent 
of such suppression is difficult to assess clinically, heart rate is taken as a 
physiological surrogate of sympathetic tone.
188, 189 Two studies have confirmed 
this by showing positive results using strict heart rate control in the 
perioperative setting with a reduction in perioperative myocardial ischaemia, 
troponin T release and improved long-term outcome.
198, 199 The POISE trial 
randomised treatment of controlled-release metoprolol just before surgery, and 
the maximum recommended therapeutic dose was already achieved within the 
first day after surgery. This is in contrast to the DECREASE studies, where a low 
dose of bisoprolol at an average 12.5% of the maximum recommended 
therapeutic dose was carefully up-titrated during a mean of 30-days. Although 
the POISE trial showed a reduction of perioperative MI, there was an excess of 
overall mortality and increased risk of stroke. The message may be that if beta-
blockade is to be used it should be carefully titrated with guidelines on 
discontinuation of therapy. It may also be that the beneficial effect of beta-
blockers is best seen in high risk patients, as shown in a retrospective cohort 
study of 782,969 patients who underwent major noncardiac surgery.
200 Beta- 
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blocker use showed no benefit but possible harm in low-risk patients, but had a 
significant beneficial effect in high risk patients. This may account for the 
negative outcome of the MAVS and DIPOM trials which included many low risk 
patients including 60% of the MAVS cohort. 
At present, the weight of evidence suggests that beta-blockers lower rates of 
perioperative myocardial ischaemia or infarction and cardiovascular death 
among high risk patients undergoing major vascular surgery. However, there 
appears to be a concurrent risk of adverse events associated with these 
medications if patients are not monitored properly during the perioperative 
period. Despite this, it seems clear that perioperative beta-blockers, where 
adequately titrated and monitored, should continue to occupy a prominent role 
in the therapeutic armamentarium for improving outcomes among high-risk 
patients undergoing major vascular surgery.  
1.6.2.2  Statins 
Statins are widely prescribed to patients to decrease low-density lipoprotein 
(LDL) cholesterol in patients with, or at risk of, coronary artery disease, and 
have been shown to decrease the number of future cardiovascular events. 
Besides lowering cholesterol, statins have other important effects, known as 
pleiotropic effects. These effects include atherosclerotic plaque stabilisation, 
oxidative stress reduction and a reduction of vascular inflammation.
201 In human 
carotid plaques, statins have been demonstrated to decrease lipids, lipid 
oxidation, inflammation, matrix metalloproteinases and cell apoptosis, and to 
increase tissue inhibitors of metalloproteinases and collagen. These properties of 
statins may stabilise coronary artery plaques, thereby preventing plaque rupture 
and subsequent MI in the perioperative period.
202 
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A number of large clinical trials have shown a beneficial effect of statins with 
regards to safety and long-term outcome, whilst improving symptoms related to 
peripheral non-coronary atherosclerosis.
203, 204 There is however only one 
published blinded, placebo-controlled, randomised clinical trial evaluating the 
effects of statin therapy on perioperative cardiovascular complications in which 
100 patients were randomised to 20mg atorvastatin or placebo.
205 After 6 months 
the incidence of cardiac events (cardiac death, non-fatal MI, stroke or unstable 
angina) was more than 3 times higher with placebo than with atorvastatin (26% 
vs 8%, p=0.031). This study suggested that even short-term treatment with a 
statin could significantly reduce the incidence of major cardiovascular events in 
vascular surgery.  
There have been a number of other case-control and retrospective trials 
published that evaluate the effect of statin therapy on perioperative cardiac 
outcomes, all of which demonstrate some benefit. The earliest case-control 
study, published in 2003, concluded that statin therapy reduced perioperative 
mortality in patients undergoing major vascular surgery with statin therapy less 
common among cases than controls (8% vs 25%) and similar results in subgroups 
of patients according to other cardiac therapy or risk factors.
206 A later 
retrospective study of 570 patient who underwent AAA repair revealed that 30-
day mortality and non-fatal MI (overall 8.9%) were lower in statin users than in 
nonusers (3.7% vs 11%).
207 Although the statin users had a different risk profile, 
the reduced risk remained after adjustment for this difference and was 
independent of beta-blocker use. A large retrospective cohort study of 780,591 
patients undergoing major noncardiac surgery at 329 hospitals revealed that 
after correction for baseline differences, the 70,159 statin users had a 1.4 fold 
reduced risk of in-hospital mortality.
208 In addition, the long-term benefit of 
statins was reported in patients undergoing AAA repair when followed up over a 
median of 4.7 years.
209 
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Reviews of studies to determine the strength of data have again demonstrated a 
benefit with statin therapy. One meta-analysis found that preoperative statin 
therapy was associated with a 4.4% absolute reduction in the risk of early 
mortality after vascular surgery (1.7% vs 6.1%, p<0.001).
210 When including 
noncardiac surgery, a 1.1% absolute reduction in the risk of early mortality was 
observed (2.2% vs 3.3%, p<0001). A further comprehensive review of 11 papers 
on perioperative statin use concluded that all demonstrated an improved 
postoperative cardiac outcome.
211  
A major concern of statin therapy is the potential side effects, such as statin-
induced myopathy and rhabdomyolysis. Perioperatively, patients might be 
unaware of these symptoms, owing to sedation and analgesic agents. There is 
also a concern regarding the possible increased risk of statin induced myopathy 
in the perioperative period due to impaired renal function and multiple drug use 
during anaesthesia, risking the subsequent development of rhabdomyolysis and 
acute renal failure. No studies have however been published supporting these 
concerns, except for a few case reports.
212-214 One retrospective study of 981 
consecutive patients undergoing vascular surgery has been published.
215 This 
study measured CK blood levels and clinical status in those already on statins or 
recently commenced. After correcting for cardiac and clinical risk factors for 
myopathy, length of surgery remained the only independent predictor of 
myopathy. No cases of rhabdomyolysis were observed.  
The optimal dosing and timing of statins for the prevention of perioperative 
events has still to be elucidated. An important concern is the continuation of 
statins in the perioperative period. Unintended interruption in the immediate 
postoperative period is a well-known phenomenon because of the unavailability 
of an intravenous formula of statins. From patients with CAD, it is known that 
sudden withdrawal can be harmful,
216 with a similar risk recently demonstrated 
in vascular surgery patients in whom statin withdrawal was associated with an 
increased risk for postoperative troponin release and cardiac events.
217 The 
extended release of fluvastatin appeared to have beneficial effects over other 
statins when discontinued in this same study.  
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1.6.2.3  Other Pharmacological Therapies 
Acetylsalicylic acid (ASA) is one of the cornerstones in the primary and 
secondary prevention of cardiovascular diseases. The evidence of ASA in the 
perioperative period in patients undergoing noncardiac surgery is less clear. In a 
randomised trial of carotid endarterectomy patients, ASA was shown to be 
effective in preventing intraoperative and postoperative stroke but with no 
effect on death or non-fatal MI.
218 In another trial comparing low-dose and high-
dose ASA in carotid surgery, there was an observed reduced mortality, MI and 
stroke in the low-dose group.
219 A meta-analysis of 10 trials using antiplatelet 
therapy during lower limb bypass surgery showed a reduction in serious vascular 
events and vascular death in patients with peripheral vascular disease, although 
this did not reach statistical significance.
220 No randomised trial exists of 
preoperative discontinuation of ASA. A meta-analysis of 41 studies observed that 
ASA increased the risk of bleeding complications 1.5-fold but did not lead to 
higher levels of severe bleeding complications.
221 A systematic review in subjects 
at risk for or with CAD demonstrated that ASA non-adherence/withdrawal was 
associated with a 3-fold higher risk of MACE.
222 
Alpha-2-adrenergic agonists (clonidine, mivazerol) dilate post-stenotic coronary 
vessels and attenuate the severity of perioperative haemodynamic 
abnormalities, an effect which may reduce cardiovascular complications.
223, 224 
Previous small scale studies have failed to demonstrate that clonidine reduces 
the incidence of cardiac death or non-fatal MI compared with placebo.
225, 226 A 
number of meta-analyses performed claim to demonstrate a reduced incidence 
of myocardial ischaemia,
227, 228 however these reviews were dominated by one 
large-scale randomised trial of 2854 patients in whom there was no overall 
effect on the endpoints of cardiac death and nonfatal MI.
229 
The prophylactic use of intravenous nitroglycerin and diltiazem for the 
prevention of cardiac complications after non-cardiac surgery has also been 
studied. These small-scale randomised studies failed to find any difference in 
the incidence of intraoperative and perioperative myocardial ischaemia in 
patients receiving nitroglycerin or diltiazem compared with placebo.
230-232 
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1.6.3 Anaesthesia and Monitoring Techniques 
In recent years, the attention in cardiac risk reduction has been focused on 
preoperative cardiac risk assessment to modify cardioprotective medication or 
consider revascularisation in an attempt to improve perioperative outcome. Less 
attention has been given to the role of anaesthesia and monitoring techniques in 
the cardiac management of high-risk patients. Despite this, evidence exists to 
support the theory that adequate operative haemodynamic control such as 
prevention of tachycardia, hypotension and possibly hypertension with the use of 
modern monitoring techniques may prevent myocardial ischaemia and reduce 
the incidence of perioperative cardiac complications. 
1.6.3.1  Inhalational Anaesthesia 
A number of laboratory studies have shown that halogenated volatile 
anaesthetics have a protective effect on the ischaemic myocardium. In these 
studies, volatile anaesthetic use was associated with improved post-ischaemic 
recovery and smaller myocardial infarction size.
233, 234 This has been termed 
pharmacological preconditioning, similar to ischaemic preconditioning, of which 
the exact mechanism appears to be protection of the cardiomyocytes via an 
effect on ATP-regulated potassium channels.
235 Volatile anaesthetics may also 
exert ‗post-conditioning‘, directly on the myocyte but also indirectly through 
modulation of neutrophil-mediated damage, protecting against myocardial 
reperfusion injury.
236, 237 The key issue however is haemodynamic stability and a 
number of volatile anaesthetics have been studied. A large scale study of 4 
anaesthetic agents (isoflurane, enflurane, fentanyl and halothane) looked at 
perioperative outcome in 17 201 surgical patients.
238 The incidence of death, 
myocardial infarction and stroke (0.04%) was so low that no definite conclusions 
could be made, although marked differences in their haemodynamic properties 
were noted. Halothane use was associated with ventricular dysrhythmia, 
fentanyl with severe hypertension and bronchospasm and isoflurane with severe 
tachycardia. Further clinical studies comparing sevoflurane and isoflurane 
suggest that both have similar cardiovascular effects, and do not alter outcomes 
such as myocardial infarction and death in patients with coronary artery 
disease.
239-241 The choice of agent is therefore often based on other factors such 
as experience, availability and the ease of emergence from anaesthesia.
242  
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1.6.3.2  Epidural Anaesthesia/Analgesia and Intraoperative Normothermia 
Early studies of epidural anaesthesia claim that, due to better suppression of 
surgical stress, positive effects on postoperative nitrogen balance, more stable 
cardiovascular haemodynamics, reduced blood loss, better peripheral vascular 
circulation and postoperative pain control, perioperative outcomes may be 
improved with this anaesthetic modality.
243, 244 A number of later studies 
involving more than 600 patients who underwent aortic surgery have failed to 
demonstrate any benefit with epidural anaesthesia and analgesia in the 
prevention of myocardial ischaemia, myocardial infarction and mortality.
245-249 In 
contrast a systematic review of all randomised controlled trials using data from 
9559 patients revealed a 30% reduction in all-cause mortality and a 33% 
reduction in myocardial infarction compared to standard therapy in non-cardiac 
surgery.
250 The use of neuraxial blockade also reduced the risk of all-cause 
mortality by 34% in a subgroup of patients who underwent vascular surgery. More 
recent randomised controlled trials have attempted to readdress this issue. The 
first clinical trial involved 1021 patients scheduled for abdominal aortic, gastric, 
biliary or colonic surgery, who were randomly assigned to general anaesthesia 
and postoperative analgesia with parenteral opioids or a combination of epidural 
and light general anaesthetic with postoperative epidural morphine.
251 The 
results showed no significant difference in the incidence of 30-day mortality and 
major complications between the two groups. However, subgroup analysis of the 
AAA group revealed a significantly lower incidence of major cardiovascular (10% 
vs 18%), pulmonary (14% vs 28%) and cerebral complications (0.5% vs 5%) 
compared to patients without epidural anaesthesia. This was felt to be due to 
the high-risk status of the aortic surgical patients many of whom had a history of 
hypertension or chronic obstructive pulmonary disease, and to the longer mean 
operating time. In a similar study of 915 high risk patients undergoing abdominal 
surgery the use of epidural anaesthesia and analgesia did not reduce the 
incidence of morbidity (57% vs 61%) or mortality (5% vs 4%).
252 The incidence of 
respiratory failure was significantly lower in patients managed using epidural 
techniques (23% vs 30%). Nevertheless, these studies suggested that by 
improvement in analgesia, reduction in respiratory failure and the observed low 
risk of serious adverse consequences, many high-risk patients undergoing major 
abdominal surgery would receive substantial benefit from an intraoperative  
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combination of general and epidural anaesthesia with continuing postoperative 
analgesia.  
Hypothermia is common around the perioperative period and triggers 
sympathetically-mediated hypertension resulting from an increase in circulating 
levels of noradrenaline and generalised systemic vasoconstriction.
253 Decrease in 
the core body temperature by approximately 1.0 
oC results in shivering and 
increased total-body oxygen consumption, which places increased demands on 
the cardiovascular system. These adrenergic and metabolic responses to 
hypothermia can lead to an imbalance in myocardial oxygen supply and demand, 
resulting in myocardial ischaemia or infarction.
33, 254, 255 Two clinical trials have 
explored the issue of unintentional hypothermia and postoperative myocardial 
ischaemia. The first studied 100 patients undergoing lower extremity vascular 
reconstruction and revealed that a larger proportion of patients in the 
hypothermic group (temp. <35 
oC) developed ischaemic ECG changes than in the 
normothermic group (36% vs 13%, p=0.008).
33 In a subsequent study of 300 
patients undergoing abdominal, thoracic or vascular surgical procedures the 
perioperative maintenance of normothermia was associated with a significantly 
lower incidence of cardiac events compared to those with hypothermia (1.4% vs 
6.3%, p=0.02).
255 It seems, therefore, that measures used to ensure 
normothermia would benefit, especially in those at high risk of suffering 
perioperative MACE. 
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1.7 Aims of the Thesis 
The need for adequate preoperative cardiac risk stratification in major vascular 
surgery is clearly demonstrated in the above chapters, not only in identifying 
high risk patients that may benefit from those interventions described above, 
but in surgical decision making. The importance of this in a prophylactic 
operation to prevent rupture of an AAA, where a balance of risks is essential 
prior to making a decision regarding surgery, is further emphasised, especially in 
the case of the small AAA. 
A number of case reports have described preoperative elevation in cTnI in 
vascular surgery and described the associated poor outcome in these patients. At 
the time of writing, there is no published research that has further investigated 
this and therefore the initial aims of this thesis are to investigate the true 
incidence of preoperative elevated cTnI in asymptomatic individuals prior to 
undergoing a major vascular procedure. Further, these identified patients will 
be followed-up in the immediate postoperative period and their outcome 
determined.  
Whilst cTnI is of interest, the current research regarding preoperative cardiac 
biomarkers as a marker of outcome is aimed primarily at investigating BNP or 
NT-proBNP. Although there are numerous papers reporting outcome with regards 
BNP in major vascular surgery, no research has concentrated on the elective 
open AAA repair population, where the decision to operate has added 
importance. The foremost aim of this thesis is to investigate the ability of BNP to 
predict outcome in the elective open AAA repair population. Outcomes to be 
measured are major adverse cardiac events (non-fatal MIs and cardiac death), 
all-cause mortality and postoperative elevated cTnI (with or without a diagnosed 
cardiac event), measured in the immediate (<30 days), intermediate (30 days - 1 
year) and long-term (>1year) postoperative periods.  
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Non-invasive cardiac testing, such as dobutamine stress echocardiography, is 
expensive, relatively inaccessible and rarely used in the decision making process 
with regards elective open AAA repair in the West of Scotland. Therefore 
decisions are often helped by estimates from current cardiac or all-cause 
mortality based risk indices devised around AAA surgery. The further aim of this 
thesis is therefore to compare these risk indices to BNP with an emphasis on 
predicting MACE and all-cause mortality in the immediate postoperative period. 
Finally, EVAR has recently had an increasing but uncertain role in repair of a 
patients AAA. Currently there are no published papers looking at the use of BNP 
in decision making when considering EVAR. The final aim of this thesis is to 
investigate if BNP can predict outcome in patients undergoing elective EVAR, 
again concentrating on MACE and all-cause mortality in the immediate 
postoperative period. 
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Chapter 2 
 
Patients and Methods 
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2.1 Recruitment 
Patients were recruited from within the Glasgow tertiary referral centres 
specialising in vascular surgery, where distinct geographical borders and minimal 
migration resulted in a geographically defined prospective cohort with minimal 
selection bias, and facilitated complete follow-up. The patients were recruited 
in 2 groups.  
In the first group consecutive patients undergoing elective major vascular 
surgery in Gartnavel General Hospital and the Western Infirmary were 
prospectively identified using theatre diaries. Patients were included if they 
were over 40 years of age and undergoing vascular surgery with a >5% estimated 
cardiac risk including abdominal aortic surgery, infrainguinal bypass surgery and 
major extremity amputation. All patients were approached the day prior to 
surgery and informed consent was obtained (appendix 1). Patients were 
excluded if the surgery could not be delayed by more than 24 hours (due to 
clinical need), if they were unable to give informed consent or were being 
included in another study. 
In the second group all patient undergoing elective open AAA surgery or 
endovascular AAA repair were prospectively identified in the 3 major Glasgow 
vascular units; Gartnavel General Hospital, Glasgow Royal Infirmary and the 
Southern General Hospital. Patients were prospectively identified using theatre 
diaries, regular check of theatre lists and weekly contact with surgical 
secretaries. All patients were approached the day prior to surgery and informed 
consent was obtained (appendix 2). Patients were excluded if the surgery was 
required on an emergency basis, if they were unable to give informed consent or 
were being included in another study.  
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2.2 Clinical Details 
Patients‘ clinical details were gathered prospectively from case-note review or 
history taking and were recorded on a common study proforma on the day prior 
to surgery (appendix 3). These details included basic patient and demographic 
data including aneurysm size and operative procedure.  
2.2.1 Details of Cardiac Risk 
Factors relating to cardiac risk of surgery were recorded including age, sex, 
smoking history, medical diagnoses of angina, myocardial infarction, heart 
failure, hypertension, hyperlipidaemia, cerebrovascular disease, medically 
treated diabetes and renal impairment with estimated glomerular filtration rate. 
In addition to cardiac risk, a history of chronic obstructive airways disease was 
noted. 
2.2.2 Details of Current Cardiac Medications 
All patients‘ current medications were noted with particular attention to the 
inclusion of those related to cardiac disease and to preoperative cardiac risk 
intervention including beta-blockers, statins, anti-platelets, diuretics, ACE-
inhibitors, calcium-channel antagonists and anti-anginals. 
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2.3 Preoperative Testing 
2.3.1 Basic Measures 
Data relating to basic haemodynamic parameters were recorded including pulse 
and resting blood pressure, oxygen saturations on air, and body temperature to 
ensure there was no underlying current or acute ill health.  
2.3.2 Electrocardiography 
All patients underwent 12-lead electrocardiography which was recorded in a 
standard fashion at a paper speed of 25mm/second by a qualified cardiac 
technician. All preoperative ECGs were analysed by a cardiologist of consultant 
or senior registrar grade, to ensure that there was no evidence of acute or 
unstable ischaemia and to allow postoperative comparison.  
2.3.3 Further Cardiac Investigation 
Selected patients underwent transthoracic echocardiography with estimate of 
left ventricular ejection fraction (LVEF) to allow function to be recorded as 
normal (LVEF >55%), mildly impaired (LVEF 45-54%), moderately impaired (LVEF 
30-44%) or severely impaired (LVEF<30%) in accordance with the 
recommendations of the American Society of Echocardiography and the 
European Association of Echocardiography.
256  
Additional investigations including DSE, thallium scanning, angiography and 
pulmonary function tests were performed at the discretion of the surgical, 
anaesthetic or cardiology staff involved in individual patient care. 
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2.4 Preoperative Blood Sampling and Analysis 
Samples were collected and analysed by collection of an aliquot of venous blood 
obtained from recumbent patients the evening before surgery. 
2.4.1 Cardiac Troponin I 
5ml venous blood samples were collected in sterile lithium heparin tubes for 
serum cTnI measurement using the ARCHITECT STAT Troponin I immunoassay 
(Abbot Diagnostics) which had an assay range of 0.02-50 ng/ml with a sensitivity 
of 0.01 ng/ml. Assay precision was 10% of the concentration value (CV) for 
samples ≥0.20 ng/ml. The lowest assay value exhibiting a 10% CV on the 
precision profile was 0.032 ng/ml. A positive result was taken as a cTnI >0.02 
ng/ml. cTnI results were not initially made available to clinicians. However, as 
documented in chapter 3, positive results were given to appropriate medical 
staff towards the end of the study period.  
2.4.2 B-type Natriuretic Peptide 
2.4.2.1  Sample Handling 
A 10 ml sample was collected from patients who had lain supine for 20 mins. 
This was collected in chilled sterile EDTA and aprotonin (Trasylol®, Bayer, 
LeverKusen, Germany; 50units/ml) and immediately centrifuged at 3000rpm at 
4
oC for 10 minutes. The serum was then removed from the tube using a pipette, 
placed in a plain tube and stored in a freezer at -22
oC. 
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2.4.2.2  BNP Testing 
BNP was batch analysed in lots of 100 samples at the end of the study period 
using a direct immunoradiometric assay kit (Shinoria BNP kit) supplied by Shinogi 
& Co, Ltd. (Osaka, Japan). This used two monoclonal antibodies which recognise 
the carboxyl terminal sequence and the ring structure of human BNP, 
respectively, measuring BNP concentration between the two antibodies without 
plasma extraction. The minimum detectable quantity of human BNP was 2 pg/ml 
and the degree of cross reactivity with human ANP was less than 0.001%. The 
within-assay and between-assay co-efficient of variation were both <5%. 
2.4.3 Biochemistry Analyses 
A 5ml sample was taken in a sterile lithium heparin tube and sent to the 
biochemistry laboratory for measurement of serum urea and electrolytes, 
magnesium, C-reactive protein, non-fasting total cholesterol, triglycerides and 
high-density lipoprotein fraction of cholesterol. 
2.4.4 Haematological Analyses 
A 5ml sample was taken in a sterile EDTA tube for analysis of haemoglobin 
concentration, white cell count and platelet count. A further 5ml sample was 
collected in a citrate tube for coagulation screening which included pro-
thrombin time, activated partial pro-thromboplastin time and fibrinogen.  
 
 
 
  
                   
103 
2.5 Clinical and Cardiac Risk Scoring 
Clinical variables were recorded preoperatively to allow calculation of risk of 
cardiac events and mortality using established clinical scoring systems. 
2.5.1 The Glasgow Aneurysm Score (GAS) 
154 
GAS was calculated for all patients undergoing AAA repair. Scores were 
calculated on the basis of several risk factors, each allocated a weighted value: 
age (n=age), presence of shock (n=17), history of myocardial disease (n=7), 
history of cerebrovascular disease (n=10) and a history of renal disease (n=14). 
Based on the original description for GAS, shock was defined as documented 
tachycardia, hypotension, pallor and sweating. Myocardial disease included a 
previous myocardial infarction and/or angina. Cerebrovascular disease referred 
to all grades of stroke including a transient ischaemic attack. Renal disease 
included chronic and acute renal failure. 
No further categorisation or grouping has been shown of use with GAS and 
therefore the score represents a point within a linear degree of risk. Increasing 
scores suggest higher risk of all-cause mortality. 
2.5.2 The Vascular Physiological and Operative Severity Score for 
the enUmeration of Mortality and Morbidity (V-POSSUM) 
V-POSSUM, as previously described, is a vascular surgical modification of POSSUM 
in which the original developers examined 62 physiological parameters and used 
multi-variate analysis to identify the most powerful predictors of mortality. This 
eventually reduced the 62 to 12 physiological and 6 operative parameters. In the 
preoperative period only the 12 physiological parameters can be collected.  
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The 12 physiological parameters required include age, evidence of cardiac 
failure (categorised based on current cardiac medication and on clinical 
evidence of heart failure), evidence of pulmonary disease (categorised based on 
severity of dyspnoea or evidence of consolidation), preoperative ECG changes 
(based on rate, ectopics, Q-waves and ST changes), systolic BP, resting pulse 
rate, Glasgow Coma Scale scoring, and serum levels of haemoglobin, white cell 
count, urea, sodium and potassium. These were placed into the online V-POSSUM 
calculator at www.riskprediction.org.uk to calculate individual scores. 
2.5.3 Vascular Biochemical and Haematological Outcome Model 
(VBHOM) 
166 
All patients undergoing open AAA repair were given VBHOM scores based on 
gender, mode of admission (elective or emergency), age at time of admission, 
serum urea, sodium, potassium, haemoglobin concentrations and white cell 
count. These were then placed into the following calculation to give a final 
VBHOM score: 
VBHOM = lne(R/1-R) = −2.257 + (0.1511 × sex) + (0.9940 × mode of admission) +  
(0.05923 × age on admission[years]) + (0.001401 × urea[mmol/l]) + (−0.01303 × 
sodium[mmol/l]) + (−0.03585 × potassium[mmol/l]) + (−0.2278 × 
haemoglobin[g/dl]) + (0.02059 × white cell count[×10
9/l]) 
R is the risk of death. Sex takes the value 0 for female and 1 for male, and mode 
of admission takes the value 0 for elective and 1 for non-elective admissions. 
The VBHOM score was not categorised but expressed as a numerical value, 
higher values being associated with high estimated risk of mortality. 
2.5.4 Lee’s Revised Cardiac Risk Index (RCRI) 
64 
All patients were given a RCRI score based on six clinical variables: high-risk 
surgery, history of ischaemic heart disease, history of congestive heart failure, 
history of cerebrovascular disease, preoperative treatment with insulin, and 
preoperative creatinine >2.0 mg/dl (>176 μmol/l), with each factor being 
attributed a value of 1 (maximum score of 6)  
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Ischaemic heart disease was defined as a previous MI, history of a positive 
exercise test, current complaint
 of chest pain considered to be secondary to 
myocardial ischemia,
 use of nitrate therapy or ECG with pathological Q waves. 
Congestive heart failure was defined as a history of congestive heart failure, 
pulmonary oedema
 or paroxysmal nocturnal dyspnoea, physical examination 
showing bilateral
 rales or S3 gallop, or chest radiography showing pulmonary 
vascular
 redistribution. Cerebrovascular disease was defined
 as a history of 
transient ischemic attack or stroke.  
Patients were categorised on the basis of RCRI into four groups of increasing 
cardiac risk: 1. patients with 0 risk factors, 2. patients with 1 risk factor, 3. 
patients with 2 risk factors, and 4. patients with 3+ risk factors. As open AAA 
surgery was considered high risk, all patients admitted for this procedure had a 
score of 1 and thus could not be placed in the lowest risk group using RCRI. 
2.5.5 Preoperative Risk Score of the Estimation of Physiological 
Ability and Surgical Stress Score (PRS of E-PASS)
 257 
The PRS component of the E-PASS score was calculated for all patients based on 
the following equation: 
PRS = -0.0686+0.00345(age) + 0.323(cardiac score) + 0.205(pulmonary score) + 
0.153(diabetes score) + 0.148(performance status index) + 0.0666(ASA) 
Age was expressed in years. Cardiac, pulmonary and diabetes scores were scored 
1 for the presence of the disease, or 0 in its absence. Cardiac disease was 
defined as heart failure (New York Heart Association Class III or IV) or severe 
arrhythmia requiring mechanical support. Pulmonary disease was defined as any 
condition with a vital capacity of less than 60% and/or a forced expiratory 
volume in 1 second of less than 50%. Diabetes mellitus was defined according to 
the World Health Organization criteria as the presence of either fasting venous 
plasma glucose levels of 7.0 mmol/L (126 mg/dL) or greater, or 2-hour venous 
plasma glucose levels of 11.1 mmol/L (200 mg/dL) or greater after a 75 g oral 
glucose tolerance test. The ASA score was allocated according to table 1.3.   
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Performance status was based on that of the Japanese Society of Cancer Therapy 
as follows: 
  Grade 0 - conditions without symptoms that do not restrict social 
activities.  
  Grade 1 - conditions with mild symptoms that restrict muscular labour, 
but do not restrict walking or mild exertion.  
  Grade 2 - conditions that require some physical assistance for daily living, 
but do not restrict walking or mild exertion; grade 2 patients are not in 
bed for more than half of the day.  
  Grade 3 - conditions that require frequent physical assistance for daily 
living; grade 3 patients are in bed for more than half of the day. 
  Grade 4 - conditions that require constant physical assistance; grade 4 
patients are in bed all day long. 
2.6 Intraoperative Details 
Intraoperative details were extracted from anaesthetic charts and operative 
notes. 
2.6.1 Intraoperative Blood Loss 
Blood loss was recorded from charted suction volumes and weighed swabs 
documented in intraoperative anaesthetic records. 
2.6.2 Operative Time 
Operative time was recorded for all patients from anaesthetic charts using the 
time from induction to last recorded observation.   
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2.6.3 Intraoperative Hypotension 
Intraoperative hypotension was recorded for all patients from anaesthetic 
charts. This was defined as systolic blood pressure below 90mmHg for a period of 
greater than 5 minutes. 
2.6.4 Intraoperative Hypothermia 
Intraoperative hypothermia was recorded for all patients from anaesthetic 
charts. Hypothermia was defined as core body temperature below 34.5 
oC. 
2.6.5 Cross-clamp Level and Time 
In all patients undergoing open AAA repair, the anatomical level of aortic cross-
clamp and duration of aortic occlusion was recorded. Cross-clamp level was 
either infrarenal or suprarenal and was determined from operative notes. Cross-
clamp time was calculated from anaesthetic charts. 
2.7 Postoperative Testing and Follow-up 
2.7.1 Short-term Testing (<30 days post-op) 
All patients underwent postoperative screening for cardiac events. This 
consisted of daily clinical assessment, with serial ECGs and cTnI measurement 
conducted on the morning of the 2nd and 5th postoperative days. If a patient 
was due to be discharged prior to the fifth postoperative day, tests were 
conducted on the morning of discharge. ECG and cTnI were also measured if 
there was clinical need outside these fixed times. ECGs and cTnI measurements 
were conducted in the same manner as previously stated. Postoperative ECGs 
were analysed by consultant or senior registrar grade cardiologist to identify 
acute myocardial ischaemia, development of a myocardial infarction or new 
cardiac pathology. Those analysing ECGs were blinded to patient and clinical 
details. 
  
                   
108 
In addition to cTnI measurement, blood samples were sent for serum creatinine. 
This was primarily measured to ensure that there was no new acute renal 
dysfunction that could account for elevations in cTnI. All other postoperative 
investigations were conducted at the discretion of the treating physician or 
surgeon. 
2.7.2 Intermediate (30 days – 1 year) and Long-term Follow-up (>1 
year) 
Patients were routinely followed up at a surgical outpatient clinic 6-8 weeks 
after surgery. Patients who defaulted from their follow-up clinic appointment 
were identified and recent progress accounted for through hospital records and 
GP phone-calls. 
Three-year follow-up was performed on all patients undergoing elective open 
AAA repair through GP phone-calls. Information was gathered on mortality and 
cause of death. 
Patient inclusion and follow-up numbers in those identified for elective open 
AAA repair and EVAR are shown in Figure 2.1. 
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Figure 2.1 Inclusion and follow-up patient numbers of those included in the multicentre 
preoperative BNP in elective open AAA repair and EVAR trials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Met Study Criteria 
n=153 
2 Refused Consent 
5 ↑ Preoperative cTnI 
Open AAA Repair 
Inclusion 
n=106 
EVAR 
Inclusion 
n=40 
Post-op Day 2 
n=105 
1 Death 
Post-op Day 5 
n=103 
2 Deaths 
1 Death 
Post-op Day 30 
n=97 
2 Deaths following 
Discharge 
Post-op Day 2 
n=39 
Post-op Day 5 
n=39 
6-month Follow-up 
n=95 
2 Deaths 
1 Year Follow-up 
n=95 
Final 30-day 
Follow-up 
n=39 
2 Year Follow-up 
n=87 
3 Year Follow-up 
n=79 
7 Deaths 
1 Lost to 
Follow-up 
4 Lost to 
Follow-up 
4 Deaths 
4 In-hospital Deaths  
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2.8 Study Endpoints 
The primary study endpoints were Major Adverse Cardiac Event or MACE (non-
fatal myocardial infarction or cardiac death). Secondary endpoints were all-
cause mortality and elevated postoperative cTnI with or without a defined 
cardiac event. 
2.8.1 Major Adverse Cardiac Event (MACE) 
2.8.1.1  Non-fatal Myocardial Infarction 
The definition of a nonfatal myocardial infarction used was that of the Joint 
European Society of Cardiology/American College of Cardiology Committee. This 
required a typical rise and gradual fall in cTnI with at least one of: ischaemic 
symptoms, development of pathological Q-waves on the ECG, ECG changes 
indicative of ischaemia (ST segment elevation or depression), or coronary artery 
intervention. 
2.8.1.2  Cardiac Death 
Cardiac death was defined as death secondary to myocardial infarction, 
cardiogenic shock or intractable dysrhythmia following review by 2 cardiologists 
blinded to preoperative BNP levels. 
2.8.2 All-cause Mortality 
All-cause mortality was simply defined as death due to any cause. The cause of 
death was recorded for anecdotal interest but was not used as a secondary end-
point. 
2.8.3 Elevated cTnI 
Postoperative cTnI was defined as any postoperative cTnI elevation, independent 
of clinical outcome and regardless of presence or absence of symptoms, where 
the level was greater than 0.02 ng/ml.  
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2.9 Definitions of Preoperatively Recorded Conditions 
2.9.1 Myocardial Infarction 
Myocardial infarction was defined as the presence of a previous medically 
confirmed myocardial infarction from hospital or GP records. 
2.9.2 Angina Pectoris 
Angina pectoris was defined as the presence of a previous medical diagnosis of 
angina, the presence of symptoms of angina or current medical treatment for 
angina. 
2.9.3 Heart Failure 
Heart failure was defined as the presence of a previous medical diagnosis of 
heart failure, the presence of symptoms or signs of heart failure, previous or 
current treatment of heart failure, or objective signs of impaired left ventricular 
function or lung congestion on either echocardiography or plain chest 
radiography. 
2.9.4 Hypertension 
Hypertension was defined as the presence of a medical diagnosis of hypertension 
preoperatively (treated or untreated).  
2.9.5 Hyperlipidaemia 
Hyperlipidaemia was defined as a preoperative total cholesterol of >5.5mmol/l. 
2.9.6 Cerebrovascular Disease 
Cerebrovascular disease was defined as a previous medically confirmed transient 
ischaemic attack (TIA) or stroke.  
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2.9.7 Diabetes Mellitus 
Diabetes was defined as the presence of a medical diagnosis of diabetes mellitus 
with the current use of insulin or oral hypoglycaemic agents. 
2.9.8 Renal Impairment 
Renal impairment was defined as a preoperative creatinine of >130 μmol/l or an 
eGFR of <60. The eGFR was calculated using the Modification of Diet in Renal 
Disease (MDRD) Study equation: 
GFR (mL/min/1.73 m
2) = 186 x (Serum creatinine)
-1.154 x (Age)
-0.203 x (0.742 if female) x 
(1.212 if African-American)  
Patients were then categorised by chronic kidney disease (CKD) stage using eGFR 
as derived from the NICE, SIGN and Renal Association guidelines 2009.
258-260 
2.9.9 Chronic Obstructive Pulmonary Disease 
Chronic obstructive pulmonary disease (COPD) was defined as the presence of a 
medical diagnosis of COPD or the presence of current active treatment for 
COPD. 
2.10 Classification of Operative Procedures 
Procedures were classed urgent if they were conducted on the same admission 
as a referral from the emergency department or another source, but did not 
require to be conducted within 24 hours. Procedures were considered elective if 
patients were admitted from home for treatment.  
2.10.1  Vascular Procedures 
Vascular procedures included open or endovascular AAA repair, aorto-bifemoral 
bypass grafting, infra-inguinal vascular reconstruction or major lower extremity 
amputation due to vascular insufficiency.  
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2.10.2  Elective Open AAA Repair 
The open elective AAA repair patients included those brought in from home by 
planned admission undergoing AAA tube graft or aortic bifurcation graft repair. 
2.10.3  Elective Endovascular AAA Repair 
The elective EVAR group included those brought in from home by planned 
admission for endovascular repair primarily performed due to their AAA. 
Endovascular techniques were varied but principally involved exclusion of the 
aneurysm sac by insertion of stent grafts. 
2.11 Ethical Approval 
Local Research and Development, and Central Ethics Committee approval was 
obtained for the study (REC reference number 06/S0703/148). All patients were 
provided with an information sheet and signed a study consent form (Appendices 
1+2) prior to inclusion. This study involved no additional risk to patients other 
than extra blood tests and non-invasive cardiac imaging. 
2.12 Statistical Analyses 
Statistical analysis was conducted using SPSS® statistical software package 
(SPSS, Chicago, Illinois, USA). Non-parametric continuous variables were 
reported as median (interquartile range) and compared using Mann-Whitney U 
and Kruskall-Wallis analyses. A two tailed Fisher‘s exact test was used to analyse 
the differences between independent categorical data. Normally distributed 
data was reported as mean (+/- standard deviation) and compared using a 2-
sample t-test. Regression analysis was performed to assess the association of 
BNP with MACE and all-cause mortality, adjusting for preoperative and operative 
variables identified through univariate analysis. ROC analysis was performed to 
determine the association between BNP and outcome. Kaplin-Meier survival 
analyses were performed to estimate the survival function allowing for censoring 
on long-term follow-up. A p-value of less than 0.05 was considered statistically 
significant.  
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Chapter 3 
 
The Prognostic Value of Raised Preoperative 
Cardiac Troponin I in Major Vascular Surgery 
 
 
 
 
 
 
 
  
                   
115 
3.1 Introduction 
Vascular disease is a systemic disorder, with 50-60% of patients undergoing 
peripheral vascular procedures having co-existent severe coronary artery disease 
and only 10% having normal coronary arteries.
67, 261 It is predictable therefore 
that vascular surgery is associated with a substantial risk of major adverse 
cardiovascular
 events (MACE) and death.
24, 261 
Cardiac Troponin I (cTnI) is a contractile protein that is released into the 
circulation after myocardial cell injury. Unlike other cardiac-related enzymes, 
cTnI is not found in skeletal muscle and it is therefore a highly sensitive and 
specific marker of myocardial necrosis,
133,262 and a specific marker of myocardial 
infarction following surgery.
133 Elevated cTnI after major vascular surgery is 
associated with an increased risk of short-term mortality and morbidity,
140 and is 
an independent predictor of intermediate and long term outcomes.
140-143, 263-264 It 
is widely recognised that known preoperative impaired cardiac function 
correlates with MACE. The impact of adverse cardiac function on postoperative 
outcome is well established and has been refined since Goldman‘s first risk 
stratification.
60 The sophistication of cardiac testing has changed dramatically 
since then with both functional and stress testing with radioisotope scanning, 
biochemical tests, ECG, echocardiographic and angiographic studies. However 
50% of postoperative cardiac events and 29% in the general population are 
asymptomatic and detected principally through cTnI analysis.
43 Whilst 
asymptomatic elevation in cTnI has been widely correlated with angiographic 
findings and outcome in patients presenting to cardiology,
43 there have been no 
studies that have systematically addressed the incidence of elevated 
preoperative cTnI and the impact on MACE postoperatively other than a case-
report and a series of amputation patients.
265,266 
The aim of this case series is to report the incidence of asymptomatic elevated 
preoperative cTnI and it‘s associated outcome in 213 consecutive patients 
undergoing major vascular surgery.  
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3.2 Patients and Methods 
3.2.1 Patients 
A prospective, observational single centre cohort study was performed over a 2 
year period (April 2004 and April 2006) in Glasgow, to assess cardiac risk 
stratification and novel markers in non-cardiac surgery. Inclusion criteria for 
participation included an estimated procedure-related cardiac event rate of >5% 
(lower limb revascularisation, aneurysm repair, major amputation). In addition 
to preoperative tests done at the discretion of anaesthetic and surgical teams, 
each patient had a preoperative measurement of cTnI and an electrocardiogram 
(ECG) performed on the day before surgery. The cTnI level was available to the 
anaesthetic and surgical teams if requested, but was not routinely sought. Basic 
demographic data and factors relating to the risk of surgery were prospectively 
gathered for each patient. Patients were excluded if there was evidence of 
unstable coronary artery disease preoperatively (cardiac chest pain or ischaemic 
ECG changes), if the surgery was emergency (<24 hours) or if they were unable 
to provide informed consent. COREC and local Research and Development 
committee approval was obtained for the study. 
3.2.2 Sample Collection and Analysis 
Preoperative venous blood samples were collected the evening before surgery in 
sterile lithium heparin tubes. Serum cTnI was measured using the ARCHITECT 
STAT Troponin I immunoassay (Abbot Diagnostics) which had an assay range of 
0.02-50 ng/ml with a sensitivity of 0.01 ng/ml. Assay precision was 10% of the 
concentration value (CV) for samples ≥0.20 ng/ml. The lowest assay value 
exhibiting a 10% CV on the precision profile was 0.032 ng/ml. A positive result 
was taken as a cTnI >0.02 ng/ml. 
  
                   
117 
3.2.3 Postoperative Follow-up 
Postoperative screening for cardiac events consisted of daily clinical assessment, 
and serial ECGs and cTnI measurement on postoperative days 2 and 5. These test 
results were made available to the treating clinicians. Other investigations were 
performed as indicated. Clinical follow-up continued to 6-weeks post-procedure. 
A cardiologist blinded to the study data compared the paired pre- and 
postoperative ECGs at the end of the study. Endpoints were non-fatal myocardial 
infarction (MI) and cardiac death. MI was defined by the presence of a typical 
rise and fall of plasma cardiac troponin I with either ischaemic symptoms +/- 
development of Q-waves on ECG +/- ischaemic changes noted on ECG +/- 
coronary artery intervention. Cardiac death was determined by review of all 
postoperative data by two cardiologists blinded to preoperative cTnI levels. 
3.2.4 Statistical Analysis 
Statistical analysis was conducted using SPSS® statistical software package. All 
analyses were performed between groups using a two tailed Fisher‘s exact test. 
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3.3 Results 
3.3.1 Population 
During the 2 year study, a total of 222 patients underwent an elective major 
vascular procedure of which 213 (144 male, 69 female) were included in the 
study. Nine patients were excluded (5 unable to give informed consent, 3 
unstable cardiac disease and 1 missing preoperative cTnI sample). Seventy four 
(35%) patients underwent a major lower extremity amputation, 72 (34%) 
abdominal aortic surgery, 37 (17%) infrainguinal bypass and 30 (14%) extra-
anatomical bypass. Co-morbidity included 84 (39%) patients with ischaemic heart 
disease, 44 (21%) with congestive cardiac failure, 23 (11%) with renal impairment 
and 60 (28%) with diabetes mellitus. Sixty (28%) patients were prescribed a 
preoperative statin and 28 (13%) a beta-blocker. All patients were on anti-
platelet therapy. 
Eleven (5.2%) of the 213 patients had an asymptomatic raised preoperative cTnI 
(median cTnI 0.22 ng/ml [0.08-14.8] ng/ml). All 11 patients had significant co-
morbidity: 5 patients had known ischaemic heart disease, 5 had cerebrovascular 
disease, 4 had diabetes mellitus and 3 had renal impairment. Eight out of the 11 
patients had multiple risk factors [Table 3.1]. 
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Table 3.1 Co-morbidity and outcome. 
 
 
Case  cTnI 
(ng/ml) 
Creatinine 
(μmol/l) 
Cholesterol 
(mmol/l) 
IHD  Diabetes  COPD  CVD  βblocker  Statin  Urgent (U) 
Elective (E) 
Eagle  RCRI  Outcome 
AFB  0.08  118  2.7              E  2  3  Cardiac Death 
BKA  0.8  126  3.6              U  3  4  Cardiac Death 
BKA  0.3  172  2.7              U  4  3  Cardiac Death 
BKA  14.8  50  5.4              U  0  1  Non-fatal MI 
BKA  0.11  70  2.7              U  1  2  Death (sepsis) 
BKA  0.4  189  1.6              U  2  2  Death (sepsis) 
AAA  0.12  120  3.7              U  1  0  ARF 
AAA  0.64  95  3.4              E  3  2  - 
TA  0.22  483  2.2              U  1  2  - 
AKA  0.09  68  4.6              E  2  2  - 
 
 
AFB - axillary-femoral bypass, BKA – below knee amputation, AKA – above knee amputation, AAA – abdominal aortic aneurysm repair, TA – toe amputation, IHD – 
ischaemic heart disease, COPD – chronic obstructive pulmonary disease, ARF – acute renal failure, RCRI – Revised Cardiac Risk Index, Eagle – cumulative score, 
scoring 1 for each of: >70 yrs, diabetes mellitus, Angina, Q-waves on ECG, vent. Arrhythmias.
119  
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Pre-existing cerebrovascular disease was significantly more prevalent in patients 
shown to have an elevated preoperative cTnI (p=0.023). Although none of the 
other risk factors were statistically significantly associated with raised 
preoperative cTnI, the proportions of elevated asymptomatic cTnI patients with 
renal impairment (24% vs 12%), who were prescribed beta-blockers (27% vs 12%) 
or had an urgent procedure (36% vs 13%) were more than double compared to 
the normal cTnI patients [Table 3.2].  
3.3.2 Outcome 
Patients with an asymptomatic elevated preoperative cTnI were more likely to 
be undergoing major lower extremity amputation (7/11 [64%]), with nearly 
double the proportion compared to the normal cTnI group (67/202 [33%]), 
although this difference was not significant (p=0.262). Other procedures 
included 2 for open abdominal aortic aneurysm (AAA) repair and an axillary-
femoral bypass. The management of patients with an elevated cTnI varied with 
initially 8 of the 11 patients having no change in their routine perioperative 
course. As a consequence of the poor outcome in those with preoperative 
elevated cTnI, noted early in the study period, preoperative cTnI levels were 
subsequently made available to both anaesthetist and surgeon. Of the remaining 
patients with elevated preoperative cTnI one was started on a perioperative 
beta-blocker, and one of the lower extremity amputations was delayed to 
remeasure cTnI and was taken to theatre uneventfully with a persistently 
elevated cTnI. One final patient scheduled to undergo an aorto-bifemoral bypass 
was delayed for cardiac investigation and subsequently underwent triple 
coronary artery bypass grafting. This patient consequently had an uncomplicated 
aorto-bifemoral graft at a later date with a normal preoperative cTnI.  
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Table 3.2. Preoperative risk factors and outcome by cTnI. 
 
Risk Factor    n           PreOperative cTnI 
 
              <0.02ng/ml     ≥0.02ng/ml    p 
 
Sex (male)    144      135               9    0.64 
            (67%)              (73%)  
   
IHD      84      79               5    0.76 
            (40%)              (45%) 
   
DM      60      56              4    0.52 
            (28%)              (36%) 
   
CVD      29      24              5    0.023 
            (12%)              (45%) 
   
COPD      44      42              2    1.0 
            (21%)              (18%) 
   
Renal Impairment  23      20              3    0.12 
            (10%)              (27%) 
   
Urgent Procedure  30      26              4    0.079 
            (13%)              (36%) 
   
Beta-Blocker   28      25      3    0.18 
            (12%)      (27%) 
   
Statin     60      55      5    0.33 
            (27%)      (45%) 
   
Total      213      202              11        
 
MACE      31      27      4             0.087 
            (13%)      (40%) 
   
Cardiac death  15      12      3    0.044 
            (6%)      (30%) 
   
Mortality    23      18      5    0.0089 
            (9%)      (50%) 
 
IHD – ischaemic heart disease, DM – diabetes mellitus, CVD – cerebrovascular disease, COPD – 
chronic obstructive pulmonary disease, MACE – major adverse cardiac event. 
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The incidence of MACE in the 10 patients that proceeded to theatre with 
preoperative asymptomatic elevated cTnI was three times more common (4/10 
(40%) vs 27/202 (13%), p=0.087), although this was not statistically significant. 
Of these 10 patients, 4 suffered a postoperative major adverse cardiac event: 3 
cardiac deaths (30%) and 1 non-fatal MI (10%). There were a total of 5 deaths 
(50%), the 2 further deaths occurring secondary to sepsis. The number of 
postoperative MACE in the ‗normal‘ cTnI group was 27 (13%) with 12 cardiac 
deaths (6%) and 15 non-fatal MIs (7%).  There was a total of 18 deaths (9%) in the 
‗normal‘ cTnI group, with the 6 additional deaths due to sepsis (3), respiratory 
failure (2) and multi-organ failure (1). There was a statistically significant 
difference in cardiac death (p=0.044) and in all cause mortality (p=0.0089) 
between those with a normal preoperative cTnI and those with an asymptomatic 
elevation of cTnI, with poorer outcome in the elevated cTnI group.  
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3.4 Discussion 
This is the first inclusive study to report the incidence of asymptomatic elevated 
preoperative cTnI and associated clinical outcome. Of the 213 patients included, 
5.2% had an asymptomatic elevated cTnI. These patients had a significantly 
higher risk of cardiac death and all cause mortality, with a trend towards an 
increased proportion of MACE, the pre-op assay thus predicting poor outcome. 
The outcome in these patients was poor with death in 5 of 10 patients. A total of 
4 patients had a major adverse cardiac event of which 3 were cardiac death. All 
of the patients who suffered an event were urgent cases most of whom required 
a lower extremity amputation for critical ischaemia. The preoperative EAGLE 
63 
and revised cardiac risk index (RCRI) 
64 scores for these patients was ≥2, 
predictive of poor cardiac outcome in patients undergoing vascular surgery.
64,267 
In addition asymptomatic elevations have been shown to identify patients who 
are at increased risk of first cardiac events and who have increased mortality 
over 10 years irrespective of surgery, with potential contributing subclinical 
silent myocardial damage.
268, 269 This implies that preoperative asymptomatic 
elevations in cTnI could identify a subset of patients from an already high risk 
population in whom the outcome is likely to be considerably worse.  
Evidence for a potential cause of the elevated cTnI was present in the majority 
of cases such as sepsis in the amputation patients,
268 and renal impairment 
269-271 
[Table 3.3].
272-274 Co-morbidity was common in patients who had elevated cTnI, 
with a significantly greater prevalence of cerebrovascular disease in the 
elevated cTnI group. There was a high prevalence of cardiac risk determinants 
such as diabetes mellitus, chronic kidney disease and ischaemic heart disease, 
known to be associated with asymptomatic elevations in cardiac troponin.
274  
The most concerning alternative reason for such an elevation, however, include 
acute coronary syndrome and pulmonary embolism. Further investigation may 
therefore be of benefit in such cases and could involve investigating the cause of 
their elevated cTnI and obtaining a cardiology opinion. A pragmatic approach 
may be to delay operative stress where feasible, and await a fall in levels, such 
as that seen in a cardiac event. This could allow further patient optimisation or 
cardiac intervention.
207 Where delay and intervention is not practicable, other  
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options could involve change in anaesthetic modality, closer perioperative 
monitoring or modification of surgical procedure. 
In summary, this case series presents 11 patients with an elevated preoperative 
cTnI associated with poor prognosis. Although the numbers are limited, this is 
the largest case series of patients with a preoperative elevation in cTnI in the 
literature. This study could be taken forward to commence routine preoperative 
cTnI measurement in those patients already at high postoperative cardiac risk to 
further help identify those that might benefit from delay or preoperative cardiac 
optimisation. 
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Table 3.3 Conditions associated with elevated cTnI levels. 
 
Myocardial related 
  Acute coronary syndrome 
  – Myocardial infarction and unstable angina 
  Cardiac contusion/amyloidosis 
  Cerebrovascular accident 
  Coronary vasospasm 
  Heart Failure 
  Cardioversion 
  Left ventricular hypertrophy 
  Myocarditis 
  Pericarditis 
  Pulmonary thromboembolism 
  Postoperative – cardiac surgery 
  Sepsis/Septic shock 
  Sub-arachnoid haemorrhage 
  Tachycardia 
  Ultraendurance exercise (marathon running) 
  Scorpion envenomation 
  Chemotherapy 
 
Other 
Assay cross-reactivity 
  Antibody cross-reactivity 
  Heterophile antibody 
  Rheumatoid factor positive 
Decreased clearance 
  Renal failure, acute or chronic 
Miscellaneous 
  Central nervous system disorder 
  Haematological malignancy 
  Labour/Delivery 
  Pre-eclampsia 
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Chapter 4 
 
B-type Natriuretic Peptide Predicts Immediate 
Outcome after Elective Open Abdominal Aortic 
Aneurysm Repair  
                   
127 
4.1 Introduction 
About 6000 men die annually from ruptured abdominal aortic aneurysm (AAA) in 
the UK. Prophylactic surgical repair is associated with a mortality of around 5-6% 
in the UK.
17,18 The UK Small Aneurysm Trial comparing surgical repair with 
observation of small AAA demonstrated a greater risk of death from surgery than 
from rupture in the observation group for the first three years of follow-up.
18 
The majority of postoperative deaths in the operative group were related to 
cardiac complications such as myocardial infarction. This level of postoperative 
cardiac mortality has led to the development of endovascular aneurysm repair 
(EVAR). Trials of EVAR have shown that whilst perioperative mortality is lower, 
there is a constant level of device failure that requires regular surveillance and 
reintervention with consequent increased cost.
21,22 Greater discrimination of 
those at risk of perioperative cardiac complications or with poorer short-term 
survival would improve management. Current strategies for cardiac–risk 
assessment are limited by subjectivity (clinical assessment) and poor sensitivity 
and specificity, whilst imaging or functional assessment is limited by availability 
and expense. 
B-type natriuretic peptide (BNP), originally identified in the porcine brain, is one 
of a family of cardiac peptides secreted almost exclusively by the myocardium in 
a non-specific response to wall stress.
82 It is a vasodilator and diuretic that 
serves to counter the renin-angiotensin system.
83 A correlation has been 
demonstrated between the concentration of BNP and cardiac risk factors in the 
general population in the West of Scotland, as well as with short-term 
survival.
275 It has proven predictive value in the clinical assessment of heart 
failure, ventricular dysfunction and risk stratification of patients with acute 
coronary syndrome.
101, 276 A number of studies have evaluated preoperative 
concentrations of BNP in non-cardiac surgery as a method of predicting cardiac 
complications and it is now clear that there is a direct association between 
increasing levels of BNP and risk of postoperative cardiac events in both the 
elective and emergency settings.
111-120 To date however there have been no 
adequately powered studies of preoperative BNP in the elective open AAA 
surgical population.  
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The aim of the present study is to determine if a single preoperative BNP value 
can predict cardiac complications and thus be of help in the selection of patients 
for elective open AAA repair. 
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4.2 Methods 
4.2.1 Study Population and Power 
A prospective, observational, multi-centre cohort study was performed involving 
the 3 major vascular units within Glasgow (Gartnavel General Hospital, Glasgow 
Royal Infirmary and the Southern General Hospital). Consecutive patients 
admitted for elective open AAA surgery between August 2005 and September 
2007 were prospectively included in the study with the aim of recruiting a 
minimum of 100 patients based on a power calculation using a cardiac event rate 
of 15-20% and a spread of BNP concentration with a cut-off level at 100 pg/ml 
(selected through BNPs diagnostic capability for heart failure with values above 
this threshold, and through its ability to predict MACE with higher BNP levels in 
non-cardiac surgery, as identified through previous derivation and validation 
studies in Glasgow).
101, 116 There was no uniform criterion with regards patient 
selection for surgery. Inclusion was based on consultant selection taking into 
account individual patient factors such as AAA size, co-morbidity, pre-operative 
testing (see section 1.5.7) and patient preference, and was in line with current 
practice at that time. All patients were approached the evening prior to surgery 
and informed consent obtained. Patients were excluded if their surgery required 
to be undertaken within less than 24 hours of admission on clinical grounds or if 
they were unable to give informed consent. 
4.2.2 Patients 
Basic demographic data and factors relating to the cardiac risk of surgery were 
gathered for each patient by a combination of history taking and case-note 
review. This included age, sex, smoking and medical history. Patients requiring 
either insulin or oral hypoglycaemics were considered diabetic. Angina, 
congestive cardiac failure, cerebrovascular disease and renal impairment were 
all recorded using the definitions in chapter 2. All patients‘ medication were 
noted with particular attention to the prescription of anti-platelets, statins, 
beta-blockers, diuretics, anti-hypertensives and anti-anginals. Preoperative 
pulse, blood pressure and oxygen saturation of haemoglobin by pulse oximetry 
on air were noted. Weight and height were recorded to allow calculation of BMI.   
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Chronic renal impairment (defined as preoperative serum creatinine of >130 
μmol/l or an eGFR of <60 ml/min) was recorded. Estimated Glomerular Filtration 
Rate (eGFR) was calculated from serum creatinine using the Modification of Diet 
in Renal Disease (MDRD) Study equation: 
GFR (mL/min/1.73 m
2) = 186 x (Serum creatinine)
-1.154 x (Age)
-0.203 x (0.742 if female) x 
(1.212 if African-American)  
This also allowed patient categorisation by Chronic Kidney Disease (CKD) stage 
as derived from the NICE, SIGN and Renal Association guidelines 2009.
258-260 
Factors required for the Revised Cardiac Risk Index (RCRI) were also recorded 
and each patient scored accordingly (see section 2.5.4). 
4.2.3 Preoperative Assessment 
Preoperative assessment and investigation was largely at the discretion of the 
surgical and anaesthetic teams; however preoperative venous blood samples 
were sent for all patients for urea and electrolytes, lipid screen, C-reactive 
protein, magnesium, full blood count and coagulation screen, as well as for 
serum cTnI which was measured using the ARCHITECT STAT Troponin I 
immunoassay (Abbot Diagnostics, assay range of 0.02-50 ng/ml, sensitivity of 
0.01 ng/ml). This ensured that patients with evidence of preoperative unstable 
cardiac disease were excluded from the study. All patients also underwent 
preoperative electrocardiography (ECG) performed by a cardiac technician. 
Information on further preoperative testing such as echocardiography, 
pulmonary function tests or coronary angiography was collected if available, but 
was not routinely performed on all patients. 
Preoperative BNP samples were collected and analysed in a standard fashion. An 
aliquot of venous blood was obtained from recumbent patients the evening 
before surgery. This was collected in chilled EDTA and aprotonin (Trasylol®, 
Bayer, Leverkusen, Germany; 50units/ml) and immediately centrifuged at 
3000rpm for 10 minutes. The serum was then removed from the tube using a 
pipette, placed in a plain tube and stored in a freezer at -22
oC. BNP 
concentrations were analysed in batches at the end of the study using a standard 
radioimmunoassay.  
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4.2.4 Intraoperative Details 
Intraoperative details were obtained from the anaesthetic records 
postoperatively. Hypotension was recorded if systolic blood pressure remained 
below 90 mmHg for a period of 5 minutes or more. Hypothermia was recorded if 
temperature dropped below 34.5 
oC. Aortic cross clamp times and length of 
operation were recorded. Blood loss was collected from intraoperative 
anaesthetic records. Immediate postoperative blood gasses were performed and 
analyses included hydrogen ion, bicarbonate and lactate concentrations, and 
base excess calculations where facilities allowed. 
4.2.5 Postoperative Testing 
Postoperative investigations were mainly conducted at the discretion of the 
treating physician or surgeon. In addition postoperative screening for cardiac 
events was performed. This consisted of daily clinical assessment, with serial 
ECGs and cTnI measurement on the morning of the 2nd and 5th postoperative 
days. If a patient was due to be discharged prior to the fifth postoperative day, 
tests were conducted on the morning of discharge instead of day 5. Patients 
were then reviewed at an outpatient clinic 6 to 8 weeks post-procedure. All 
ECGs were interpreted by two cardiologists of consultant or senior registrar 
grade who were blinded to all other data and patient details. Cardiology 
comments included the presence of any abnormal findings on the preoperative 
ECG and of ECG evidence of myocardial infarction. 
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4.2.6 Endpoints 
Endpoints for the study were non-fatal myocardial infarction (MI) and cardiac 
death. The definition of a nonfatal myocardial infarction used was that of the 
Joint European Society of Cardiology/American College of Cardiology Committee 
requiring a typical rise and gradual fall in cTnI with at least one of: ischaemic 
symptoms, development of pathological Q-waves on the ECG, ECG changes 
indicative of ischaemia (ST segment elevation or depression), or coronary artery 
intervention. Cardiac death was defined as death secondary to myocardial 
infarction, cardiogenic shock or intractable dysrhythmia, and was determined by 
a review of postoperative data by two cardiologists blinded to preoperative BNP 
levels. 
4.2.7 Statistical Analysis 
Statistical analysis was performed using the SPSS
® statistical software package 
(SPSS, Chicago, Illinois, USA). BNP values were reported as median (interquartile 
range) with continuous variables compared using Mann-Whitney U and Kruskall-
Wallis analyses. Fisher‘s exact test was used to analyse the differences between 
independent categorical data. Receiver operating characteristics (ROC) curves 
were plotted and the area under the curve estimated. Multivariate logistic 
regression analysis was performed to determine independent factors associated 
with cardiac complications. A p-value <0.05 was considered significant. 
4.2.8 Ethical Approval 
Local Research and Development, and Central Ethics Committee approval was 
obtained for the study. All patients were provided with an information sheet and 
signed a study consent form. This study involved no additional risk to patients 
other than extra blood tests and non-invasive cardiac imaging. 
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4.3 Results 
4.3.1 Patient Characteristics and BNP Levels 
During the study period 111 patients met the inclusion criteria and were invited 
to participate. Two refused consent and a further 3 were found to have elevated 
preoperative cTnI and were not included, resulting in 95% inclusion. None of the 
5 excluded patients developed a cardiac complication on follow-up. The median 
age of the remaining 106 patients was 73 (66-77) years. The median 
preoperative BNP level was 39.5 (18.8-97.2) pg/ml. Further baseline 
characteristics are shown in table 4.1. The male to female ratio shows a male 
predominance of 5:1. The majority of patients had smoked at some point in their 
life (85%). One fifth of patients had suffered a previous MI with similar numbers 
having suffered from cerebrovascular disease. In addition 13 patients (12%) 
suffered from congestive cardiac failure (CCF). As shown in table 4.2, despite 
the known pathology of a AAA only 59% patients were on an anti-platelet agent 
and 62% on a statin.  
The median AAA size was 6.4 (5.7-7.2) cm. The largest AAA repaired was 9.8cm 
with the smallest 4.7cm. Only 8 patients had an AAA under 5.5cm whilst a 
further 47 patients had an AAA measuring between 5.5 and 6cm. There was no 
significant difference in median BNP in those with a small AAA compared to 
those with an AAA >5.5cm (median BNP in those with small AAA 51 [14-179] vs 40 
[19-98] pg/ml, p=0.914).  
BNP levels were found to be significantly higher in those that had suffered a 
previous MI (median BNP 70 [31-175] vs 35 [17-85] pg/ml, p=0.031) or suffered 
angina (median BNP 63 [31-154] vs 35 [17-81], p=0.007). Levels were also 
significantly higher in those that had CCF (median BNP 184.5 [72-392] vs 35 [17-
60] pg/ml, p=0.002). Although not significant, BNP levels were noted to be lower 
in those patients prescribed a preoperative beta-blocker (median BNP 34 [14-61] 
vs 60 [25-129] pg/ml, p=0.050). BNP levels were also lower in those patients on 
antiplatelet, diuretic and anti-anginal therapy and those found to have a 
preoperative CRP<6, although in each case this was not significant.  
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Table 4.1 Clinical details and BNP levels in elective open AAA patients. 
 
 
          Patient    BNP level 
          Characteristic  (pg/ml)     
          n=106           p value 
 
Sex   
Male      88 (83%)    42 (26-74) 
    Female    18 (17%)    38.5 (17-99)    0.433 
  Angina     
    Present    25 (24%)    63 (31-154) 
    Absent    81 (76%)    35 (17-81)    0.007 
  Previous MI 
    Present    23 (22%)    70 (31-175)     
    Absent    83 (78%)    35 (17-85)    0.031 
Hypertension       
    Present    72 (67%)    14 (17-75) 
Absent    34 (33%)    39 (19-100)    0.915 
Hyperlipidaemia 
    Present    15 (14%)     30 (17-82) 
    Absent    91 (86%)    40 (19-98)    1.0 
Diabetes       
Present    9 (8%)     40 (18-93) 
Absent    97 (92%)    39 (32-105)    0.139 
  Current smoker     
Present    35 (33%)    37 (18-85) 
Absent    71 (67%)    56 (21-98)    0.713 
  Smoked ever      
Present    90 (85%)    62 (14-212) 
Absent    16 (15%)    40 (19-83)    0.093 
  CVD         
Present    22 (21%)    47 (21-100) 
Absent    84 (79%)    30 (12-55)    0.289 
  CCF 
    Present    13 (12%)    184.5 (72-392) 
    Absent    93 (88%)    35 (17-60)    0.002 
  COPD         
Present    25 (24%)    38 (17-100) 
Absent    81 (76%)    52 (23-75)    0.609 
  CRF         
Present    8 (8%)     39 (17-91) 
Absent    98 (92%)    50 (36-114)    0.634 
 
 
Patient characteristics by BNP reveal significant differences in BNP levels in patients that had 
angina, suffered a previous MI or had CCF (p=0.007, p=0.031 and p=0.002 respectively) when 
analysed using Mann-Whitney U test. MI – myocardial infarction, CVD – cerebrovascular disease, 
CCF – congestive cardiac failure, COPD – chronic obstructive pulmonary disease, CRF - chronic 
renal failure.  
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Table 4.2 Selected other patient details and BNP. 
 
          Patient    BNP level 
          Characteristic  (pg/ml)     
          n=106           p value 
 
  Anti-platelet      
Present    63 (59%)    35 (17-64) 
Absent    43 (41%)    52 (20-99)    0.151 
  Statin        
Present    66 (62%)    37 (14-85) 
Absent    40 (38%)    43 (22-98)    0.444 
  Beta-blocker      
Present    43 (41%)    34 (14-61) 
Absent    63 (59%)    60 (25-129)    0.050 
  Antianginal       
Present    23 (22%)    39 (17-98) 
Absent    83 (78%)    61 (22-85)    0.186 
  Diuretic 
    Present    35 (33%)    35 (17-73) 
    Absent    71 (67%)    44 (21-110)    0.213 
  RCRI 
    1      31 (29%)    32 (15-98)   
    2      35 (33%)    40 (22-73) 
    ≥3      40 (38%)    56 (23-100)    0.193 
  eGFR 
    >60      42 (40%)    35 (17-81) 
    ≥60      64 (60%)    55 (27-100)    0.461 
  CKD 
    1      9 (8%)     21 (11-108) 
    2      55 (52%)    35 (17-82) 
    3      40 (38%)    55 (26-100) 
    4      1 (1%)     545 
    5      1 (1%)     37      0.386 
  CRP 
    <6      62 (58%)    35 (15-60) 
    ≥6      44 (42%)    55 (20-100)    0.078 
 
   
 
Although not significant, BNP levels were lower in those on antiplatelets, antianginals, diuretics 
and in those with a preoperative CRP<6. BNP levels were also lower in those on preoperative 
beta-blockers, although this did not quite reach statistical significance with p=0.050. Analyses 
were determined using Mann-Whitney and Kruskall-Wallis for RCRI and CKD. RCRI – revised 
cardiac risk index, eGFR – estimated glomerular filtration rate, CKD – chronic kidney disease, CRP 
– C-reactive protein.  
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Renal failure by chronic kidney disease stage did not show variation in BNP 
levels. Two patients had an eGFR <30 ml/min, one of whom had a BNP of 37 
pg/ml and had an uncomplicated postoperative recovery, and the second patient 
had a BNP of 545pg/ml and suffered cardiac death.  As a further potential 
confounder body mass index was calculated in all. No patient was found to have 
a BMI of either <20 kg/m
2 or ≥35 kg/m
2. The median BMI was 28(24-31) kg/m
2.   
4.3.2 Primary Outcome and BNP  
Sixteen patients (15%) suffered MACE within 30 days of their open AAA repair, of 
whom 5 suffered a cardiac death and 11 had a non-fatal MI. Of those suffering a 
non-fatal MI, 3 were of the non-ST elevation type, with 3 of the remaining 8 
patients suffering asymptomatic ST-elevation MIs. As detailed in Table 4.3, 
patients with preoperative CCF were significantly more likely to suffer MACE 
(p=0.026). Patients were more likely to suffer MACE if they had preoperative 
hypertension, diabetes mellitus or increasing grades of CKD, although this was 
not statistically significant. The median estimated GFR was 54 (49-75) ml/min in 
those with MACE compared to 63 (51-77) ml/min in those without (p=0.283). As 
detailed in table 4.4 no preoperative cardiac medication appeared to be 
protective. Although not statistically significant, there was a greater proportion 
of patients suffering MACE in those taking a preoperative beta-blocker 
(p=0.180), and in longer operating times (median time 200 [183-240] vs 180 [150-
210] mins; p=0.055) [Table 4.4]. 
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Table 4.3 Case mix and Major Adverse Cardiac Events (MACE). 
 
Total Cohort   MACE       
          (n=106)    (%)      p value 
 
Sex   
Male      88 (83%)    13/88 (15%) 
    Female    18 (17%)    3/18 (17%)    0.733   
  Angina 
    Present    25 (24%)    4/25 (16%) 
    Absent    81 (76%)    12/81 (15%)    1.0 
Previous MI 
    Present    23 (22%)    5/23 (22%) 
    Absent    83 (78%)    11/83 (13%)    0.332 
Hypertension       
    Present    72 (67%)    14/72 (19%) 
Absent    34 (33%)    2/34 (6%)    0.085 
Hyperlipidaemia 
    Present    15 (14%)     3/15 (20%) 
    Absent    91 (86%)    13/91 (13%)    0.416 
Diabetes       
Present    9 (8%)     3/9 (33%) 
Absent    97 (92%)    13/97 (13%)    0.134 
Current smoker     
Present    35 (33%)    5/35 (14%) 
Absent    71 (67%)    11/71 (15%)    1.0 
Smoked ever      
Present    90 (85%)    12/90 (13%) 
Absent    16 (15%)    4/16 (25%)    0.258 
CVD         
Present    22 (21%)    2/22 (9%) 
Absent    84 (79%)    14/84 (17%)    0.515 
CCF 
    Present    13 (12%)    5/13 (38%) 
    Absent    93 (88%)    11/86 (12%)    0.026 
CRF         
Present    8 (8%)     0/8 (0%) 
Absent    98 (92%)    16/98 (16%)    0.604 
CKD 
    1      9 (8%)     1/9 (11%) 
    2      55 (52%)    6/55 (11%) 
    3      40 (38%)    8/40 (20%) 
    4      1 (1%)     1/1 (100%) 
    5      1 (1%)     0/1 (0%)    0.184 
eGFR 
    <60      42 (40%)    9/42 (21%) 
    ≥60      64 (60%)    7/64 (11%)    0.294 
The likelihood of MACE was significantly higher in those with CCF (p=0.026). MACE was also more 
likely in the presence of preoperative hypertension, diabetes mellitus and increasing CKD, 
although this was not significant. Analyses were determined using Fisher‘s Exact Test.  MI – 
myocardial infarction, CVD – cerebrovascular disease, CCF – congestive cardiac failure, CKD – 
chronic kidney disease, eGFR – estimated glomerular filtration rate.   
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Table 4.4 Other selected characteristics and Major Adverse Cardiac Events (MACE). 
 
          Total Cohort   MACE       
          (n=106)    (%)      p value 
 
Anti-platelet      
Present    63 (59%)    11/63 (17%) 
Absent    43 (41%)    5/43 (12%)    0.582 
Statin        
Present    66 (62%)    8/66 (12%) 
Absent    40 (38%)    8/40 (20%)    0.280 
Beta-blocker      
Present    43 (41%)    9/43 (21%)       
Absent    63 (59%)    7/63 (11%)    0.180 
Antianginal       
Present    23 (22%)    3/23 (13%) 
Absent    83 (78%)    13/83 (16%)    1.0 
Diuretic 
    Present    35 (33%)    7/35 (20%) 
    Absent    71 (67%)    9/71 (13%)    0.390 
RCRI 
    1      31 (29%)    6/31 (19%)   
    2      35 (33%)    4/35 (11%) 
    ≥3      40 (38%)    6/40 (15%)    0.943 
Hypotension      
    Present    48 (45%)    7/48 (15%) 
    Absent    58 (55%)    9/58 (16%)    1.0 
Hypothermia 
    Present    4 (4%)     1/4 (25%)       
    Absent    102 (96%)    15/102(15%)   0.486 
Blood Loss 
    750ml    39 (37%)    6/39 (15%) 
    >750ml    67 (63%)    10/67 (15%)    0.512 
Cross Clamp time 
    60 mins    71 (67%)    9/71 (13%) 
    >60 mins    35 (33%)    7/35 (20%)    0.430 
Operating times 
     3 hours    58 (55%)    4/58 (7%) 
    > 3 hours    48 (45%)    12/48 (25%)    0.098 
CRP 
    <6      62 (58%)    8/62 (13%) 
    ≥6      44 (42%)    8/44 (18%)    0.121 
 
Although not significant, shorter operating and cross clamp times made MACE less likely. The use 
of a preoperative beta-blocker did not appear to protect against MACE and infact there was a 
suggestion that MACE was more likely with its use. Analyses were determined using Fisher‘s 
Exact Test. RCRI – revised cardiac risk index, CRP – C-reactive protein. 
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The median preoperative BNP concentration was significantly higher in patients 
who had MACE than in those who did not (median BNP 206 [118-454] vs 35 [17-
61] pg/ml, p=0.001) [Figure 4.1]. The BNP in patients with cardiac death alone 
was significantly higher than in those that did not (median BNP 496 [280-881] vs 
38 [18-84] pg/ml, p=0.043) [Figure 4.2]. To allow logistic regression modelling, 
BNP was found to best fit a base-e logarithmic transformation [Figure 4.3]. 
Logistic regression analysis, using eLogBNP as the covariate revealed a highly 
significant relationship between eLogBNP and MACE (p<0.001) with an odds ratio 
of 11.24 (95% CI 3.61-34.95). In a logistic regression model adjusting for 
hypertension, CCF, diabetes mellitus and operating time, BNP remained a highly 
significant predictor of MACE (p<0.001) [Table 4.5a]. The odds ratio for eLogBNP 
in this multivariate analysis was very large with a wide confidence interval (OR 
155.03, 95% CI 6.46-3717.62; p=0.002), partly as a function of size of the ratio, 
but also due to the small size of the dataset. Further, the use of factors which 
are highly correlated with one and other (eLogBNP and CCF) has resulted in 
collinearity with a very low odds ratio for CCF. Logistic regression adjusting for 
CCF and operating time alone still revealed a large odds ratio for eLogBNP with 
again a wide confidence interval (OR 81.94, 95% CI 7.07-949.16; p<0.001) [Table 
4.5b]. It should, however, be borne in mind that the sample size here is 
generally considered too small for a multivariate analysis. A univariate analysis is 
also significant for eLogBNP [Table 4.5c], and although the confidence intervals 
for the odds ratio are still wide, the lower end of it is large enough to show that 
BNP values are an important predictor of MACE. 
4.3.3 ROC Curve Analyses and BNP 
To find the BNP concentration that would best predict MACE, a receiver-operator 
characteristic (ROC) curve analysis was performed [Figure 4.4]. This revealed a 
cut-off value of 99.5 pg/ml and an area under the curve (AUC) of 0.927. With 
this cut-off value, sensitivity was 88% and specificity 89%. The positive 
predictive value (PPV) was 61% and the negative predictive value (NPV) 98%. 
ROC analysis was also used to predict a BNP concentration that would predict 
cardiac death [Figure 4.5]. A cut-off value of 448 pg/ml was identified with an 
AUC of 0.963. Sensitivity was 80% and specificity 100%. The PPV was 100% and 
NPV 99%.   
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Figure 4.1 BNP concentration and Major Adverse Cardiac Event (MACE). 
 
 
 
 
     
 
The median preoperative BNP concentration was significantly higher in those that had MACE than 
those that did not (median BNP 206 [118-454] vs 35 [17-61] pg/ml, p=0.001) as analysed by 
Mann-Whitney U test. The dots represent outliers. The asterisks/stars represent extreme outliers 
where the level marked is >3 times the height of the boxes. N is number of patients. 
 
 
 
 
 
 
N=          90              16  
                   
141 
Figure 4.2 BNP concentration and cardiac death. 
 
 
 
 
 
 
The median BNP was significantly higher in those that died of a cardiac origin compared to those 
that did not (median BNP 496 [280-881] vs 38 [18-84] pg/ml, p=0.043) as analysed by Mann-
Whitney U test. The dots represent outliers. The asterisks/stars represent extreme outliers 
where the level marked is >3 times the height of the boxes. N is number of patients. 
 
 
 
 
 
 
N=          101              5  
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Figure 4.3 Histogram of eLogBNP. 
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Table 4.5 Logistic regression model of eLogBNP and MACE. 
 
a. Correcting for hypertension, diabetes mellitus (DM), congestive cardiac failure (CCF), 
length of operation (Op-time) and beta-blocker use – multivariate analysis. 
 
 
Variable  Coef  SE Coef  Significance  Odds Ratio  95% CI 
Lower 
95% CI 
Upper 
Constant  -32.877  10.649  0.002       
eLogBNP  5.043  1.621  0.002  155.034  6.463  3717.626 
Hypertension  1.712  1.368  0.211  5.542  0.380  80.898 
DM  -0.083  1.534  0.957  0.921  0.046  18.603 
CCF  -4.525  2.248  0.004  0.011  0.000  0.888 
Op-time  0.034  0.016  0.030  1.035  1.003  1.067 
Beta-Blocker  -0.162  1.048  0.878  0.851  0.109  6.637 
 
 
b. Correcting for CCF and length of operation alone – multivariate analysis. 
 
Variable  Coef  SE Coef  Significance  Odds Ratio  95% CI 
Lower 
95% CI 
Upper 
eLogBNP  4.406  1.250  0.000  81.944  7.075  949.161 
CCF  -3.477  1.632  0.033  0.031  0.001  0.758 
Operating time  0.031  0.011  0.007  1.032  1.009  1.054 
 
c. Univariate analysis for eLogBNP, CCF and length of operation. 
 
Variable  Coef  SE Coef  Significance  Odds Ratio  95% CI 
Lower 
95% CI 
Upper 
eLogBNP  3.260  0.841  0.000  26.045  5.009  135.424 
CCF  1.397  1.560  0.026  1.601  1.104  1.934 
Operating time  0.020  0.009  0.089  1.021  1.003  1.039 
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Figure 4.4 ROC curve: BNP concentration and Major Adverse Cardiac Event (MACE). 
 
 
 
ROC analysis revealed a cut-off value of 99.5 pg/ml and an area under the curve (AUC) of 0.927, 
with a sensitivity of 88% and specificity 89% (SE 0.039, 95% CI 0.850-1.004; p<0.001).  
 
 
 
 
 
 
cut-off  
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Figure 4.5 ROC curve: BNP concentration and Cardiac Death. 
 
 
 
 
ROC analysis revealed a cut-off value of 448 pg/ml with an AUC of 0.963. Sensitivity was 80% 
with a specificity of 100% (SE 0.034, 95% CI 0.896-1.031; p<0.001). 
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4.3.4 Best Performing BNP for Prediction of MACE 
Using a threshold level of 99.5 pg/ml as identified from ROC curve analyses, BNP 
predicted outcome independently of almost all preoperative risk factors or 
intraoperative factors. Only in the presence of a previous MI, diabetes mellitus 
or current use of a diuretic did this BNP level not predict MACE [Table 4.6]. 
There were no episodes of MACE in the presence of a BNP <99.5 pg/ml with both 
a CRP <6 and eGFR ≥60. 
4.3.5 Secondary Outcome Measures and BNP 
The 30-day all-cause postoperative mortality was 8.5% (9 deaths), of which 7 
deaths occurred prior to hospital discharge (6.6% in-hospital mortality). As 
previously described 5 of these deaths were cardiac in origin. Others were: 
1.  Respiratory failure secondary to pneumonia on background of COPD. 
2.  Pulmonary thromboembolism. 
3.  Postoperative major haemorrhage secondary to operative complications 
resulting in multiorgan failure. 
4.  Acute mesenteric ischaemia.  
The median preoperative BNP concentration was significantly higher in those 
that died than in those that survived the immediate postoperative period 
(median BNP 100 [84-521] vs 35 [17-81]  pg/ml, p=0.028) [Figure 4.6]. ROC 
analysis revealed a cut-off of 93 pg/ml to predict 30-day all-cause mortality 
[Figure 4.7]. The AUC was 0.860 with associated sensitivity of 78% and specificity 
of 79%. Although the PPV was 30% the NPV for this value was 99%. In univariate 
analysis CCF was also a significant predictor of postoperative all-cause mortality 
(p=0.042), whereas in multivariate analysis BNP was the only significant 
predictor of 30-day all-cause mortality (p<0.001). However, the very low number 
of events (n=9) means even univariate analysis is not appropriate. 
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Postoperative elevations of cTnI were observed in 24 patients (23%). Of these, 8 
patients (33%) had neither chest pain nor ECG changes. The median preoperative 
BNP concentration was significantly higher in those that had postoperative 
elevations of serum cTnI compared to those that did not (median BNP 75 [34-
200] vs 35 [17-75], p=0.002) [Figure 4.8]. ROC analysis was less convincing with a 
cut-off of 54 pg/ml and an AUC of 0.704, and associated sensitivity of 64% and 
specificity 63% [Figure 4.9]. In univariate analysis both operative time and the 
presence of CCF were significant predictors of postoperative elevations of cTnI 
(p=0.007 and p=0.023 respectively). This was also true in multivariate analyses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                   
148 
Table 4.6 MACE by a BNP cut-off of 99.5 pg/ml and by risk factors. 
 
 
 
  Patient      BNP level    MACE    p-value 
  Characteristic    (pg/ml)       
 
Previous MI 
    Present    <99.5      1/14  (7%) 
          ≥99.5      4/9  (44%) 
                    0.056 
    Absent    <99.5      1/68  (1%) 
          ≥99.5      10/15 (67%) 
                    <0.001 
Diabetes       
Present    <99.5      1/6  (17%) 
      ≥99.5      2/3  (67%) 
                0.226 
Absent    <99.5      1/76  (1%) 
          ≥99.5      12/21 (57%) 
                    <0.001 
Diuretic 
    Present    <99.5      1/18  (6%) 
          ≥99.5      2/5  (40%) 
                    0.107 
Absent    <99.5      1/64  (2%) 
          ≥99.5      12/19 (63%) 
                    <0.001 
CRP 
    <6      <99.5      0/49  (0%) 
          ≥99.5      8/16  (50%) 
                    <0.001 
≥6      <99.5      2/33  (6%) 
      ≥99.5      6/8  (75%) 
                    0.002 
eGFR 
    ≥60      <99.5      0/51  (0%) 
          ≥99.5      7/13  (54%) 
                    <0.001 
<60      <99.5      2/31  (6%) 
          ≥99.5      7/11  (64%) 
                    0.004 
 
 
 
Only in the presence of a previous MI, diabetes mellitus or current use of a diuretic BNP did not 
predict MACE. There were no episodes of MACE in the presence of a BNP <99.5 pg/ml with both a 
CRP <6 and eGFR ≥60. Analyses were performed using Fisher‘s Exact Test. 
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Figure 4.6 BNP concentration and all-cause mortality. 
 
 
 
 
 
The median preoperative BNP concentration was significantly higher in those that died compared 
to those that survived the immediate perioperative period (median BNP 100 [84-521] vs 35 [17-
81] pg/ml, p=0.028) when analysed with Mann-Whitney U test. The dots represent outliers. The 
asterisks/stars represent extreme outliers where the level marked is >3 times the height of the 
boxes. N is number of patients. 
 
 
 
 
 
N=          97              9  
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Figure 4.7 ROC curve: BNP concentration and all-cause mortality. 
 
 
 
ROC analysis revealed a cut-off of 93 pg/ml to predict all-cause mortality with an AUC of 0.860 
and associated sensitivity of 78% and specificity of 79% (SE 0.052, 95% CI 0.757-0.962; p<0.001). 
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Figure 4.8 BNP concentration and elevated cTnI. 
 
 
 
 
The median preoperative BNP concentration was significantly higher in those that had 
postoperative elevations of serum cTnI compared to those that did not (median BNP 75 [34-200] 
vs 35 [17-75] pg/ml, p=0.002) when tested using Mann-Whitney U analyses. The dots represent 
outliers. The asterisks/stars represent extreme outliers where the level marked is >3 times the 
height of the boxes. N is number of patients. 
 
 
 
 
 
N=          82              24  
                   
152 
Figure 4.9 ROC curve: BNP concentration and elevations in cTnI. 
 
 
 
ROC analysis revealed a cut-off of 54 pg/ml with an AUC of 0.704, and associated sensitivity of 
64% and specificity 63% (SE 0.057, 95% CI 0.591-0.816; p=0.002). 
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4.3.6 Preoperative Echocardiography 
Preoperative transthoracic echocardiography was performed in 75 patients 
(71%). This showed moderate left ventricular (LV) dysfunction in 7, mild LV 
dysfunction in 8 and normal function in 60. No patient was noted to have severe 
LV dysfunction in the preoperative period. Median BNP levels correlated with 
recorded LV ejection fraction [Table 4.7]. MACE however did not correlate well 
with the presence of LV dysfunction or with grade of dysfunction according to 
transthoracic echocardiography.  
 
 
 
 
Table 4.7. Left ventricular function, BNP levels and Major Adverse Cardiac Events (MACE). 
 
 
Patients  BNP    MACE 
          (n=75)   (pg/ml)   
   
 
LV Function 
    Normal    60 (80%)  39 (20-89)  11/60   (18%) 
    Mild dysfunction  8 (11%)  42 (13-150)  0/8  (0%) 
    Mod dysfunction  7 (9%)   79 (10-496)  2/7  (28%)   
                     
                  p=0.305 
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4.3.7 Immediate Postoperative Arterial Blood Gas and Lactate 
Concentrations 
Immediate postoperative arterial blood gas (ABG) analysis was performed in 66 
cases. The median hydrogen ion concentration was 44.5 (40.9-48.7) nmol/l. Of 
the 66 patients who had available ABG analyses, 7 suffered MACE. Immediate 
postoperative hydrogen ion concentration did not predict MACE (median 
concentration in MACE of 45.1 [42.7-58] nmol/l vs 44.6 [40.6-48.5] nmol/l 
without, p=0.808) or all-cause mortality (median concentration in those that 
died 47.3 [43.9-61.0] nmol/l vs 42.3 [40.2 -48.2] nmol/l in those that survived, 
p=0.207). Base excess calculations had similarly poor predictive capabilities for 
both MACE and all-cause mortality. 
Despite postoperative arterial blood gas analysis being performed in 66 patients, 
serum lactate concentrations were only available in 19 of these cases. Median 
lactate concentration was 1.7 (0.8-2.3) mmol/l. Two patients in this subgroup 
suffered MACE. There were no cardiac deaths in this group. Immediate 
postoperative serum lactate levels did not predict either MACE or all cause 
mortality in the 3 patients that died of a non-cardiac cause (p=0.387 and 
p=0.781 respectively).  
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4.4 Discussion 
The prospective data from the elective open AAA cohort demonstrates that 
preoperative BNP levels predict both non-fatal MI and cardiac death in the 30-
day postoperative period. Using a cut-off point of 99.5 pg/ml, similar to that 
seen in the diagnosis of heart failure
277, there is a 7-fold increased risk of MACE. 
With a sensitivity of 88% and specificity of 89%, preoperative BNP appears to 
outperform currently available non-invasive testing and supersedes the current 
gold standard of either Dipyridamole Stress Echocardiography (sensitivity ~ 74%, 
specificity ~ 86%) or Dobutamine Stress Echocardiography (sensitivity ~ 85%, 
specificity ~ 70%) as the objective cardiac risk stratification tool of choice.
72  
Around 78% (83 of 106) of patients had a serum BNP level <99.5 pg/ml. Of those 
only 2 suffered MACE, both of which were non-fatal MIs. No cardiac deaths 
occurred with a serum BNP level below this cut-off. There were 3 deaths from 
other causes which were pulmonary thromboembolism, major postoperative 
haemorrhage and acute mesenteric ischaemia.  
At present in the West of Scotland, there is no single cardiac risk stratification 
method for assessing elective open AAA patients and often the decision to 
operate or not is based on a balance of subjective and objective markers. This 
study however revealed that many current methods of identifying patients at 
risk of MACE are not accurate. The RCRI did not predict MACE; indeed the 
highest proportion of MACE was seen in the lowest risk group according to this 
index. The only other risk factor that significantly predicted MACE was CCF.  
However this is often inaccurately recorded or subjectively identified. Decisions 
based on this factor alone are therefore imprecise. LV function as measured by 
ejection fraction on preoperative echocardiography was also poor at identifying 
those at risk of MACE. As LV function is a marker of heart failure and therefore 
impacts on the serum level of BNP 
101 it is not clear why this did not predict 
MACE, although BNP levels did correlate with the degree of heart failure.   
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Using an upper limit of 99.5 pg/ml for BNP in combination with both a CRP<6 
mg/l and eGFR ≥60 ml/min, it is possible to identify a group of patients who are 
very likely to have an uncomplicated perioperative period given that in these 
patients no events were identified. Conversely it appears that identifying 
patients at high risk of cardiac death can be done by BNP level alone where this 
is found to exceed 448 pg/ml, with an AUC of 0.963 and combined sensitivity of 
80% and specificity of 100%. Given the 100% PPV for cardiac death with a BNP 
over this cut-off, it would seem delaying a prophylactic procedure would be 
preferable to risking the considerable risk of cardiac death. Indeed one could 
argue that delaying or cancelling AAA repair in this group would be preferable to 
facing the apparent near-certainty of cardiac death. 
The predictive value of BNP for 30-day all-cause mortality was unexpectedly 
high. Despite the fact that only 5 of the 9 deaths were cardiac in origin ROC 
curve analysis revealed a cut-off value of 93 pg/ml with a NPV of 99%. Given the 
significant perioperative mortality seen in the Small Aneurysm Trial
18 BNP may 
help to identify a group of patients who would yet benefit from having their 
small aneurysms repaired. This is further supported by the fact that in open AAA 
surgery cardiac death is the leading cause of death.
18, 19 Given the ability of BNP 
to predict cardiac events in this particular scenario, further identification of the 
candidates most at risk should be possible. The full conclusions regarding 
postoperative all-cause mortality are in long term follow-up which is explored in 
more detail in Chapter 5.  
As described in chapter 3, numerous studies have demonstrated that 
postoperative elevations in cTnI, whether as a defined cardiac event or 
asymptomatic and without evidence of a cardiac event, are a poor prognostic 
marker and are associated with increased short-, intermediate- and long-term 
mortality.
140-143, 263, 264 This chapter demonstrates that BNP has the ability to 
select patients who had postoperative elevations of cTnI. The ROC curve analysis 
was less convincing with poor sensitivity and specificity. Of interest was that 
longer operating time was a significant factor in postoperative elevation in cTnI, 
possibly due to the excessive cardiac strain as a result of prolonged surgical 
stress causing myocardial ischaemia.
 Prolonged operating times were also more 
likely in those patients who suffered MACE, although this was not statistically 
significant.  
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In most patients who have very high serum BNP levels it would seem advisable to 
cancel their elective open AAA surgery, especially if the aneurysm is small and 
the risk of repair is deemed to outweigh the risk of observation. If the AAA is 
large and the risk of rupture considerable, other options might include 
consideration for EVAR or preoperative medical cardiac optimisation. A few 
patients with a high BNP may be deemed not suitable for EVAR. In those cases 
the decision to proceed with elective open surgery would be difficult and 
medical optimisation would be the only avenue currently left open. As discussed 
in the introduction, the use of statins has been explored; however in this study, 
although the proportion of patients who suffered MACE was lower in those on 
statins, this did not reach statistical significance. Preoperative beta-blockade 
has also been widely researched. Papers differ in their conclusions with many 
suggesting a benefit from beta-blockade and many not identifying any difference 
in outcome. In this study there were a greater proportion of events in those on 
beta-blockade therapy. The reason for this is unclear but may be due to 
collation of data, as while the use of preoperative beta-blockade was noted, 
whether it was given on the days (or indeed hours) directly before surgery was 
not, and no consideration was given to the type of beta-blockade. Some recent 
research has suggested that epidural anaesthesia in addition to general 
anaesthesia can reduce BNP levels and potentially cardiac risk.
278  
There is also evidence that aggressive medical management, in a similar manner 
to treating heart failure, can reduce a patients BNP level
105, 279, but whether this 
would then change perioperative outcome is unknown. There is no evidence to 
date looking at the impact of preoperative lowering of BNP on perioperative 
outcome in the elective AAA population.  
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There are some limitations in the present study. The small sample size often 
made statistical analysis difficult with only the most striking differences 
reaching statistical significance. This was also seen in ROC analysis where, with 
small numbers, the results at times appear unsatisfactory, for example in ROC 
analysis with cTnI elevations. However, a larger cohort study for this type of 
surgery would require at least region-wide if not national data collection to 
make the results meaningful. The other concern lies with the applicability of 
these results with populations outside Glasgow. This is clearly a limitation of this 
and other studies that look into perioperative BNP and this particular issue is 
discussed further in the final chapter. 
This chapter describes a suitably powered, prospective cohort study that takes 
into account confounding biochemical issues, where BNP has been shown to hold 
important prognostic information. It outperforms all previous cardiac risk 
stratification tools and is both simple and objective. The use of this blood test in 
an outpatient clinic could prove vital in helping make the correct decision 
regarding the need for elective open AAA repair. 
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Chapter 5 
 
B-type Natriuretic Peptide Predicts Intermediate 
and Long-term Outcome after Elective Open 
Abdominal Aortic Aneurysm Repair 
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5.1 Introduction 
The decision to proceed to elective open repair of an AAA requires careful 
assessment of factors that influence rupture risk, operative mortality and life 
expectancy. In the case of asymptomatic AAAs management depends on the size 
of the aneurysm, as no medical therapy has been shown to reduce the risk of 
aneurysmal rupture.
17,280  Based upon the best available current evidence, 5.5cm 
is the best threshold for consideration of repair in the ―average‖ patient, as it is 
generally accepted that the risk of rupture outweighs the operative risk at 
aneurysmal diameters above this. However, subsets of younger, low-risk patients 
or aneurysms at higher rupture risk may be identified in whom repair at smaller 
sizes could be justified.
281  Despite this statement, published by the vascular 
surgical societies of America in 2003, the management of small AAAs remain a 
grey area in clinical practice. 
To address the issue of management of the small (4-5.5cm) asymptomatic AAA a 
number of randomised controlled trials have been published.
20,282-285 The two 
studies that come closest to answering this question are the UK Small Aneurysm 
Trial Participants (UKSAT) and the Aneurysm Detection and Management study 
screening programme (ADAM). These large and well-conducted studies 
randomised patients with small asymptomatic AAAs to either immediate surgery 
or ultrasound surveillance and have published results progressively in journals 
over the last 15 years. In both studies the 30-day operative mortality in the 
immediate surgery group (5.8% UKSAT [Figure 5.1] and 2.1% ADAM) led to an 
early disadvantage in terms of survival.
18,286 Long-term mortality results however 
revealed that there was no survival advantage in either group (surgery vs 
surveillance; 63.9% vs 67.3% UKSAT; 25.1% vs 21.5% ADAM).
20,285 It is therefore 
important that when considering risk stratification in elective AAA surgery that 
not only do we consider perioperative survival, but that we also look to predict 
long-term outcome. 
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Figure 5.1 Overall survival by treatment group in the UK Small Aneurysm Trial. 
 
 
 
 
Due to the perioperative mortality rate of 5.8% survival was worse initially in the early surgery 
group. Survival was subsequently worse in the surveillance group so that the survival curves 
crossed at approximately 3 years. There were however no significant differences in mortality at 
2 years, 4 years or 6 years. Kaplan-Meier estimates, log-rank test p=0·56. Adapted from 
18. 
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As described, cardiovascular complications have been shown to be the leading 
cause of perioperative death in the elective open AAA repair population. This 
finding is also seen to hold on long-term follow-up [Table 5.1].
18 Impaired left 
ventricular function and inducible myocardial ischaemia are strong predictors of 
perioperative cardiovascular complications. Preoperative elevations in BNP have 
been shown to correlate with postoperative MACE in the short term.
111-120 
Furthermore, a number of studies have demonstrated a greater risk of long-term 
MACE and all-cause mortality after major non-cardiac surgery in the presence of 
elevation of preoperative BNP.
114, 117, 120, 122 This has also been shown to be the 
case locally where preoperative BNP predicts long term survival following major 
non-cardiac surgery, independent of other prognostic characteristics.
287  
The study in chapter 4 has shown that preoperative elevation of BNP is 
associated not only with perioperative MACE, but with perioperative cardiac 
death and all-cause mortality. This could aid the identification of those suitable 
for repair of their asymptomatic small aneurysm. Whether this prognostic value 
remains in the long-term, in this cohort, is unknown. This chapter aims to 
answer the question of whether preoperative elevation in BNP can predict both 
all-cause mortality in the intermediate and long-term, and whether, when 
considering data from the UKSAT, BNP can help select suitable patients for 
repair of their small asymptomatic AAA. 
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Table 5.1 Numbers of deaths according to reported underlying cause on the death 
certificate by treatment group from the UKSAT. 
 
          Deaths in surveillance Deaths in early surgery 
          group (n=150)    group (n=159) 
 
Cardiovascular deaths 
Total          105      94 
Stroke          7      5         
Ruptured thoracic aneurysm    6      2 
Ruptured AAA*        17      6 
After AAA repair†      18      26 
Other cardiovascular deaths    27      31 
 
Cancer deaths 
Total          27      40 
Lung cancer        10      14 
Other cancer deaths      17      26 
 
Other          17      23 
Unknown‡        1      2 
 
 
 
* - ten (43%) of 23 ruptured AAA had diameter >5.5 cm, † - underlying cause of death, within 14 
days of operative repair, ‡ - patient died abroad, cause of death not known, AAA – abdominal 
aortic aneurysm. Adapted from 
18. 
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5.2 Methods 
5.2.1 Study Population and Power 
The study population was recruited as in chapter 4, and therefore comprised a 
prospective observational multi-centre cohort from the 3 major vascular units 
within Glasgow. Patients were identified from August 2005 until September 2007 
and followed up for 3 years, with final follow-up data collected in September 
2010. With expected all-cause mortality rate of 15-20% at 3 years
18 a minimum 
of 100 patients would need to be recruited and followed-up to 3 years.  
5.2.2 Patients and Preoperative Assessment 
Collection of patient data was identical to that described in chapter 4. 
Preoperative BNP samples were collected in the manner previously described. 
5.2.3 Postoperative Follow-up 
Immediate postoperative testing is described in detail in chapter 4. All patients 
were initially followed through an area wide interhospital computer database. If 
a patient had died, the date and cause of death were noted. If no cause of death 
was noted, then a death certificate review was performed. Where no recent 
contact was recorded, the patient‘s General Practice (GP) was contacted again, 
in the case of death, date and cause of death were noted and death certificates 
reviewed if necessary.  
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5.2.4 Endpoints 
Endpoints for the study were MACE and all-cause mortality. Individual cause of 
death was noted but not considered separately. Due to the wide regional and 
national spread, case notes were not individually reviewed. 
5.2.5 Statistical Analysis 
Statistical analysis was performed using the SPSS
® statistical software package 
(SPSS, Chicago, Illinois, USA). BNP values were reported as median (interquartile 
range) with continuous variables compared using Mann-Whitney U Test. Fisher‘s 
Exact Test was used to analyse the differences between independent categorical 
data. Receiver operating characteristics were plotted and the area under the 
curve estimated. Kaplan-Meier estimates were performed with a log rank test 
when comparing survival. 
5.2.6 Ethical Approval 
Local Research and Development, and Central Ethics Committee approval were 
obtained for the study. All patients were provided with an information sheet and 
had signed a study consent form. GPs were sent individual letters to inform them 
of their patients‘ inclusion in the study. 
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5.3 Results 
5.3.1 Patients Characteristics and Long-term Outcome 
All basic patient characteristics are described in chapter 4 and in table 5.4 and 
table 5.5. Of the 106 patients that underwent elective open AAA repair 97 
survived the 30-day postoperative period. All patients were followed-up to a 
minimum of 3 years after their AAA repair. In 5 cases there had been no recent 
contact with the hospital or GP at 3 year follow-up. The last point of patient 
contact in these individual cases was at follow-up day 481, 780, 847, 996 and 
1052. Median BNP in this group (n=5) was 58 (16-139) pg/ml. In none of these 
cases had either GP or hospital been notified of the patients‘ death, or had the 
GP been advised of geographical change in medical practice. The 3-year all-
cause mortality rate was 21% (n=22) with a total of 79 patients confirmed still 
alive at 3 years. In the 13 deaths that occurred between 30-days and 3 years, 
the leading cause of death was cardiac in origin (n=3) [Table 5.2]. Other causes 
included respiratory disease (n=3), cerebrovascular disease (n=2), renal failure 
(n=2) and cancer of different primary origins (n=3). 
The survival rates at 6 months, 1 year, 2 years and 3 years were 89.6%, 89.6%, 
83% and 79.2% respectively. The median BNP level in those that died compared 
to those that survived for each time interval is shown in table 5.3. The median 
preoperative BNP in those who survived beyond 30 days was significantly higher 
in those who died in the first year (late mortality) than in those who survived 
over that time (median BNP 201 [97-496] vs 35 [17-73] pg/ml, p<0.001) [Figure 
5.2]. The median preoperative BNP was significantly higher in those who died 
during the 3 year follow-up than in those who survived the study period (median 
BNP 98.5 [58-285] vs 32 [17-71.5] pg/ml, p<0.001) [Figure 5.3].  
Despite the fact that death was attributed to a cardiac cause in only 3 cases, 
those that did suffer a cardiac death between 30 days and 3 years had a 
significantly higher preoperative BNP level compared to those that did not 
(median BNP 112[46-435] vs 35[17-75] pg/ml, p=0.049) on Mann-Whitney U 
analysis. 
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Table 5.2 Cause of death in 13 of the 97 patients that died within 3 years of elective open 
AAA repair. 
 
 
              No. 
 
 
Fatal myocardial infarction      2 
 
Ventricular rupture         1 
 
Respiratory disease         3 
 
Cerebrovascular accident        2 
 
End-stage renal failure        1 
 
Acute renal failure 2e to sepsis      1 
 
Oesophagogastric carcinoma      1 
 
Colonic carcinoma          1 
 
Bronchial carcinoma        1 
 
 
Causes of death between postoperative day 30 and 3 years reveal cardiac and respiratory causes 
as the most frequent cause. Cancer compromised 23% of deaths, similar to that seen in both 
UKSAT and ADAM. 
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Table 5.3 Long-term outcomes by median BNP level. 
 
              n (%)      BNP*      p value 
     
Perioperative     Yes  9/106 (8.4%)    100 (84-521) 
All-cause mortality    No  97/106 (91.6%)  35 (17-81)    0.028 
 
Late Mortality     Yes   11/106 (10.4%)  201 (97-496) 
(30-days to 1 year)    No  95/106 (89.6%)  35 (17-73)    <0.001 
 
Mortality at 1 year    Yes  11/106 (10.4%)  201 (97-496) 
            No  95/106 (89.6%)  35 (17-73)    <0.001 
 
Mortality at 2 years    Yes  18/106 (17%)    98.5 (42.25-291.25) 
            No  88/106 (83%)    34.5 (17-77.5)   0.002 
 
Mortality at 3 years    Yes   22/106 (20.8%)  98.5 (58-285) 
            No  84/106 (79.2%)  32 (17-71.5)    <0.001 
 
Univariate analyses reveal a significant difference in median BNP levels between those that died 
and those that survived at all stages of follow up with higher levels in those that died. Analyses 
were performed using Mann-Whitney U test. 
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Figure 5.2 BNP concentration and late mortality (30 day-1 year). 
 
 
 
  
 
 
The median BNP was significantly higher in those that died between 30 postoperative days and 1 
year, compared to those that did not (median BNP 201 [97-496] vs 35 [17-73]  pg/ml, p<0.001) as 
calculated by Mann-Whitney U test. The dots represent outliers. The asterisks/stars represent 
extreme outliers where the level marked is >3 times the height of the boxes. N is number of 
patients. 
 
 
 
 
 
N=          95              11  
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Figure 5.3 BNP concentration and 3-year mortality. 
 
 
 
 
 
 
The median BNP was significantly higher in those that died by 3 postoperative years compared to 
those that did not (median BNP 98.5 [58-285] vs 32 [17-71.5] pg/ml, p<0.001) as calculated by 
Mann-Whitney U test. The dots represent outliers. The asterisks/stars represent extreme outliers 
where the level marked is >3 times the height of the boxes. N is number of patients. 
 
 
 
 
 
 
N=          84              22  
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The median age in those that died after 30 days but in the first year was 74 (67-
77) years compared to 72 (66-77) years in those that survived (p=0.324). The 
median age in those that died by 3 postoperative years was 74 (67-78) years 
compared to 72 (65-76) years in those that survived. Univariate analysis of other 
patient characteristics at all stages of follow up reveal that the presence of CCF 
was a significant predictor of outcome with death more likely (late mortality 
p<0.001, 3 year mortality p<0.001). The presence of worsening renal function in 
relation to CKD stage also made death more likely at 3 years (p=0.031) [Table 
5.4]. Although not significant, a longer operating time made late mortality more 
likely (p=0.081). The presence of a previous MI made 3 year mortality more 
likely, but not significantly so (p=0.063). None of these studied intraoperative 
factors or preoperative medication was found to predict outcome at any stage 
on univariate analyses [Table 5.5].  
Multivariate analysis for factors with a p<0.100 in univariate analysis included 
preoperative MI, CCF, CKD and BNP. In this model only BNP was an independent 
predictor of both late and 3 year mortality although the odds ratio was low (OR 
0.992, 95% CI 0.986-0.999, p=0.017 for late mortality; OR 0.991, 95% CI 0.985-
0.995, p=0.012 for 3-year mortality).  
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Table 5.4 Case mix and outcome. 
 
Total     Periop   Late    3-year  
Cohort  Mortality  Mortality  Mortality   
      (n=106)  n (%)    n (%)    n (%) 
 
Sex   
Male    88 (83%)  7/88 (8%)  9/88 (10%)  19/88 (22%) 
  Female  18 (17%)  2/18 (11%)  2/18 (11%)  3/18 (17%)   
Previous MI 
  Present  23 (22%)  3/23 (13%)  4/23 (17%)  8/23 (35%) 
  Absent  83 (78%)  6/83 (7%)  7/83 (8%)  14/83 (17%) 
Hypertension       
  Present  72 (67%)  7/72 (10%)  8/72 (11%)  15/72 (21%) 
Absent  34 (33%)  2/34 (6%)  3/34 (9%)  7/34 (21%) 
Hyperlipidaemia 
  Present  15 (14%)   0/15 (0%)  1/15 (7%)  3/15 (20%) 
  Absent  91 (86%)  9/91 (10%)  10/91 (11%)  19/91 (21%) 
Diabetes       
Present  9 (8%)   2/9 (22%)  2/9 (22%)  2/9 (22%) 
Absent  97 (92%)  7/97 (7%)  9/97 (9%)  20/97 (21%) 
Current smoker     
Present  35 (33%)  4/35 (11%)  5/35 (14%)  8/35 (23%) 
Absent  71 (67%)  5/71 (7%)  6/71 (8%)  14/71 (20%) 
Smoked ever      
Present  90 (85%)  8/90 (9%)  9/90 (10%)  19/90 (21%) 
Absent  16 (15%)  1/16 (6%)  2/16 (13%)  3/16 (19%) 
CVD         
Present  22 (21%)  4/22 (18%)  4/22 (18%)  6/22 (27%) 
Absent  84 (79%)  5/84 (6%)  7/84 (8%)  16/84 (19%) 
CCF 
  Present  13 (12%)  5/13 (38%)‡  7/13 (54%)§  9/13 (69%)§ 
  Absent  93 (88%)  4/86 (5%)  4/86 (5%)  13/86 (15%) 
CRF         
Present  8 (8%)   1/8 (13%)  1/8 (13%)  1/8 (13%) 
Absent  98 (92%)  8/98 (8%)  10/98 (10%)  21/98 (21%) 
CKD 
  1    9 (8%)   0/9 (0%)†  0/9 (0%)  0/9 (0%)† 
  2    55 (52%)  2/55 (4%)  4/55 (7%)  10/55 (18%) 
  3    40 (38%)  6/40 (15%)  6/40 (15%)  10/40 (25%) 
  4    1 (1%)   1/1 (100%)  1/1 (100%)  1/1 (100%) 
  5    1 (1%)   0/1 (0%)  0/1 (0%)  1/1 (100%) 
eGFR 
  <60    42 (40%)  7/42 (17%)†  7/42 (17%)  12/42 (29%) 
  ≥60    64 (60%)  2/64 (3%)  4/64 (6%)  10/64 (16%) 
The likelihood of perioperative death was significantly higher in those with CCF, CKD and a lower 
eGFR (p=0.002, p=0.010 and p=0.027). Only in CCF was late mortality more likely (p<0.001). The 
likelihood of 3 year mortality was significantly higher in those with CCF and CKD (p<0.001 and 
p=0.031). Analyses were determined using Fisher‘s Exact Test.  MI – myocardial infarction, CVD – 
cerebrovascular disease, CCF – congestive cardiac failure, CKD – chronic kidney disease, eGFR – 
estimated glomerular filtration rate. †p<0.050, ‡p<0.010, §p<0.001.  
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Table 5.5 Other selected characteristics and outcome. 
 
Total     Periop   Late    3-year  
Cohort  Mortality  Mortality  Mortality   
      (n=106)  n (%)    n (%)    n (%) 
 
Anti-platelet      
Present  63 (59%)  6/63 (10%)  7/63 (11%)  11/63 (17%) 
Absent  43 (41%)  3/43 (7%)  4/43 (9%)  11/43 (26%) 
Statin      
Present  66 (62%)  5/66 (8%)  5/66 (8%)  13/66 (20%) 
Absent  40 (38%)  3/40 (8%)  6/40 (15%)  9/40 (23%) 
Beta-blocker      
Present  43 (41%)  3/43 (7%)  5/43 (12%)  8/43 (19%) 
Absent  63 (59%)  6/63 (10%)  6/63 (10%)  14/63 (22%) 
Antianginal       
Present  23 (22%)  2/23 (9%)  2/23 (9%)  3/23 (13%) 
Absent  83 (78%)  7/83 (8%)  9/83 (11%)  19/83 (23%) 
Diuretic 
  Present  35 (33%)  2/35 (6%)  2/35 (6%)  5/35 (14%) 
  Absent  71 (67%)  7/71 (10%)  9/71 (13%)  17/71 (24%) 
Hypotension      
  Present  48 (45%)  4/48 (8%)  6/48 (13%)  11/48 (23%) 
  Absent  58 (55%)  5/58 (9%)  5/58 (9%)  11/58 (19%) 
Hypothermia 
  Present  4 (4%)   0/4 (0%)  0/4 (0%)  1/4 (25%) 
  Absent  102 (96%)  9/102(9%)  11/102 (11%) 21/102 (21%) 
Blood Loss 
  750ml  39 (37%)  4/39 (10%)  4/39 (10%)  8/39 (21%) 
  >750ml  67 (63%)  5/67 (7%)  7/67 (10%)  14/67 (21%) 
Cross Clamp time 
  60 mins  71 (67%)  7/71 (10%)  7/71 (10%)  16/71 (23%) 
  >60 mins  35 (33%)  2/35 (6%)  4/35 (11%)  6/35 (17%) 
Operating times 
   3 hours  58 (55%)  3/58 (5%)  3/58 (5%)  10/58 (17%) 
  > 3 hours  48 (45%)  6/48 (13%)  8/48 (17%)  12/48 (25%) 
CRP 
  <6    62 (58%)  7/62 (11%)  8/62 (13%)  14/62 (23%) 
  ≥6    44 (42%)  2/44 (5%)  3/44 (7%)  8/44 (18%) 
 
Although not significant, shorter operating time made late mortality less likely (p=0.063). There 
were no other factors that made death at any stage more likely. Analyses were performed using 
Fisher‘s Exact Test. CRP – C-reactive protein. 
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5.3.2 ROC Analysis and Outcome 
The receiver operating characteristic (ROC) curve analysis was performed to 
identify the BNP concentration threshold that best predicted late and long term 
mortality [Table 5.6]. With regards to late mortality, a BNP concentration of 
93.0 pg/ml had the best combined sensitivity (81%) and specificity (82%), and 
the area under the curve (AUC) was 0.885 (SE 0.043, 95% CI 0.80-0.97, p<0.001) 
[Figure 5.4]. When analysing preoperative BNP concentration with regards to 3 
year mortality a cut-off of 60.5 pg/ml had the best combined sensitivity (68%) 
and specificity (73%) with an AUC of 0.761 (SE 0.060, 95% CI 0.645-0.878, 
p<0.001) [Figure 5.5].  
 
 
5.3.3 Postoperative MACE, Elevations in cTnI and Long-term 
Outcome 
Postoperative MACE, without death, was significantly associated with 1 year 
mortality (2/11 [18%] vs 0/86 [0%], p<0.001). While mortality at 2 years (2/11 
[18%] vs 8/86 [9%], p=0.285) and 3 years (3/11 [27%] vs 10/86 [12%], p=0.155) 
was more common in those with postoperative MACE, this was not statistically 
significant. 
Immediate postoperative elevation in cTnI, regardless of clinical outcome or the 
presence of a defined event, was associated with increased long-term mortality, 
although this was not statistically significant. All-cause mortality rates were 
higher in this group of patients at all studied time intervals (1 year 4/26 [15%] vs 
7/80 [9%], p=0.066; 2 years 6/26 [23%] vs 12/80 [15%], p=0.076; 3 years 7/26 
[27%] vs 15/80 [19%], p=0.100). 
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Table 5.6 Results of receiver operating characteristic curve analysis for BNP according to outcome. 
 
        AUC    95% CI   SE  p-value    cut-off  Sens.  Spec.    PPV  NPV 
 
Perioperative Death    0.860    0.757-0.962  0.057  <0.001    93.0 pg/ml   78%   79%    30%  99% 
 
Late Mortality    0.885     0.80-0.97  0.043  <0.001   93.0 pg/ml   81%   82%    35%  97% 
(30 days-1 year) 
 
2-year Mortality    0.733    0.597-0.896  0.069  0.002    68.5 pg/ml   61%   74%    33%  90% 
 
3-year Mortality    0.761    0.645-0.878  0.060  <0.001    60.5 pg/ml  68%  73%    41%  90% 
 
ROC curve analysis of BNP in relation to outcome reveals that BNP performs well when predicting death at all stages of follow-up. The cut-off value is seen to 
decrease as follow-up time increases however degree of significance stays similarly low throughout. As follow-up time increases the PPV improves and the NPV 
diminishes. AUC – area under the curve, CI – confidence interval, SE- standard error, Sens. – Sensitivity, Spec. – Specificity, PPV – positive predictive value, NPV – 
negative predictive value. 
175  
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Figure 5.4 ROC curve: BNP concentration and late mortality (30 days – 1 year). 
 
 
ROC analysis revealed a cut-off value of 93.0 pg/ml and an area under the curve (AUC) of 0.885, 
with a sensitivity of 81% and specificity 82% (SE 0.043, 95% CI 0.80-0.97; p<0.001). 
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Figure 5.5 ROC curve: BNP concentration and 3-year mortality. 
 
 
ROC analysis revealed a cut-off value of 60.5 pg/ml and an area under the curve (AUC) of 0.761, 
with a sensitivity of 68% and specificity 73% (SE 0.060, 95% CI 0.645-0.878; p<0.001). 
 
 
 
 
 
 
 
cut-off  
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5.3.4 Survival Analysis 
5.3.4.1  Cut-off BNP 99.5 pg/ml (MACE) and 93.0 pg/ml (perioperative death) 
The mean survival of patients with a BNP >99.5 pg/ml was 1291 (95% CI 882-
1701) days compared with 1916 (95% CI 1774-2057) days when BNP <99.5 pg/ml 
(p<0.001) [Figure 5.6]. During the first six months the rate of postoperative 
death in those with a BNP >99.5 pg/ml was 8.6 times greater than in those with 
a BNP below this threshold (32% vs 3.7%, p<0.001). At the minimum point of 
follow-up (3 postoperative years) the rate of death was 3.4 times greater in 
those with a BNP >99.5 pg/ml (48% vs 14%, p<0.001). In those who survived 
beyond the first 6 postoperative months, there was no significant difference in 
survival thereafter between those with a BNP >99.5 pg/ml (1923 [95% CI 1623-
2334] days) and those with a BNP <99.5 pg/ml (1988 [95% CI 1866-2109] days) 
(p=0.442) [Figure 5.7].  
Similarly significant differences in mean survival figures were observed between 
those with a BNP <93 pg/ml compared to a level of >93 pg/ml (1320 [95% CI 931-
1708] days vs 1931 [95% CI 1791-2070) days, p<0.001) [Figure 5.8]. During the 
first six months the rate of postoperative death was 13.2 times higher in those 
with BNP levels above the threshold (33% vs 2.5%, p<0.001). At 3 years the rate 
of death was 3.2 times higher in those with BNP levels >93.0 pg/ml (44% vs 
13.9%, p<0.001). When analysis was restricted to those who survived beyond 6 
postoperative months there was no significant difference in outcome. Within this 
subgroup the mean survival in those with a BNP >93.0 pg/ml compared to those 
with a BNP <93.0 pg/ml was 1966 days (95% CI 1618-2236) vs 1980 days (95% CI 
1856-2105), p=0.653. 
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Figure 5.6 Kaplan-Meier curve of survival according to BNP level with a cut-off of 99.5 pg/ml. 
 
 
Patients at risk: 
<99.5 pg/ml    82    79    72   66  35   15 
>99.5 pg/ml    24    16    14   12   8     4 
 
 
Kaplan-Meier survival analysis reveals a significant difference in long term outcome when 
comparing groups based on a cut-off BNP level of 99.5 pg/ml (mean survival 1291 [95% CI 882-
1071] vs 1916 [95% CI 1774-2057] days, p<0.001). Longer survival was seen in those with lower 
BNP levels.  
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Figure 5.7 Kaplan-Meier curve of survival according to BNP level with a cut-off of 99.5 pg/ml 
in only those that survived beyond six postoperative months. 
 
 
Patients at risk: 
<99.5 pg/ml    79    79    72   66   35   15 
>99.5 pg/ml    16    16    14   12    8     4 
 
 
Kaplan-Meier survival analysis reveals no difference in long term outcome when including only 
those that survived beyond 6 months and comparing groups based on a cut-off BNP level of 99.5 
pg/ml (mean survival 1923 [95% CI 1623-2334] vs 1988 [95% CI 1866-2109] days, p=0.442). 
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Figure 5.8 Kaplan-Meier curve of survival according to BNP level with a cut-off of 93 pg/ml. 
 
 
Patients at risk: 
<93.0 pg/ml    79    76    69   63  32   12 
>93.0 pg/ml    27    19    17   15  11     7 
 
 
Kaplan-Meier survival analysis reveals a significant difference in long term outcome when 
comparing groups based on a BNP level of 93.0 pg/ml (mean survival 1320 [95% CI 931-1708] vs 
1931 [95% CI 1791-2070] days, p<0.001). Longer survival was seen in those with lower BNP levels.  
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5.3.4.2  Cut-off BNP 60.5 pg/ml (3-year mortality) 
The mean survival of patients with a BNP >60.5 pg/ml compared to a BNP <60.5 
pg/ml was 1439 days (95% CI 1128-1751) vs 1967 days (95% CI 1825-2110) 
(p<0.001) [Figure 5.9]. During the first six months the rate of postoperative 
death in those with a BNP >60.5 pg/ml was 19 times greater (27% vs 1.4%, 
p<0.001) than in those with a BNP below this threshold. At the minimum point of 
follow-up (3 postoperative years) the rate of death was 3.8 times greater in 
those with a BNP > 60.5 pg/ml (38% vs 10%, p<0.001). Survival in only those that 
survived beyond the first 6 postoperative months revealed that there was no 
significant difference in outcome with the mean survival in those with a BNP 
>60.5 pg/ml of 1945 days (95% CI 1731-2159) vs 1996 days (95% CI 1864-2129) in 
those with a BNP below this level (p=0.298) [Figure 5.10].  
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Figure 5.9 Kaplan-Meier curve of survival according to BNP level with a cut-off of 60.5 pg/ml. 
 
 
Patients at risk: 
<60.5 pg/ml    68      67    60   55  31   9 
>60.5 pg/ml    38    28    26   21  11    3 
 
 
Kaplan-Meier survival analysis reveals a significant difference in long term outcome when 
comparing groups based on a BNP level of 60.5 pg/ml (mean survival 1439 [95% CI 1128-1751] vs 
1967 [95% CI 1825-2110] days, p<0.001), with longer survival in those with lower BNP levels.  
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Figure 5.10 Kaplan-Meier curve of survival according to BNP level with a cut-off of 60.5 
pg/ml in only those that survived beyond six postoperative months. 
 
 
Patients at risk: 
<60.5 pg/ml     67    67    60   55  31   9 
>60.5 pg/ml     28    28    26   21  11    3 
 
Kaplan-Meier survival analysis reveals no difference in long term outcome when including only 
those that survived beyond 6 months and comparing groups based on a cut-off BNP level of 60.5 
pg/ml (mean survival 1945 [95% CI 1731-2159] vs 1996 [95% CI 1864-2129] days, p=0.298). 
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5.4 Discussion 
This study demonstrates that, not only can a single preoperative serum BNP level 
predict perioperative outcome in elective open AAA repair, but it can also 
predict long-term all-cause mortality and specifically cardiac death. At all time 
points of follow-up BNP levels significantly predicted mortality outcomes. Only 
in the presence of CKD or CCF was late mortality more likely, although on 
multivariate analysis only BNP was found to be a significant predictor.  
In chapter 4 the importance of BNP as a strong predictor of immediate 
postoperative outcome is clearly established. However in addition to its strength 
in the perioperative period the results of this study reveal that BNP also has a 
long term predictive value. ROC curve analysis reveals a lower cut-off value of 
serum BNP for predicting death over time. In addition BNP becomes a less 
sensitive and specific predictor of death, and its predictive values lose meaning 
over the same time period. The lowering cut-off level over time may be 
indicative that, at lower levels, BNP can predict long term mortality in the 
general population, as previously demonstrated in Glasgow where random 
population sampling in 1640 individuals revealed a significant difference in 4 
year mortality (BNP ≥17.9 pg/ml mortality 14.9 % vs BNP <17.9 pg/ml mortality 
3.1%, p<0.001).
275  
Although all analyses showed that preoperative serum BNP levels predicted 3 
year mortality, when removing the outcome data relating to the first 6 
postoperative months there was no significant difference in survival based on 
differing BNP levels. There was however an apparent, but not statistically 
significant, increased survival rate in those with lower BNP levels at 3 years in 
this same group.  
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Survival rates after open elective AAA repair were 89.6% at 1 year and 79.2% at 3 
years. This is comparable to other larger studies 
288, 289 including the recently 
published long term outcomes of 7697 patients following elective AAA repair in 
Sweden, with reported rates of 90.8% at 1 year and ~81% at 3 years.
290 The 
slightly poorer outcome seen in the West of Scotland could be in part due to the 
small sample size in this cohort. In addition, and despite similar age groups, 
there was greater comorbidity in the studied population and therefore the 
results are not unexpected.  
In the UKSAT, long term survival outcomes in the operative group were similar to 
that described above. When using discriminatory BNP levels, the survival rates in 
the present studied population were higher in those with lower BNP levels. The 
survival rates in those with a BNP <99.5 pg/ml at 1 and 3 years were 96.7% and 
86.7% respectively. Survival rates in those with a BNP >99.5 pg/ml were 65.2% at 
1 year and 52.2% at 3 years. Crude estimates of the UKSAT reveal survival rates 
of approximately 91% and 81% at 1 and 3 years in the operative group, and of 
95% and 81% at 1 and 3 years in the surveillance group. These survival rates from 
UKSAT are lower than in those patients with a BNP level <99.5 pg/ml in the 
current study. It is therefore not unreasonable to propose that, when 
considering the UKSAT data, selecting patients on the basis of BNP alone could 
reduce perioperative mortality and possibly improve long term outcomes in the 
operative group.  
The main limitation of this study was the relatively low number of patients. 
However, the inclusion of consecutive patients makes this a representative 
sample of the patient population presenting for AAA repair in the West of 
Scotland and make the results relevant to current clinical practice. The 
incomplete 3 year follow-up data may impact on the results; however as neither 
GP nor hospital were notified of death or change of address an assumption of 
survival can be made. This assumption was taken into account through censoring 
on Kaplan Meier analyses, and, even after correction for this, a significant 
difference in survival persisted between the two groups with differing BNP 
levels.  
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Few studies have described the relation between long term outcomes and BNP 
levels in noncardiac surgery. These include the studies of Feringa et al
120, who 
found that NT-proBNP predicted long term outcome in 335 patients undergoing 
vascular surgery, and Cuthbertson et al
118, who found similar results in 204 
patients undergoing noncardiac surgery. More recently, in a 345 patient cohort 
from Glasgow, BNP has been found to independently predict long term survival 
after major noncardiac surgery.
287 The present study, according to the current 
published literature, is the first to report on survival outcome following elective 
open AAA repair alone, whilst being appropriately powered to do so. The results 
highlight the importance of BNP in the perioperative period whilst revealing its 
value in predicting long term survival. Its value as a basis on which to select 
patients who would be suitable for repair of their small asymptomatic AAA 
remains unknown; however there is sufficient evidence to suggest that this 
question should now be addressed in a prospective trial. 
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Chapter 6 
 
Objective Scoring Systems in Elective Open 
Abdominal Aortic Aneurysm Repair  
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6.1 Introduction 
As previously discussed in detail, there is a need to identify patients whose risk 
of AAA rupture exceeds the risk of perioperative mortality and for whom surgery 
consequently offers a survival advantage. During the last two decades several 
surgical risk indices have been developed to help quantify the risk of 
perioperative death for a given patient. The risk scores available to date have 
been discussed in section 1.5.5 of chapter 1. The complexity and lack of 
validation of many of these scores make routine preoperative use rare and/or 
unreliable.  
The Eagle
63 and Vanzetto
291 scores, which use physiological factors in 
conjunction with ECG analysis and thallium scanning, have been shown to be 
useful in predicting cardiac events in major vascular surgery. However, despite 
further external validation in predicting mortality after elective open AAA 
repair
161, their requirement for cardiac testing places them out of the reach of 
many centres.  
The Leiden score and modifications
292 were derived from retrospective data of 
patients undergoing elective surgery between 1977 and 1988; they are unique in 
that they employ a corrective factor for institution-specific mortality rates. 
However, the Leiden score has never shown good predictive capabilities. When 
applied to UK Small Aneurysm Trial data it predicted death with only moderate 
accuracy (AUC 0.72), and was shown to have poor predictive power and 
calibration.
293 
The Estimation of Physiological Ability and Surgical Stress (E-PASS) was found to 
accurately predict postoperative outcome in open elective AAA surgery.
257 The 
E-PASS consists of a preoperative risk score (PRS) and a surgical stress score 
(SSS), combining to give a comprehensive risk score (CRS). As a preoperative risk 
scoring tool, this brings some limitations; however the PRS alone has been shown 
to give a positive predictive value similar to the overall CRS in AAA surgery.
161 
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The Glasgow Aneurysm Score (GAS)
154, Physiological and Operative Severity 
Score for enumeration of Mortality (POSSUM)
162 and Vascular Biochemical and 
Haematological Outcome Model (VBHOM)
165,166 have all been validated, show 
good predictive capabilities and can be used as preoperative scoring systems.
294 
In addition, Lee‘s revised cardiac risk index (RCRI)
295 has been shown to predict 
mortality in vascular surgery including elective open AAA repair.
296  
The aim of this chapter is to compare five validated preoperative risk 
stratification scoring systems and to assess their ability to predict major adverse 
cardiac events and all-cause mortality in the perioperative period. These risk 
scores will be the GAS, RCRI, VBHOM, the physiology only component of the 
Vascular-POSSUM and the PRS component of E-PASS. 
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6.2 Methods 
6.2.1 Study Population 
A prospective, observational, multi-centre cohort study was performed involving 
the 3 major vascular units within Glasgow (Gartnavel General Hospital, Glasgow 
Royal Infirmary and the Southern General Hospital). A cohort of consecutive 
patients admitted electively for open AAA repair was identified between August 
2005 and September 2007.  
6.2.2 Patients and Preoperative Assessment  
Collection of patient data was identical to that described in chapter 4. Data 
were collected to allow calculation of the 5 scoring systems named above. 
6.2.2.1  Glasgow Aneurysm Score 
The Glasgow Aneurysm Score was calculated for each patient according to the 
following formula: 
GAS = Age + (17 for shock) + (7 for myocardial disease) + (10 for cerebrovascular 
disease) + (14 for renal disease) 
Refer to 2.5.1 for further definitions. 
6.2.2.2  Vascular (physiology only) - Physiological and Operative Severity 
Score for enUmeration of Mortality 
All 12 physiological parameters (age, degree of cardiac failure, degree of 
dyspnoea related to chronic obstructive airways disease, ECG changes, systolic 
BP, resting pulse rate, haemoglobin concentration, white cell count, urea, 
sodium, potassium and Glasgow Coma Score) were measured preoperatively in 
all patients and placed in the online calculator for the V(p)-POSSUM score at 
http://www.riskprediction.org.uk/vasc-index.php  
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6.2.2.3  Vascular Biochemical and Haematological Outcome Model 
The results of preoperative serum urea, sodium, potassium, haemoglobin and 
white cell count, in addition to age and gender were applied to the following 
equation: 
VBHOM = lne(R/1-R) = −2·257 + (0·1511 × sex) + (0·9940 × mode of admission) +  
(0·05923 × age on admission[years]) + (0·001401 × urea[mmol/l]) + (−0·01303 × 
sodium[mmol/l]) + (−0·03585 × potassium[mmol/l]) + (−0·2278 × 
haemoglobin[g/dl]) + (0·02059 × white cell count[×10
9/l]) 
R is the risk of death. Sex takes the value 0 for female and 1 for male, and mode 
of admission takes the value 0 for elective and 1 for non-elective admissions. 
6.2.2.4  Lee’s Revised Cardiac Risk Index 
The RCRI was calculated on the sum of the risk factors in each patient. These 
risk factors were high-risk surgery (intraperitoneal, intrathoracic or 
suprainguinal vascular), ischaemic heart disease, congestive heart failure, 
cerebrovascular disease, the use of insulin therapy for diabetes mellitus or a 
preoperative creatinine level >2mg/dl (>176μmol/l), each factor being 
attributed a value of 1. Refer to 2.5.4 for further definitions. 
6.2.2.5  Preoperative Risk Score of the Estimation of Physiological Ability 
and Surgical Stress Score 
The PRS component of the E-PASS score is calculated based on the following 
equation: 
PRS = -0.0686+0.00345(age) + 0.323(cardiac score) + 0.205(pulmonary score) + 
0.153(diabetes score) + 0.148(performance status index) + 0.0666(ASA) 
Refer to 2.5.5 for further definitions.  
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6.2.3 Postoperative Follow-up 
Immediate postoperative testing is described in detail in chapter 4. In cases of 
death, the date and cause of death were noted. Where the cause of death was 
not included review of the death certificate was performed. 
6.2.4 Endpoints 
Endpoints for the study were non-fatal MI and all-cause mortality. MACE was 
defined as described in chapter 4 and was determined by a review of 
postoperative data by two cardiologists who were unaware of preoperative BNP 
levels. All-cause mortality was immediate postoperative death (<30 days) of any 
cause. 
6.2.5 Statistical Analysis 
Statistical analysis was performed using the SPSS
® statistical software package 
(SPSS, Chicago, Illinois, USA). Normal distributed data was reported as mean +/- 
standard deviation. Non-parametric data was reported as median and 
interquartile range. Mann-Whitney U test was used to test the differences 
between non-parametric continuous variables in different subgroups. A 2-sample 
t-test was used to compare continuous variables in normally distributed data. 
Receiver operating characteristics were plotted and the area under the curve 
estimated. A p-value <0.05 was considered significant. 
6.2.6 Ethical Approval 
Local Research and Development, and Central Ethics Committee approval was 
obtained for the study. All patients were provided with an information sheet and 
had signed a study consent form. GPs were sent individual letters to inform of 
their patients‘ inclusion in the study. 
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6.3 Results 
6.3.1 Patient Characteristics, BNP Levels and Outcome 
Patient characteristics are as detailed in chapter 4. Preoperative laboratory 
variables are further detailed in table 6.1. The majority of laboratory variables 
were within normal reference ranges for the local population. Laboratory 
variables by outcome are also detailed in table 6.1. Platelet levels were 
significantly lower, and prothrombin time levels significantly higher in those that 
died of a cardiac death. Serum urea levels were significantly higher in those 
patients that died of any cause. Serum urea levels were higher in those that 
suffered cardiac death, although this was not statistically significant. 
Haemoglobin levels were lower in those that died of any cause, although again 
this was not statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
  
                   
195 
Table 6.1 Preoperative laboratory results and their distribution according to outcome. 
 
 
Laboratory      Mean    MACE    Cardiac   All-cause 
Variable      (+/- SD)      Death   Mortality   
 
Urea (mmol/l)    7.5 (3.7) 
Yes          8.43(4.48)  10.68(7.19)  9.98(5.66) 
  No          7.35(3.56)  7.36(3.44)  7.28(3.43) 
            p=0.285    p=0.050    p=0.037   
     
Serum Na
+ (mmol/l)    4.2 (0.48)     
  Yes          139.7(1.82)  139.6(2.07)  138.8(2.68) 
  No          138.9(2.84)  139.0(2.75)  139.1(2.74) 
            p=0.324    p=0.655    p=0.741 
 
Serum K
+ (mmol/l)    139.1 (2.7) 
  Yes          4.14(0.75)  4.24(0.53)  4.32(0.53) 
  No          4.22(0.41)  4.21(0.48)  4.20(0.47) 
            p=0.558  p=0.880    p=0.456 
 
Haemoglobin (g/dl)   13.3 (1.9)   
  Yes          12.90(2.37)  11.96(3.48)  12.14(2.50) 
No          13.34(1.77)  13.33(1.76)  13.38(1.78) 
          p=0.391    p=0.108    p=0.058 
 
White Cell Count (x10
3/µl) 7.9 (1.8) 
  Yes          8.43(1.26)  8.08(1.70)  8.23(1.56) 
  No          7.79(1.93)  7.88(1.86)  7.86(1.88) 
            p=0.208    p=0.818    p=0.574 
 
Platelets (x10
3/µl)    231.4(83.2) 
  Yes          214.5(111.2) 146.6(30.1)  212.2(115.7) 
  No          234.4(77.6)  235.6(82.8)  233.2(80.1) 
            p=0.381    p=0.019    p=0.473 
 
PT (seconds)     11.98(1.94) 
  Yes          12.37(2.52)  14.2(3.96)  12.89(3.26) 
  No          11.91(1.83)  11.87(1.76)  11.9(1.78) 
            p=0.382    p=0.008    p=0.144 
 
 
 
Laboratory variables reveal a significant difference in platelet levels and prothrombin time in 
relation to cardiac death (p=0.019 and p=0.008 respectively), and in serum urea levels in relation 
to all-cause mortality (p=0.037). There was also a difference in serum urea levels in relation to 
cardiac death (p=0.050) and in haemoglobin in relation to all-cause mortality (p=0.058), although 
this was not significant. MACE – major adverse cardiac event, PT – Prothrombin time. All analyses 
performed using a 2-sample t-test. 
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6.3.2 Risk Indices and Outcome 
Complete datasets required for the calculation of all 5 preoperative risk indices 
were collected in all 106 patients who underwent elective open AAA repair. 
6.3.2.1  Glasgow Aneurysm Score 
The median (interquartile range) GAS was 77 (72-84) [Table 6.2]. The median 
GAS in those who suffered MACE was not significantly different to that in those 
without (median GAS 79 [71-84] vs 71 [72-84], p=0.846) [Figure 6.1a]. The 
median GAS in patients suffering a cardiac death was again not significantly 
different (median GAS 77 [70-85] vs 71 [72-84], p=0.911) [Figure 6.1b]. The 
median GAS in all causes of mortality was also not significantly different (median 
GAS 84 [74-87] vs 77 [71-83], p=0.227) [Figure 6.1c]. ROC analysis revealed an 
AUC of 0.515, 0.515 and 0.622 for MACE, cardiac death and all-cause mortality 
respectively. Sensitivities and specificities were poor and the GAS appeared to 
perform poorly in all outcomes [Table 6.3]. 
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Figure 6.1 Boxplots of the Glasgow Aneurysm Score and outcome. 
a.  GAS and MACE. 
 
b.  GAS and cardiac death. 
 
c.  GAS and all-cause mortality. 
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6.3.2.2  Vascular (physiology only) - Physiological and Operative Severity 
Score for enUmeration of Mortality 
The median (interquartile range) V(p)-POSSUM was 29 (27-34). There was a 
significant difference in median V(p)-POSSUM with higher scores in those who 
suffered MACE than in those without (median V(p)-POSSUM 33 [28-37] vs 29 [26-
32], p=0.028) [Table 6.2]. ROC analysis revealed an AUC of 0.681 (95% CI 0.549-
0.814, SE 0.067; p=0.021) [Figure 6.2a]. The best cut off for V(p)-POSSUM in 
predicting MACE was 20.5 with a sensitivity of 63% and specificity of 67%. At this 
cut-off the PPV was 35% and the NPV was 93% [Table 6.3].  
The median V(p)-POSSUM was significantly higher in those who suffered cardiac 
death than in those who did not (median V(p)-POSSUM 34 [32-37] vs 29 [26-33], 
p=0.030) [Table 6.2]. ROC analysis revealed an AUC of 0.762 (95% CI 0.596-
0.928, SE 0.085; p=0.048) [Figure 6.2b] with a cut-off of again 20.5. Sensitivity 
at this cut-off was 80% and specificity was 65% with a PPV of 15% and NPV of 99% 
[Table 6.3]. 
The median V(p)-POSSUM was significantly higher in the all-cause mortality 
group than in the survivors (median V(p)-POSSUM 34 [29-37] vs 29 [26-33], 
p=0.038) [Table 6.2]. ROC analysis revealed an AUC of 0.780 (95% CI 0.667-
0.893, SE 0.057; p=0.006) [Figure 6.2c] with once again a cut-off of 20.5. 
Sensitivity was 89% and specificity was 68% with a PPV of 21% and NPV of 99% 
[Table 6.3].  
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Figure 6.2 ROC curve: V(p)-POSSUM and outcome. 
a.  V(p)-POSSUM and MACE (AUC 0.681). 
 
b.  V(p)-POSSUM and cardiac death (AUC 0.762). 
 
c.  V(p)-POSSUM and all-cause mortality (AUC 0.780). 
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6.3.2.3  Vascular Biochemical and Haematological Outcome Model 
The median (interquartile range) VBHOM was -2.66 (-3.07 to -2.23) [Table 6.2]. 
There was no significant difference in median VBHOM in those who suffered 
MACE than in those who did not (median VBHOM -2.53 (-2.96 to -2.08) vs -2.67 (-
3.12 to -2.26), p=0.232), although this did not reach statistical significance 
[Figure 6.3a]. There was again no significant difference in median VBHOM 
between those who suffered cardiac death and those who did not (median 
VBHOM -2.57 (-2.78 to -1.85) vs -2.66 (-3.08 to -2.23), p=0.340) [Figure 6.3b]. 
There was also no significant difference in median VBHOM score in the all-cause 
mortality group when compared to the survivors (median VBHOM -2.33 (-2.62 to    
-2.21) vs -2.72 (-3.10 to -2.30), p=0.069) [Figure 6.3c]. ROC analysis revealed an 
AUC of 0.592, 0.626 and 0.684 for MACE, cardiac death and all-cause mortality 
respectively. Sensitivities and specificities were poor and the VBHOM performed 
poorly in all outcomes [Table 6.3]. 
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Figure 6.3 Boxplots for VBHOM and outcome. 
a.  VBHOM and MACE. 
 
b.  VBHOM and cardiac death. 
 
c.  VBHOM and all-cause mortality. 
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6.3.2.4  Lee’s Revised Cardiac Risk Index 
The median RCRI was 2 (interquartile range 1-3). There was no significant 
difference in median RCRI in those that suffered MACE, cardiac death and all-
cause mortality (p=0.735, p=0.448 and p=0.415 respectively) [Table 6.2]. ROC 
analysis revealed an AUC of 0.525, 0.596 and 0.578 respectively. Sensitivities 
and specificities were poor and the RCRI appeared to perform poorly in all 
outcomes [Table 6.3].  
6.3.2.5  Preoperative Risk Score of the Estimation of Physiological Ability 
and Surgical Stress Score 
The median (interquartile range) PRS was 0.46 (0.26-0.64). The median PRS was 
significantly higher in those who suffered MACE than in those who did not 
(median PRS 0.63 [0.46-0.67] vs 0.42 [0.25-0.60], p=0.019) [Table 6.2]. ROC 
analysis revealed an AUC of 0.682 (95% CI 0.559-0.805, SE 0.063; p=0.021) 
[Figure 6.4a]. The best cut off for PRS in predicting MACE was 0.55 with a 
sensitivity of 69% and specificity of 64%. At this cut-off the PPV was 27% and the 
NPV was 93% [Table 6.3].  
The median PRS was significantly higher between those who suffered cardiac 
death and those who did not (median PRS 0.65 [0.59-1.02] vs 0.44 [0.26-0.62], 
p=0.017) [Table 6.2]. ROC analysis revealed an AUC of 0.821 (95% CI 0.697-
0.945, SE 0.063; p=0.016) [Figure 6.4b] with a cut-off of 0.63. Sensitivity at this 
cut-off was 80% and specificity was 76% with a PPV of 15% and NPV of 99% [Table 
6.3]. 
The median PRS was higher in the all-cause mortality group than in the survivors 
(median PRS 0.65 [0.40-0.93] vs 0.44 [0.26-0.62], p=0.050) [Table 6.2], although 
this was just not significant. ROC analysis revealed an AUC of 0.703 (95% CI 
0.516-0.890, SE 0.095; p=0.045) [Figure 6.4c] with a cut-off of 0.55. Sensitivity 
was 78% and specificity was 63% with a PPV of 15% and NPV of 97% [Table 6.3].  
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Figure 6.4 ROC curve: PRS and outcome. 
a.  PRS and MACE (AUC 0.682). 
 
b.  PRS and cardiac death (AUC 0.821). 
 
c.  PRS and all-cause mortality (AUC 0.703). 
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Table 6.2 Preoperative risk indices and outcome. 
 
        Median (IQR) Score      MACE          Cardiac Death    All-cause Mortality 
 
GAS        77 (72-84) 
    Yes                79 (71-84)        77 (70-85)     84 (74-87) 
    No                71 (72-84)           71 (72-84)     77 (71-83) 
                    p=0.846        p=0.911      p=0.227 
V(p)-POSSUM     29 (27-34) 
    Yes                33 (28-37)        34 (32-37)     34 (29-37) 
    No                29 (26-32)            29 (26-33)     29 (26-33) 
                    p=0.028        p=0.030      p=0.038 
VBHOM      -2.66 (-3.07 to -2.23) 
    Yes                -2.53 (-2.96to-2.08)      -2.57 (-2.78to-1.85)  -2.33 (-2.62to-2.21) 
    No                -2.67 (-3.12to-2.26)      -2.66 (-3.08to-2.23)  -2.72 (-3.10to-2.30) 
                    p=0.232        p=0.340      p=0.069 
RCRI        2 (1-3) 
    Yes                2 (1-3)          3 (1-4)      2 (1-4)     
    No                2 (1-3)              2 (1-3)      2 (1-3) 
                    P=0.735        P=0.448      P=0.415 
PRS        0.46 (0.26-0.64) 
    Yes                0.63 (0.46-0.67)      0.65 (0.59-1.02)    0.65 (0.40-0.93) 
    No                0.42 (0.25-0.60)      0.44 (0.26-0.62)    0.44 (0.26-0.62) 
                    p=0.019        p=0.017      p=0.050 
 
IQR – interquartile range, MACE – Major Adverse Cardiac Event, GAS – Glasgow Aneurysm Score, V(p)-POSSUM – physiological component of Vascular Physiological 
and Operative Severity Score for enUmeration of Mortality, VBHOM - Vascular Biochemical and Haematological Outcome Model, RCRI – Revised Cardiac Risk Index, 
PRS – Preoperative Risk Score of Estimation of Physiological Ability and Surgical Stress. All analyses performed using Mann-Whitney U test. 
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Table 6.3 Results of receiver operating characteristic curve analysis for each score according to outcome. 
 
        AUC    95% CI   SE  p-value    cut-off  Sens.  Spec.    PPV  NPV 
MACE 
  GAS        0.515    0.374-0.657  0.072  0.846    77.5    50%  53%    14%  86% 
  V(p)-POSSUM    0.681    0.549-0.814  0.067  0.021    20.5    63%  67%    35%  93% 
  VBHOM      0.592    0.455-0.730  0.070  0.241    -2.59    56%  56%    16%  88% 
  RCRI       0.525    0.364-0.687  0.082  0.747    >1    63%  38%    15%  85% 
  PRS        0.682    0.559-0.805  0.063  0.021    0.55    69%  64%    27%  93% 
 
Cardiac Death 
  GAS        0.515    0.285-0.745  0.117  0.911    76.5    60%  46%    5.2%  96% 
  V(p)-POSSUM    0.762    0.596-0.928  0.085  0.048    20.5    80%  65%    15%  99% 
  VBHOM      0.626    0.430-0.822  0.100  0.344    -2.59    60%  56%    5%  96% 
  RCRI       0.596    0.285-0.907  0.159  0.470    >2    60%  68%    9%  97% 
  PRS        0.821    0.697-0.945  0.063  0.016    0.63    80%  76%    15%  99% 
 
All-cause mortality 
  GAS        0.622    0.436-0.808  0.095  0.227    77.5    56%  54%    10%  93% 
  V(p)-POSSUM    0.780    0.667-0.893  0.057  0.006    20.5    89%  68%    21%  99% 
  VBHOM      0.684    0.555-0.813  0.066  0.069    -2.48    67%  73%    15%  95% 
  RCRI       0.578    0.361-0.796  0.111  0.438    >2    45%  68%    11%  93% 
  PRS        0.703    0.516-0.890  0.095  0.045    0.55    78%  63%    15%  97% 
 
MACE – Major adverse cardiac event, GAS – Glasgow aneurysm score, V(p)-POSSUM – physiological component of  Vascular Physiological and Operative Severity Score 
for enUmeration of Mortality, VBHOM - Vascular Biochemical and Haematological Outcome Model, RCRI – Revised cardiac risk index, PRS – preoperative risk score 
of. Estimation of Physiological Ability and Surgical Stress, AUC – area under the curve, CI – confidence interval, SE- standard error, Sens. – Sensitivity, Spec. – 
Specificity, PPV – positive predictive value, NPV – negative predictive value. 
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6.3.3 Tertile Analyses of Risk Indices 
Tertile analysis was performed by dividing each index grouping into 3 equal 
classes based on even distribution with the aim of examining stepwise increase 
in MACE, cardiac death and mortality between groups. For the GAS there was no 
significant difference in the tertile rate of MACE, cardiac death and all-cause 
mortality with rates from 16% to 12% and 19% for MACE, 3% to 7% and 6% in 
cardiac death, and 3% to 7% and 16% in all-cause mortality (p=0.584, p=0.891 
and p=0.264 respectively) [Figure 6.5a].  
For V(p)-POSSUM sequential increases were seen in rates for MACE and all-cause 
mortality with rates in MACE of 4% to 13% and 29%, and in all-cause mortality of 
0% to 8% and 16% (p=0.013 and p=0.030 respectively). In cardiac death there was 
no significant rate change between tertiles with rates of 0% to 4% and 10% 
(p=0.130) [Figure 6.5b]. 
For VBHOM, although there were sequential increases in rates for MACE and all-
cause mortality, there was no significant difference in rates for outcome, with 
rates of 9% to 16% and 20 % in MACE, 0% to 8% and 6% in cardiac death, and 0% to 
11% and 14% in all-cause mortality (p=0.395, p=0.174 and p=0.070 respectively) 
[Figure 6.5c]. 
For RCRI there was no significant difference in rates between tertiles for all 
outcomes. Rates for MACE were 15% to 13% and 17 %, for cardiac death 5% to 0% 
and 9%, and for all-cause mortality 9% to 6% and 11% (p=1.0, p=0.368 and 
p=0.867 respectively) [Figure 6.5d]. 
For the PRS component of E-PASS there were significant increases in rates for all 
outcome measures with rates of 6% to 13% and 27% in MACE, 0% to 3% and 12% in 
cardiac death, and rates of 6% to 3% and 18% in all-cause mortality (p=0.038, 
p=0.015 and p=0.032 respectively) [Figure 6.5e]. 
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Figure 6.5. Tertile analysis for individual risk scores. 
 
a. 
 
GAS and outcome
0
5
10
15
20
<73 73-81 >81
Score
O
u
t
c
o
m
e
 
P
e
r
c
e
n
t
a
g
e
 
(
%
)
MACE
Cardiac Death
All-cause Mortality
 
 
b.  
V(p)-POSSUM and outcome
0
5
10
15
20
25
30
35
<16 16-21 >21
Score
O
u
t
c
o
m
e
 
P
e
r
c
e
n
t
a
g
e
 
(
%
)
MACE
Cardiac Death
All-cause Mortality
 
 
c.   
VBHOM and outcome
0
5
10
15
20
25
<-2.98  -2.98 to -
2.42 
>-2.42
Score
O
u
t
c
o
m
e
 
P
e
r
c
e
n
t
a
g
e
 
(
%
)
MACE
Cardiac Death
All-cause Mortality
 
 
  
                   
208 
d.   
RCRI and outcome
0
2
4
6
8
10
12
14
16
18
1 2 ≥3
Score
O
u
t
c
o
m
e
 
p
e
r
c
e
n
t
a
g
e
 
(
%
)
MACE
Cardiac Death
All-cause Mortality
 
 
e.   
PRS and outcome
0
5
10
15
20
25
30
<0.27 0.27-0.58 >0.58
Score
O
u
t
c
o
m
e
 
P
r
e
c
e
n
t
a
g
e
 
(
%
)
MACE
Cardiac Death
All-cause Mortality
 
 
Tertile analysis reveals a significant difference in tertile rates for V(p)-POSSUM in predicting 
MACE and all-cause mortality (p=0.013 and p=0.030) and in the PRS component of E-PASS in 
predicting all outcome measures (p=0.038 in MACE, p=0.015 in cardiac death and p=0.032 in all-
cause mortality). The RCRI and GAS indices performed poorly. All analyses were performed using 
Mann-Whitney U test. MACE – Major Adverse Cardiac Event, GAS – Glasgow Aneurysm Score, V(p)-
POSSUM – Physiological component of Vascular Physiological and Operative Severity Score for 
enUmeration of Mortality, VBHOM - Vascular Biochemical and Haematological Outcome Model, 
RCRI – Revised Cardiac Risk Index, PRS – Preoperative Risk Score of Estimation of Physiological 
Ability and Surgical Stress. 
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6.4 Discussion 
Preoperative risk stratification is of great importance in elective open AAA 
repair and, since opinion and experience alone are often the only tools of the 
vascular surgeon in selecting operative candidates, it is unsurprising that an 
ideal risk stratifier has been sought. A number of risk scoring systems derived 
from patients undergoing non-cardiac surgery have been devised over the last 
20-30 years, but most seem to lack accuracy.
294-296 Based on a review of the 
literature, the 5 most suitable preoperative risk scoring indices have been 
identified and prospectively evaluated with an emphasis on predicting MACE, 
cardiac death and all-cause mortality in the immediate postoperative period. 
The 2 scoring systems that performed well were the V(p)-POSSUM and the 
Preoperative Risk Score component of the E-PASS. In this cohort, the physiology 
component of the V(p)-POSSUM was a significant predictor of all outcome 
measures. POSSUM scoring has long been advocated as the most appropriate 
scoring system in non-cardiac surgery.
297 In addition, POSSUM has been shown to 
over-predict death in low risk patients
298, despite modification including the 
vascular adaption.
299 It is therefore expected that V(p)-POSSUM would perform 
well in predicting all-cause mortality in the elective open AAA patient, given the 
higher risk associated with this surgery type compared to other types of non-
cardiac and vascular procedures. It was unexpected that it would perform well 
in predicting MACE, although this may reflect its ability to predict morbidity in 
general. Whilst this index appears to perform well, there is overriding concern 
with the effect of area variation, and whilst V(p)-POSSUM allows for variations in 
the hospital case mix it is not robust in different geographical locations.
299, 300 
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The PRS component of the E-PASS score performed well in predicting MACE and 
cardiac death, and whilst it did not appear to predict all-cause mortality on 
univariate testing it did perform well on tertile analysis and in ROC curve 
analysis. The main concern with E-PASS is that the original scoring system 
requires operative data to calculate its overall score thus precluding its use for 
preoperative risk assessment. However a strong correlation between the PRS 
component and outcome has been shown which therefore permits its use in the 
preoperative setting.
257 It may be the very premise of this scoring system, where 
each patient‘s physiological reserve is scored, that gives a more accurate 
outcome measure. 
 
Of the other scoring systems only VBHOM showed promise in predicting all-cause 
mortality. However, this did not reach statistical significance and VBHOM 
performed poorly in predicting MACE or cardiac death. This confirms previous 
validations where VBHOM was shown to under-predict perioperative 
complications and over-predict mortality.
297 This may be explained by the fact 
that VBHOM was devised including patients who underwent emergency AAA 
repair. The supposed advantage of VBHOM, including its universal applicability as 
it relies only on a minimal dataset of blood tests and does not use operative 
data, does not hold true in this cohort. 
The GAS and RCRI performed poorly in this prospective cohort. The GAS was 
constructed using a population of 500 patients undergoing AAA repair in Glasgow 
over a 10 year period between 1980 and 1990.
154 This was a retrospective data 
analysis and produced a simple index of risk. Despite numerous validations in 
different populations
156-158, 301, 302 the GAS has been criticised for not reliably 
identifying individual high risk patients and being consistently inaccurate in 
predicting morbidity
158,161, whilst also performing poorly when compared to 
other scoring systems.
161 The GAS also fails to allow for treatment or 
optimisation of a patient‘s comorbid condition and scores for the presence of 
disease rather than the functional effects of the disease process. More surprising 
is that the score is a poor predictor in the very population from which it was 
derived, which may be in part explained by the increasing age and improving 
health states of the population.   
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The most unexpected finding is that the RCRI performed worst. This revised 
cardiac index not only failed to predict mortality but failed to predict cardiac 
events. This lack of predictive value may be due to the high risk population 
within which it was used, immediately scoring every patient 1 prior to further 
scoring. It is likely that this diminishes the sensitivity of the index, as has been 
suggested in the published literature, where concern has been expressed at the 
grouping of intraperitoneal and major vascular surgery together, and where open 
AAA repair has shown to have worse outcome than all other operation subgroups 
that are considered together in the RCRI.
66, 303  Despite this the RCRI was 
recently found to predict survival in the elective open AAA repair population in 
the UK when used with CPEX testing.
304  
The principal limitation of this prospective cohort is the small sample size. 
Although MACE occurred with sufficient frequency to draw reasonable 
conclusions, all-cause mortality and in particular cardiac death were low in real 
numbers. A larger cohort would have been more conducive to risk estimation. In 
contrast, however, the endpoints were well-defined and most vascular surgical 
practices will deal with numbers similar to this cohort. This therefore questions 
the utility of scoring systems that require large numbers to be clinically 
relevant. 
It is apparent that, when compared to the scoring systems described in this 
chapter, BNP has superior predictive capabilities. Median BNP was highly 
significant in predicting MACE, cardiac death and all-cause mortality (p=0.001, 
p=0.043 and p=0.028). BNP therefore outperformed all indices with regards to 
MACE and all-cause mortality, and was only surpassed in cardiac death by both 
PRS (p=0.017) and V(p)-POSSUM (p=0.030). When comparing ROC curve analysis, 
BNP outperformed all risk indices with regards to all outcome measures [Table 
6.4]. Further to this, on tertile analysis, although there was no stepwise increase 
in MACE and mortality there was a significant difference in tertile grouping of 
BNP in predicting all outcome measures [Figure 6.6]. More importantly, with 
tertile analysis there is little difference in outcome observed until the 3
rd tertile, 
which demonstrates that BNP predicts those that are at high risk and at very low 
risk, negating the need for decision making in the difficult intermediate risk 
patient, as seen with other risk stratification indices.  
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In conclusion, it appears that a preoperative BNP sample not only predicts MACE, 
but also outperforms current risk indices in predicting cardiac death and all-
cause mortality. Where BNP analysis is not available it appears both the PRS 
component of E-PASS and V(p)-POSSUM have advantages in outcome prediction 
over other scoring systems. Whilst V(p)-POSSUM appears to be the best 
stratification score (and easily accessible on the internet) with regard to all-
cause mortality, its inability to predict mortality rates in individual patients may 
make E-PASS a more favourable alternative, having been developed specifically 
as an aid to clinical decision-making, although further validation is required.
257, 
294 
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Table 6.4 Results of receiver operating characteristic curve analysis for B-type natriuretic peptide. 
 
        AUC    95% CI   SE  p-value    cut-off  Sens.  Spec.    PPV  NPV 
 
MACE        0.927    0.850-1.004  0.039  <0.001    99.5 pg/ml  88%  89%    61%  98%     
  (PRS      0.682    0.559-0.805  0.063  0.021    0.55    69%  64%    27%  93%) 
Cardiac Death    0.963    0.896-1.031  0.034  <0.001    448 pg/ml  80%  100%    100%  99%     
  (PRS      0.821    0.697-0.945  0.063  0.016    0.63    80%  76%    15%  99%) 
All-cause Mortality    0.860    0.757-0.962  0.052  <0.001    93 pg/ml  78%  79%    30%  99%     
  (V(p)-POSSUM    0.780    0.667-0.893  0.057  0.006    20.5    89%  68%    21%  99%) 
Comparison of BNP with the best performing of the five scoring indices (in brackets) reveals that BNP outperforms all scoring systems in terms of AUC, significance, 
sensitivity, specificity and predictive values. MACE – Major adverse cardiac event, V(p)-POSSUM – physiological component of Vascular Physiological and Operative 
Severity Score for enUmeration of Mortality, PRS – preoperative risk score of Estimation of Physiological Ability and Surgical Stress, AUC – area under the curve, CI – 
confidence interval, SE- standard error, Sens. – Sensitivity, Spec. – Specificity, PPV – positive predictive value, NPV – negative predictive value. 
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Figure 6.6. Tertile analysis for B-type natriuretic peptide and outcome. 
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Tertile analysis reveals a significant difference in tertile rates for BNP in predicting MACE, 
cardiac death and all-cause mortality (p<0.001, p=0.007 and p=0.002 respectively). All analysis 
were performed using Mann-Whitney U test. MACE – Major adverse cardiac event. 
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Chapter 7 
 
Endovascular Aneurysm Repair, BNP and Cardiac 
Outcome  
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7.1 Introduction 
Since endovascular aneurysm repair was first introduced in the late 1980s it has 
been an area of controversy with regard to satisfactory aneurysm repair, long-
term outcome measures, quality of life and cost. Potential advantages of EVAR 
over open repair include reduced time under general anaesthesia, elimination of 
the pain and trauma associated with major abdominal surgery, reduced length of 
stay in hospital and intensive care unit, and reduced blood loss.
305 Potential 
disadvantages include the development of endoleaks, which occur when blood 
continues to flow through the aneurysm due to incomplete exclusion of the 
aneurysm by the stent graft.
305 Thus, although open repair does not require any 
special follow-up, patients who have undergone EVAR require regular imaging to 
check for the presence of late endoleaks. In addition, if the EVAR procedure is 
unsuccessful or complications arise during the procedure, conversion to open 
repair may be necessary in patients who may initially have been considered unfit 
for open surgery.
305 
The recent EVAR 1, EVAR 2 and Dutch Randomized Endovascular Aneurysm 
Management (DREAM) trials addressed management of abdominal aortic 
aneurysms (AAAs) larger than 5.5 cm in diameter.
21, 22, 306-308 The DREAM and 
EVAR 1 trials randomized patients appropriate for open repair to EVAR or open 
repair, whilst the EVAR 2 trial randomized patients unfit for open repair to EVAR 
or nonoperative management. The EVAR 1 trial showed a 3% lower initial 
mortality for EVAR, with a persistent reduction in aneurysm-related death at 4 
years. However improvement in overall late survival was not demonstrated. 
Similarly, the DREAM trial observed an initial mortality advantage for EVAR, but 
overall 1-year survival was equivalent in both groups. Both trials found 
significantly higher complication and intervention rates and higher hospital costs 
with EVAR, and by 1 year, no quality of life benefit was evident. The EVAR 2 trial 
did not demonstrate a survival advantage with EVAR over non-operative 
management, whilst observing that EVAR was associated with a greater 
likelihood of treatment complications, subsequent interventions, and threefold 
higher costs. A number of methodological problems, including the exclusion of 
14 patients who died whilst awaiting EVAR, have meant that definitive 
conclusions are difficult to draw from the EVAR 2 trial.  
                   
217 
It is clear from these trials, which show short-term mortality benefits but 
questionable long-term mortality benefits, that the role of EVAR has not yet 
been fully defined. Consequently, patient selection and risk stratification remain 
important. In this chapter the aim is to evaluate the use of preoperative serum 
BNP in predicting outcome in EVAR, with emphasis on MACE and all-cause 
mortality in the immediate perioperative period. 
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7.2 Methods 
7.2.1 Study Population 
A prospective, observational, multi-centre cohort study was performed involving 
the 3 major vascular units within Glasgow (Gartnavel General Hospital, Glasgow 
Royal Infirmary and the Southern General Hospital). A cohort of consecutive 
patients admitted electively for EVAR were identified between August 2005 and 
September 2007. As the use of EVAR was not fully established throughout 
Glasgow at the beginning of the study period, with only around 20 EVARs 
performed a year, a timescale was used, rather than a recruitment endpoint, 
that ran alongside the open AAA repair cohort (2005-2007 as described above).  
7.2.2 Patients and Preoperative Assessment  
Collection of patient data was identical to that described in chapter 4. 
Preoperative BNP was collected in the manner previously described in chapter 4. 
7.2.3 Postoperative Follow-up 
Immediate postoperative testing is described in detail in chapter 4. The only 
modification to this protocol was the preference of day 5 tests on the day of 
discharge when patients were discharged home before day 5, to ensure that 
there were two complete sets of post-op measurements. All patients were then 
followed through an area-wide interhospital computer database for 30 days. 
Where no recent contact was recorded during this period the patients‘ General 
Practice (GP) was contacted, as was required in 22 cases. If a patient died 
during this period, the date and cause of death were noted.  
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7.2.4 Endpoints 
Endpoints for the study were non-fatal MI and all-cause mortality. The definition 
of MACE is that described in chapter 4 and was determined by a review of 
postoperative data by two cardiologists blinded to preoperative BNP levels. All-
cause mortality was postoperative death of any cause. 
7.2.5 Statistical Analysis 
Statistical analysis was performed using the SPSS
® statistical software package 
(SPSS, Chicago, Illinois, USA). BNP values were reported as median (interquartile 
range) with continuous variables compared using Mann-Whitney U and Kruskall-
Wallis testing. Fisher‘s Exact test was used to analyse the differences between 
independent categorical data. 
7.2.6 Ethical Approval 
Local Research and Development, and Central Ethics Committee approval was 
obtained for the study. All patients were provided with an information sheet and 
signed a study consent form prior to inclusion. GPs were sent individual letters 
to inform of their patients‘ inclusion in the study. 
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7.3 Results 
7.3.1 Patient Characteristics and BNP Levels 
During the study period 42 patients met the inclusion criteria and were invited 
to participate. Two were found to have elevated preoperative cTnI (0.11 and 
0.23 ng/ml) and were not included. Their preoperative serum BNP levels were 
742 and 16 pg/ml respectively. Both patients underwent EVAR despite their 
elevated cTnI and neither developed a cardiac complication. The median age of 
the remaining 40 patients was 78 (71-80) years. The median preoperative BNP 
level was 40 (25-98) pg/ml. Further baseline characteristics are shown in table 
7.1. The male to female ratio shows a male predominance of 8:1. The majority 
of patients had smoked at some point in their life (82%). Fifteen (38%) patients 
had suffered a previous MI and 7 (18%) suffered from CCF. Nine (23%) patients 
had been noted to suffer from chronic renal impairment. Other selected patient 
characteristics are detailed in table 7.2. 
BNP levels were found to be significantly higher in those that had known CCF 
(median BNP 210 [69-420] vs 35 [19-64] pg/ml, p=0.018). Levels were 
proportionally higher in those with hypertension, hyperlipidaemia or a history of 
previous MI, although this was not significant.  
Renal failure by chronic kidney disease stage did not show variation in BNP 
levels, although there was a tendency to higher levels with increasing degrees of 
chronic kidney disease. Two patients had an eGFR <30ml/min. Both patients had 
an uncomplicated recovery. BNP levels were 210 and 678 pg/ml respectively. 
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Table 7.1 Clinical details and BNP levels in elective EVAR patients. 
 
 
        Patient     BNP level 
        Characteristic   (pg/ml)    p value 
        n=40 
 
Sex   
Male    35 (87%)    36 (22-99) 
    Female   5 (13%)    44 (28-141)    0.893 
  Angina      
    Present   11 (28%)    45 (27-210) 
    Absent   29 (72%)    35 (19-88)    0.374 
  Previous MI 
    Present   15 (38%)    56 (36-210)     
    Absent   25 (62%)    33 (19-77)    0.268 
Hypertension       
    Present   27 (68%)    52 (26-112) 
Absent   13 (32%)    35 (13-47)    0.124 
Hyperlipidaemia 
    Present   19 (48%)     36 (26-112) 
    Absent   21 (52%)    44 (24-88)    0.184 
Diabetes       
Present   10 (25%)    29 (11-159) 
Absent   30 (75%)    45 (29-100)    0.721 
  Current smoker     
Present   11 (28%)    32 (6-99) 
Absent   29 (72%)    45 (28-98)    0.328 
  Smoked ever       
Present   33 (82%)    35 (24-83) 
Absent   7 (18%)    82 (26-103)    0.063 
  CVD         
Present   7 (18%)    36 (14-210) 
Absent   33 (82%)    45 (26-91)    1.0 
  CCF 
    Present   7 (18%)    210 (69-420) 
    Absent   33 (82%)    35 (19-64)    0.018 
  COPD        
Present   11 (28%)    34 (27-210) 
Absent   29 (72%)    45 (24-88)    0.423 
  CRF         
Present   9 (23%)    32 (15-171) 
Absent   31 (77%)    44 (26-83)    0.917 
 
Patient characteristics by BNP reveal significant differences in BNP levels in patients that had 
CCF (p=0.018) when analysed using Mann-Whitney U test. MI – myocardial infarction, CVD – 
cerebrovascular disease, CCF – congestive cardiac failure, COPD – chronic obstructive pulmonary 
disease, CRF - chronic renal failure. 
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Table 7.2 Selected other patient details and BNP. 
 
        Patient     BNP level 
        Characteristic   (pg/ml)    p value 
        n=40 
 
  Anti-platelet       
Present   28 (70%)    41 (26-103) 
Absent   12 (30%)    40 (17-68)    0.784 
  Statin         
Present   27 (68%)    35 (26-101) 
Absent   13 (32%)    45 (19-91)    0.382 
  Beta-blocker       
Present   14 (35%)    51 (33-130) 
Absent   26 (65%)    35 (15-86)    0.198 
  Antianginal       
Present   9 (22%)    36 (20-64) 
Absent   31 (78%)    44 (26-101)    0.953 
  Diuretic 
    Present   10 (25%)    55 (20-96) 
    Absent   30 (75%)    36 (26-100)    0.575 
  RCRI 
    0    11 (28%)    32 (10-45)   
    1    15 (38%)    49 (26-83) 
    2    5 (12%)    131 (59-457) 
    ≥3    9 (22%)    34 (21-161)    0.069 
  eGFR 
    <60    22 (55%)    51 (32-102) 
    ≥60    18 (45%)    32 (16-65)    0.206 
  CKD 
    1    3 (7%)     99 (32-145) 
    2    15 (38%)    22 (10-49) 
    3    20 (50%)    45 (30-91) 
    4    2 (5%)     444 (210-678) 
    5    0 (0%)     0      0.112 
  CRP 
    <6    18 (45%)    36 (31-100) 
    ≥6    22 (55%)    45 (15-87)    0.777 
 
Although not significant, BNP levels were higher in those with worsening renal failure and 
increasing risk by RCRI. Analyses were determined using Mann-Whitney U and Kruskall-Wallis for 
RCRI and CKD. RCRI – revised cardiac risk index, eGFR – estimated glomerular filtration rate, CKD 
– chronic kidney disease, CRP – C-reactive protein.  
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7.3.2 EVAR vs Open Repair Cohorts 
When comparing the cohorts for elective EVAR and elective open repair (chapter 
4) there was a significant difference in age [EVAR 78 (71-80) vs Open repair 73 
(66-77) years, p=0.002]. There were also significant differences in the proportion 
of patients with hyperlipidaemia [EVAR 19/40 (48%) vs Open repair 15/106 (14%), 
p=0.003] or chronic renal impairment [EVAR 9/40 (23%) vs Open repair 8/106 
(8%), p=0.035]. In general the EVAR cohort appeared more unhealthy with a 
greater incidence of angina, previous MI, hypertension, diabetes mellitus, 
cerebrovascular disease and chronic heart failure, although not significantly so. 
Patient characteristics are compared in tables 7.3 and 7.4. 
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Table 7.3 Patient characteristics in EVAR vs open repair. 
 
 
        Patient     Patient 
        Characteristic   Characteristic    
        n=106      n=40 
(open repair)    (EVAR)    p value 
 
Age  
  (years)   73 (66-77)    78 (71-80)    0.002 
AAA size 
  (cm)    6.4 (5.7-7.2)    6.2 (5.9-7.0)    0.259 
Sex   
Male    88 (83%)    35 (87%)   
    Female   18 (17%)    5 (13%)    0.317 
  Angina      
    Present   25 (24%)    11 (28%) 
    Absent   81 (76%)    29 (72%)    0.201 
  Previous MI 
    Present   23 (22%)    15 (38%)     
    Absent   83 (78%)    25 (62%)    0.371 
Hypertension       
    Present   72 (67%)    27 (68%) 
Absent   34 (33%)    13 (32%)    0.134 
Hyperlipidaemia 
    Present   15 (14%)     19 (48%) 
    Absent   91 (86%)    21 (52%)    0.003 
Diabetes       
Present   9 (8%)     10 (25%) 
Absent   97 (92%)    30 (75%)    0.083 
  CVD         
Present   22 (21%)    7 (18%) 
Absent   84 (79%)    33 (82%)    0.366     
  CCF 
    Present   13 (12%)    7 (18%) 
    Absent   93 (88%)    33 (82%)    0.366 
  COPD        
Present   25 (24%)    11 (28%) 
Absent   81 (76%)    29 (72%)    1.0 
  CRF         
Present   8 (8%)     9 (23%) 
Absent   98 (92%)    31 (77%)    0.035 
 
There was a greater number of patients with hyperlipidaemia (p=0.003) and CRF (p=0.035) in the 
EVAR cohort and patients were older (p=0.002). There appeared to be greater co-morbidity in 
the EVAR cohort with greater incidence of angina, hypertension, and diabetes, although this did 
not reach statistical significance. Analyses were determined using Fisher‘s Exact Test. MI – 
myocardial infarction, CVD – cerebrovascular disease, CCF – congestive cardiac failure, COPD – 
chronic obstructive pulmonary disease, CRF - chronic renal failure.  
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Table 7.4 Other patient characteristics in EVAR vs open repair. 
 
        Patient     Patient 
        Characteristic   Characteristic    
        n=106      n=40 
(open repair)    (EVAR)    p value 
 
  Anti-platelet       
Present   63 (59%)    28 (70%) 
Absent   43 (41%)    12 (30%)    0.221 
  Statin         
Present   66 (62%)    27 (68%) 
Absent   40 (38%)    13 (32%)    1.0 
  Beta-blocker       
Present   43 (41%)    14 (35%) 
Absent   63 (59%)    26 (65%)    0.346 
  Antianginal       
Present   23 (22%)    9 (22%) 
Absent   83 (78%)    31 (78%)    0.763     
  Diuretic 
    Present   35 (33%)    10 (25%) 
    Absent   71 (67%)    30 (75%)    0.127 
  eGFR 
    <60    42 (40%)    22 (55%) 
    ≥60    64 (60%)    18 (45%)    0.936 
  CKD 
    1    9 (8%)     3 (7%) 
    2    52 (49%)    15 (38%) 
    3    43 (41%)    20 (50%) 
    4    2 (2%)     2 (5%) 
    5    0 (0%)     0 (0%)     0.691 
 
Despite the apparent increased co-morbidity in the EVAR cohort there were no differences in 
cardiac medication or CKD between the two cohorts. Analyses were determined using Fisher‘s 
Exact Test. eGFR – estimated glomerular filtration rate, CKD – chronic kidney disease. 
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7.3.3 BNP and Outcome 
There were 3 (7.5%) postoperative non-fatal MIs within 30 days. There were no 
cardiac deaths; however, there was 1 (2.5%) postoperative death attributed to a 
primarily pulmonary origin. There was no significant difference in BNP between 
those that suffered MACE and those that did not (median BNP in MACE 94 [36-
101] vs 35 [24-91] pg/ml, p=0.320) [Figure 7.1]. The BNP in the patient who died 
was 69 pg/ml. There was no significant difference in any other risk factor, 
patient characteristic, intraoperative factor, current medication or preoperative 
blood testing between those that suffered MACE and those that did not. Only in 
preoperative creatinine [median serum creatinine in MACE 145 [122-172] vs 104 
[91-108] µmol/l, p=0.069] and eGFR [median eGFR in MACE 43 [36-53] vs 57 [49-
73] ml/min, p=0.116] was there a tendency to MACE in those with worse renal 
function, although this was not statistically significant. There were no 
asymptomatic postoperative elevations of cTnI without MACE. Overall 30-day 
morbidity in EVAR was 28% with 3 non-fatal MIs, 3 episodes of worsening renal 
failure (requiring dialysis in 2 cases), 2 episodes of peripheral critical ischaemia 
requiring reintervention, 1 episode of severe peptic ulceration, 1 case of florid 
post-procedure diarrhoea and 1 aspiration pneumonia. 30-day morbidity in the 
elective open repair cohort was 33% with (other than the 11 non-fatal MIs) 11 
episodes of respiratory sepsis (2 requiring supportive ventilation), 4 episodes of 
acute renal failure (2 requiring dialysis), 4 episodes of postoperative ileus, 3 
episodes of cardiac arrhythmia requiring intervention, 2 episode of congestive 
cardiac failure and 1 upper gastrointestinal bleed. 
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Figure 7.1 BNP by major adverse cardiac event (MACE). 
 
 
 
 
 
 
There was no difference in median preoperative BNP concentration between those that had 
MACE and those that did not (Median BNP in MACE 94 [36-101] vs 35 [24-91] pg/ml, p=0.320) as 
calculated by Mann-Whitney U test. The dots represent outliers. The asterisks/stars represent 
extreme outliers where the level marked is >3 times the height of the boxes. N is number of 
patients. 
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7.3.4 Preoperative Echocardiography 
Preoperative transthoracic echocardiography was available in 27 (67.5%) 
patients. See table 7.5. Of these 27 patients, 8 were found to have mild LV 
dysfunction, 1 had moderate dysfunction and 2 had severe dysfunction. The 
remainder had normal LV systolic function. Median BNP rose with worsening LV 
function. There were no episodes of MACE in those with moderate or severe LV 
dysfunction. There were insufficient cases of MACE to allow meaningful 
statistical analysis. 
 
 
Table 7.5. Left ventricular function, BNP levels and Major Adverse Cardiac Events (MACE). 
 
 
Patients  BNP      MACE 
          (n=27)   (pg/ml) 
   
 
LV Function 
    Normal    16 (59%)  35 (18-63)    2/16   (13%) 
    Mild dysfunction  8 (30%)  112 (94-145)    1/8  (13%) 
    Mod dysfunction  1 (4%)   210      0/0     
    Severe dysfunction  2 (7%)   549 (420-678)   0/0   
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7.4 Discussion 
In this prospective multi-centre cohort study no single factor was shown to 
predict MACE, cardiac death or all-cause mortality. The patients selected for 
EVAR were older than those considered for open repair. There appeared to be 
greater co-morbidity in the EVAR group, and although there were no objective 
selection criteria, in general those selected for EVAR would have been expected 
to have less favourable outcome if undergoing open repair. Given that there was 
no area-wide patient selection policy for EVAR, the results suggest that 
individual consultant preference selected similar patient types, possibly as a 
result of recently published EVAR trials. 
This study was clearly limited by the small sample size and the low number of 
cardiac events. Recruitment was restricted by the lack of established EVAR 
practice in Glasgow and the uncertain cardiac event rate in this population. 
Previous studies of EVAR have shown low cardiac event and mortality rates, and 
therefore much larger numbers of patients would require to be recruited to 
result in meaningful data. The small numbers in this cohort make it very difficult 
to draw any firm conclusions.  
From the results we have obtained, it would appear that in those who did suffer 
a cardiac event, BNP did not have the same predictive capabilities as that shown 
in open repair and in fact those with very high serum BNP levels survived the 
perioperative period without complication. These results would suggest that a 
group of patients with very high serum BNP levels who are deemed not suitable 
for open repair, due to perceived high risk, may nevertheless benefit from EVAR 
if deemed necessary. There is, however, an increasing bank of evidence that 
would not support this conclusion. 
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The hypothesis that EVAR might be better than surveillance for high risk patients 
has not been supported by the EVAR-2 trial. This study randomized 338 patients 
considered not suitable for open repair to EVAR or to no intervention.
308
 The 
operative mortality of EVAR was 9%, and there was no survival benefit, although 
the survival curves for aneurysm-related mortality did cross at 2 years, 
suggesting the possibility of a late benefit. In addition, retrospective analysis of 
a large American EVAR database revealed that there was a high-risk cohort of 
patients with a very high mortality (>10%) that would not benefit from EVAR.
309  
The use of EVAR, rather than open repair, in treating large AAAs (>5.5cm) has 
also been questioned as the early mortality benefit of EVAR is not sustained in 
the long-term. In the 1082-patient EVAR-1 study, the 30-day mortality rate was 
1.7% for EVAR versus 4.7% for open repair (p=0.001). At 4 years however, all-
cause mortality was similar for EVAR and open repair (26% vs 29% respectively; 
p=0.460).
22 In addition, those who underwent EVAR were much more likely to 
need further intervention with health care costs swelling. Similarly, in the 351-
patient DREAM trial, the 30-day mortality rate was 1.2% after EVAR versus 4.6% 
after open repair, but overall survival rates were not different at 2 years.
306, 307  
Recent publications have pointed towards a role of EVAR in small AAAs. 
Retrospective evaluations of EVAR have revealed that the use of EVAR in smaller 
AAAs results in favourable outcome. A 923-patient analysis concluded that 
patients with AAAs <5.0 cm were more favourable candidates for EVAR and had 
the best long-term outcomes, with 99% freedom from AAA death at 5 years; 
patients with large AAAs (≥6.0 cm) had shorter life expectancy and higher risks 
of rupture, surgical conversion, and AAA-related death.
310 An analysis of 6-year 
data from 700 patients in the Cleveland Clinic EVAR database yielded similar 
findings.
311 The largest retrospective analysis of 4392 patients from the 
EUROSTAR registry found correlations between large AAAs and all assessed 
outcome events (perioperative morbidity, 30-day mortality, 4-year mortality, 
freedom from AAA rupture and freedom from AAA-related death) which were 
independent and highly significant.
312  
  
                   
231 
In response to the low operative mortality rates associated with EVAR and in 
response to these retrospective analyses of EVAR databases, 2 randomised 
controlled trials of EVAR for small AAAs have commenced: the Positive Impact of 
endoVascular Options for Treating Aneurysm earLy (PIVOTAL) and Comparison of 
surveillance vs Aortic Endografting for Small Aneurysm Repair (CAESAR). Both of 
these large studies, which randomise patients to EVAR or surveillance, are due 
to publish early results soon, although CAESAR has already missed its expected 
publication of early results, initially planned for 2009.  
With the results of the trials detailed above, it is more difficult to see in what 
way BNP, by identifying high risk patients not suitable for open repair, can help 
decision making in EVAR. Due to its durability, open repair should reasonably be 
proposed in younger patients at low risk, with large and possibly with small 
AAAs. In addition, numerous studies report comparable outcome following open 
repair in elderly patients when compared to younger patients.
313, 314 It is 
therefore reasonable to advocate open repair in the elderly with low 
perioperative risk, although many may prefer to negate the high perioperative 
risk of open repair and opt instead for EVAR, as has been demonstrated when 
studying patient preference.
315 Only in those at high risk, or with high serum 
BNP, does the decision become more difficult. With the poor prognosis 
associated with high levels of BNP 
316 it is not possible to recommend EVAR in all 
given the disappointing long-term results, and decisions would have to be made 
on a case by case basis. It is therefore likely that at present EVAR is best suited 
to young patients with large AAAs who have been deemed unfit, who have a 
shorter life-expectancy, but in whom surveillance alone would be unacceptable. 
Further larger studies accounting for the low number of cardiac events and all-
cause mortality are required. 
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8.1 Cardiac Risk in Vascular Surgery 
The principal aim of this research was to attempt to provide a way of improving 
risk assessment in patients undergoing aortic aneurysm repair. However, it has 
also raised some important points in relation to the vascular surgical population 
as a whole. 
The first is in relation to the ongoing high prevalence of cardiac morbidity in this 
group of patients in Glasgow. The results revealed a MACE rate of 14.6% and a 
cardiac death rate of 7.0%. This is certainly greater than many of the published 
reviews looking at cardiac risk in major vascular surgery.
3,24,64,79 Even when 
compared to those studies designed to screen for postoperative cardiac events 
the findings of this research remain concerning, with most other studies 
revealing a MACE rate of 6-8%.
111, 114 Only rarely have such high rates been 
reported, including the recently published study investigating preoperative BNP 
in Glasgow by Gibson et al, which revealed a MACE rate in vascular surgery of 
12.5-26.8%.
116 This is likely to be indicative of the general health and lifestyle of 
the local population whom we treat. This is demonstrated in that of the entire 
studied cohort, 40% have a history of IHD, and 20% DM. To further exacerbate 
the problem, only 28% appear to be on a regular statin, known to be beneficial 
not only in those with IHD but also in those with peripheral vascular disease as 
described in section 1.6.2.2.  
Secondly, the presence of a raised preoperative cTnI level is associated with 
poor outcome following a major vascular procedure. Whilst previous studies have 
described preoperative elevations in cTnI to be a rare event
265, 266, 317, this 
research has found it to occur in 5.2% of patients presenting for major vascular 
surgery. With the associated mortality rate of 50% in these patients, the findings 
again highlight that this is therefore a high risk population. On the basis of this, 
if indeed it was felt that management would be altered based on the result, 
there is evidence to suggest that preoperative cTnI should become a routine 
marker. When delay is possible it may be that either observation and rechecking 
cTnI, or alternatively cardiac optimisation, will alter outcome as seen in the 
patients whose surgery was delayed in chapter 3.   
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The numbers of patients is too small to make definite or practice-changing 
recommendations. Further research to investigate whether the presence of an 
elevated preoperative cTnI alone predicts death, and whether delay or 
optimisation can alter this, would require recruited numbers of over 2000 
patients. These requisite numbers are outwith those possible in the West of 
Scotland and possibly still outwith those of a national level study.  
8.2 Cardiac Risk in Elective Open AAA Repair 
The numerous reviews and publications of cardiac risk in major vascular surgery 
often include patients who undergo open AAA repair. It is less common that 
these patients are considered as a separate cohort, despite the very specific 
decision making that comes with this prophylactic operation and its associated 
risks.  
8.2.1 The Risk of Repair 
The rate of MACE in the open AAA repair cohort in this thesis was 15%. This is 
consistent with studies of aortic surgery that include routine regular 
postoperative cTnI measurements with ECG analysis and review of clinical 
progress
51, although similar event screening studies occasionally quote lower 
rates for AAA repair 
116, 318, whilst many do not specify for AAA repair alone. With 
cardiac death in 5 of 106 patients the mortality rate from a cardiac cause alone 
was 4.7%, whilst the all-cause mortality was 8.5%. Whilst this mortality rate 
appears high, reports throughout the literature vary greatly between 0-12%.
319 
Of the 11 non-fatal MIs, 3 suffered asymptomatic ST-elevation MIs (the ‗silent‘ 
MI), that would not have been picked up without postoperative cardiac 
screening. This equates to 27% of events and is consistent again with many 
previous studies that have screened for cardiac events.
26, 320 
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As established in this research, the most common cause of postoperative 
mortality is cardiac.
18, 286 Not only is cardiac disease a concern with regard to 
mortality in the short term, but both a history of a perioperative MI and elevated 
postoperative cTnI confer an increased risk of mortality in the intermediate and 
long-term.
140, 143 In this research the presence of postoperative MACE, without 
associated mortality, did confer a significantly increased risk of death at 1 year. 
There were also higher death rates at 2 and 3 years in those who had suffered 
MACE, although this was not significant. Similar findings were found with regard 
to postoperative elevations of cTnI and late mortality, although again this was 
not significant. 
8.2.2 BNP as a Predictor 
As anaesthetists have attempted to improve perioperative outcomes by focusing 
on the diagnosis, prevention and treatment of myocardial ischaemia in high risk 
surgical patients, BNP has become an increasingly recognised stratification tool 
in cardiac risk assessment. This marker has attracted the interest of surgeons, 
who have seen the advantages it offers in the decision-making process, balancing 
surgical risk and the need to operate. The interest in this marker has resulted in 
numerous publications, including most recently three meta-analyses.
321-323 These 
publications reviewed the evidence relating to the utility of preoperative BNP 
and NT-proBNP in predicting MACE. In addition, two of these looked at BNPs 
predictive capabilities with regard to short- and intermediate-term mortality.
321, 
322 It was found that both BNP and NT-proBNP predicted MACE, cardiac mortality 
and all-cause mortality. However, none of the papers published to date, or 
included in the meta-analyses, studied the elective open AAA repair population 
alone.   
8.2.2.1  Discriminatory BNP Levels 
The results of this research show that a single preoperative serum BNP level can 
predict MACE, cardiac death and all-cause mortality within 30 days of elective 
open AAA repair. The cut-off value on ROC curve analysis for predicting MACE 
was 99.5 pg/ml. This value is similar to the optimal cut-off in diagnosing heart 
failure in both chronic cardiac failure and those presenting with acute dyspnoea 
(>100 pg/ml).
101, 324 Further, a level of 99.5 pg/ml is greater than that associated  
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with the diagnosis of heart failure in the ambulatory patient, which on consensus 
of expert opinions and manufacturers is >70 pg/ml
 325, and is just above the cut-
off of the normal age-adjusted value for BNP in those aged >60 years of age at 
<98 pg/ml.
326  
Not only does a BNP level <100 pg/ml exclude the likelihood of acute heart 
failure, but levels >400 pg/ml confer a positive likelihood greater than 10 in 
diagnosing heart failure.
273, 327, 328 The cut-off in this research for cardiac death 
was 448 pg/ml with a PPV of 100%. This would suggest that, although there are 
many other possible reasons for an elevated BNP [Table 1.7], a degree of heart 
failure is most likely in these patients and confers a high perioperative risk. 
Of the studies performed to date there is no consensus of which BNP (or NT-
proBNP) level predicts MACE, with wildly divergent discriminatory thresholds 
[Table 1.8]. Variations in patient cohorts with respect to age, gender, co-
morbidity, BMI and degree of pre-existing cardiac failure may make attempts to 
find a single, universally applicable, BNP discrimination point futile. The optimal 
discrimination point would therefor likely be a factor of the prevalence of 
cardiac pathology in the population being examined. Groups with high numbers 
of patients with cardiac dysfunction would have high median BNP levels, which 
would result in higher discrimination points. Alternatively, it can be argued that 
a single BNP value is acceptable when using a standardised assay with 
international quality control, and that the proportion of patients with values 
above this threshold is a marker of that population‘s demographics and 
comorbidity, as is the degree of postoperative cardiac morbidity and mortality. 
In addition, the period of observation for each study influences any derived 
threshold, with the threshold decreasing as the event horizon is extended. 
Patients with high levels of BNP have events earlier in their observation periods 
resulting in higher thresholds. This is demonstrated when looking at the 
decreasing BNP thresholds over time for predicting death in the current thesis, 
where an initial threshold of 93 pg/ml for immediate mortality reduces to 60.5 
pg/ml at 3 years. 
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Other interesting findings in the published literature include the finding that a 
BNP level >40 pg/ml was associated with a five-fold increase in the risk of 
developing new ECG abnormalities or a raised postoperative cardiac troponin.
114 
Whilst in the present research BNP in relation to ECG changes was not 
investigated, postoperative elevations in cTnI were recorded. The median 
preoperative BNP was found to be significantly higher in those with 
postoperative elevations of cTnI (p=0.002), and ROC curve analysis revealed a 
cut-off of 54 pg/ml. This is of interest in relation to the increased intermediate 
and long term mortality associated with these elevations. Although this 
association appeared to be present on long-term analysis in the studied cohort 
(section 5.3.3), this was not statistically significant. 
 
To establish whether there is a single threshold or a few important BNP 
thresholds, a substudy of the 40,000 patient international Vascular events In 
noncardiac Surgery patIents cOhort evaluatioN (VISION) study is underway.
329 
This will evaluate whether NT-proBNP is an independent predictor of MACE or 
other major complications in the first 30 days after vascular surgery, and will 
determine if there is one or multiple NT-proBNP thresholds that substantially 
influence risk prediction.  
8.2.2.2  BNP or NT-proBNP? 
In this research BNP was used for all analyses, however, whether BNP or NT-
proBNP is preferable for vascular surgical patients remains unclear. While the 
reliability of NT-proBNP may be limited by renal dysfunction
86, 88, there is some 
evidence to suggest that NT-proBNP may be a slightly better predictor of 
outcomes in medical patients with congestive cardiac failure and ischaemic 
heart disease.
101, 330 It is possible that the longer half-life of NT-pro BNP may 
result in it being less affected by perioperative haemodynamic shifts, than BNP. 
However there are no known studies that examine this phenomenon, and 
further, recent meta-analyses have shown that both BNP and NT-proBNP are 
good independent predictors of postoperative cardiac events. In addition, the 
way in which the blood samples were collected prior to analysis in this research 
was in a manner that would minimise haemodynamic stress, and samples were 
immediately centrifuged and frozen prior to later batch analysis.  
                   
238 
8.2.3 Risk Scoring in Elective Open AAA Repair 
The present thesis studies the value of the five most recognised and validated 
risk scores in open AAA repair, specifically for use in the preoperative period. 
The results show that most do not perform well in the currently studied cohort. 
The finding that the RCRI performed poorly to the extent that it showed no 
predictive capabilities is an unexpected finding. The reasons for this have been 
explored in section 6.1, and include lack of sub-grouping for differing types of 
high risk surgery, and lack of predictive capabilities when applied to highest risk 
populations (such as open AAA repair). Of greater concern is the fact that, as 
one of the simplest forms of risk score, this is possibly the most often used in the 
clinical environment. Based on the results of this thesis it would be advisable not 
to base clinical decision-making in aneurysm surgery on RCRI scoring. 
The GAS displayed similarly poor predictive capabilities despite numerous 
validation studies. Despite the fact that GAS was devised as a means of 
predicting all-cause mortality after AAA surgery, what difference it did 
demonstrate did not reach statistical significance. As RCRI and GAS were 
relatively simple scores to calculate, the finding that they lack predictive power 
is disappointing for clinical practice. Furthermore, although VBHOM is more 
complex to calculate, it remained relatively easy to use given the objective data 
entry required. However, again, this score did not show statistically significant 
predictive capabilities for any of the outcome measures. Only the most complex 
scores, E-PASS and V(p)-POSSUM, showed significant prognostic ability for all 
outcome measures.  
Both V(p)-POSSUM and PRS showed significant predictive capabilities with regard 
to all outcome measures. However, both V(p)-POSSUM and PRS contain a number 
of subjective elements making them vulnerable to miscalculation, and although 
on p-value alone these scores occasionally performed better than BNP, ROC 
analysis demonstrated that preoperative BNP had an associated PPV of 100% 
(NPV 99%) for cardiac death, and a NPV of 99% (PPV 30%) for all-cause mortality. 
In both cases therefore, these clinically relevant values outperform all risk 
scores.  
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A risk score that determines an individual patient‘s predicted risk in a specific 
hospital, that was validated in different geographical areas and that was based 
on routinely obtained objective measurements, would be of value in guiding 
surgical management of those with an expanding AAA that may require 
intervention. At present such a scoring system does not exist. Based on the 
superior predictive capabilities of BNP, and its ease of measurement, it is 
difficult to justify the routine use of any of the scoring systems listed for risk 
assessment in AAA surgery.  
8.2.4 Long-term Outcome and the Small AAA 
The results of this research show that BNP has predictive capabilities for 
intermediate and long-term mortality. This is consistent with published 
research
118, 122, and demonstrates, bearing in mind both the present and the 
published research, that BNP can predict mortality outcomes as well as cardiac 
outcomes. The value of BNP in the decision regarding the small AAA is therefore 
noteworthy in two aspects.  
The first is as a simple predictor of mortality. The ability to identify those 
patients who will survive not only the perioperative period but long-term to at 
least 3 years, makes BNP unique. Whilst some markers perform well in one of 
these outcome measures, few perform well in both. Non-invasive cardiac testing 
predicts in the immediate postoperative period, but has not been shown to be 
effective in predicting long-term outcome. Of the available scoring systems only 
GAS has been shown to potentially predict long-term outcome.
156, 160, 301 
However, as discussed above, it appears to perform poorly in the very cohort for 
which it was devised. 
Secondly, BNP has the ability to predict both immediate postoperative MACE and 
postoperative elevations of cTnI. As discussed, both non-fatal MI and 
postoperative elevations of cTnI are associated with increased intermediate and 
long-term mortality.  
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Although BNP has superior predictive capabilities in the long term, the actual 
serum level at which a decision could be made to proceed with surgery with a 
small AAA is uncertain. Whilst a threshold of 99.5 pg/ml allows the selection of a 
greater proportion of patients who are unlikely to survive the long-term 
postoperative period, a level of 60.5 pg/ml predicts a greater proportion of 
patients that will survive to 3 years. It may therefore be that a lower BNP level 
should be considered as a threshold if choosing to use BNP in the decision 
making process regarding surgical repair of small aneurysms. 
 
8.2.5 BNP and EVAR 
In this research BNP does not aid clinical decision making in endovascular 
aneurysm repair. This may be due to the low numbers recruited, and larger 
studies of BNP in EVAR may clarify this further. It seems more likely, however, 
that BNP will be of limited use in this setting due to the fact that MACE is not a 
common cause of perioperative death following EVAR.
22 Further, although BNP 
can predict intermediate and long-term mortality in open AAA, much of this 
ability is related to its capacity to predict outcome in the perioperative period.  
The importance of BNP in EVAR is therefore not yet defined. As described in 
section 7.4, although EVAR remains a preference for some, its place in AAA 
repair is currently limited. Its use in those deemed unfit (by BNP or other means) 
for open repair is not all-encompassing due to the poor long-term results of the 
EVAR trials. It may be that EVAR will be a therapeutic option for the small AAA, 
and may even be preferable to open repair if durability is proven; however 
currently no recommendations can be made to this effect.  
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8.2.6 Other Predictors of Outcome 
With regard to perioperative MACE in open AAA repair, only CCF was found to be 
a predictor of outcome (p=0.026) on univariate analysis. With BNP, a marker of 
heart failure, and CCF predicting MACE, there is clear support for the historic 
findings of Goldman that preoperative ventricular dysfunction is a strong risk 
factor for perioperative cardiac morbidity and mortality.
108 Not only was CCF 
implicated in MACE, but it was found to be a risk factor in perioperative all-
cause mortality (p=0.002) and 3-year mortality (p<0.001). Despite this 
knowledge, the results of the data collection for this thesis identified that only 
75 of the 106 patients had undergone a preoperative echocardiogram. This 
highlights the importance of diagnosing and recording the presence of heart 
failure prior to making any decision regarding operative intervention. 
The only other factor that was found to correlate with MACE was the operative 
time. Although on univariate analysis this was not significant (p=0.098), on 
multivariate analysis, it was found to correlate (p=0.0065) with MACE, along with 
CCF (p=0.033) and elogBNP (p<0.001). Although this is unlikely to alter 
preoperative decision making, this raises the importance of minimising operative 
time, whilst taking into consideration any anatomical and previous surgical 
factors that might complicate and lengthen an already complicated operative 
procedure. 
With regard to perioperative, intermediate and late mortality, renal dysfunction 
was the only significant risk factor other than CCF with regard to open AAA 
repair. Both worsening stages of CKD (p=0.010) and eGFR (p=0.027) correlated 
with perioperative mortality, whilst only CKD stage (p=0.031) correlated with 3-
year mortality. Renal function is a factor that has been considered for many 
years to impart an increased operative risk when considering postoperative 
complications and death, and is an element in all of the scoring systems that 
were investigated in this thesis. Indeed, further subgroup analysis based on a 
BNP threshold of 99.5 pg/ml, as seen in table 4.6, selects out a group based on 
an eGFR ≥60 ml/min who are likely to do well. In addition there were no deaths 
over 3 years in those classified as CKD stage 1. Accurate diagnosis and equally 
accurate documentation is once again advocated based on these findings.  
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8.3 Changes to Clinical Practice 
Were the findings of this thesis to be taken at face value, they would promote 
the routine use of preoperative BNP to guide decision-making in the treatment 
of patients with an AAA. This is, however, in contradiction to the 
recommendations of a review article by Rodseth.
107 This review reports on the 
finding of a community-based study, in which when BNP is used to identify 
patients with subclinical cardiac failure, with ejection fractions 50% or mild 
diastolic dysfunction, BNP resulted in an area under the curve <0.70, which is 
insufficient to be considered as a screening test.
331 The implication was 
therefore that BNP would not be useful, or cost effective, in every patient. 
Rodseth suggested the use of clinical risk factors to identify higher risk patients, 
and promoted the AHA/ACC guidelines as a structure around which to guide the 
use of BNP.
107 It has therefore been suggested that BNP should only be measured 
and used as a non-invasive risk stratification tool in patients undergoing major or 
intermediate risk surgery, who can not function at ≥4 METS without symptoms. 
The counter-argument would be that elective open AAA surgery is always classed 
as major surgery, and, that the assessment of metabolic equivalents is a 
subjective matter. In deciding on whether to proceed with a prophylactic 
operation, one would desire all available information before making the 
appropriate decision. 
If BNP is routinely measured, it should be possible to identify patients who are 
suitable for repair of their AAA (and possibly their small AAA) based on a BNP 
level <99.5 pg/ml. A preoperative CRP <6 mg/dl and an eGFR ≥60 ml/min would 
strengthen the case. It would also identify those with very high BNP levels (>448 
pg/ml) that should not undergo operative repair. However, there is no published 
evidence that has investigated what to do in the presence of an elevated BNP 
level that does not immediately negate a surgical option (>99.5 pg/ml). Whilst 
evidence exists with regard to BNP modification in the non-surgical population, 
none exists in the preoperative surgical population.
105, 279 There is also a lack of 
evidence on whether further cardiac testing would be of benefit in reducing risk. 
This and some other untouched areas for research will be discussed more in 
section 8.5.  
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8.4 Study Limitations 
The main findings of this thesis, as detailed in chapters 4 and 5, present an 
adequately powered study with considerable heterogeneity in regard to patient 
characteristics. There were however limitations. Although adequately powered 
to investigate the value of BNP in predicting MACE in the elective open AAA 
repair population, the sample size remained relatively low, precluding adequate 
multivariate analysis. In addition, not all patients had a preoperative 
echocardiogram performed. This made comparisons with what would be 
considered the most accessible non-invasive cardiac investigation difficult.  
In long-term analysis, five patients were lost prior to the full 3 year follow-up. 
Although this could alter the findings of long-term outcome analysis, when 
correcting for these patients on Kaplan-Meier analysis, meaningful results were 
returned.  
The greatest limitation of the thesis was the small sample size studied in the 
EVAR cohort. This combined with the low incidence of perioperative death and 
MACE, greatly limits the power of this area of research.  
In general many potential limitations were accounted for. Defined endpoints 
were used and a power calculation performed prior to commencing study. BNP 
analysis was explored for confounding variables, such as renal failure and BMI, 
and these were found not to be significant. Rigorous postoperative testing was 
performed, in order not to miss potential sub-clinical cardiac events, and all 
deaths were investigated to identify the cause. All patients had adequate data 
collection to allow complete risk scoring, and data were analysed using uniform 
statistical analyses throughout, whilst a number of BNP thresholds were chosen 
to account for the event time horizon. 
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8.5 Areas for Further Research 
A large observational cohort study of preoperative BNP would allow validation of 
the many studies of preoperative BNP that have been described, as in the 
already commenced VISION study. This and other large prospective studies would 
potentially benefit from the use of a Net Reclassification Index statistic to assess 
the added value of BNP over current used preoperative measures of risk. 
Further, there is as yet no research that has randomised treatment based on a 
patients‘ BNP level. Research comparing; surgery vs non-operative management, 
surgery vs best medical therapy, and surgery vs optimisation followed by later 
surgery, are all potential areas of interest. It is also unknown whether 
management aimed at lowering a patients‘ serum BNP would impart a reduced 
risk for delayed surgery with a now reduced serum level, and indeed what that 
lower level of BNP should be.  
Another area of uncertainty is the optimal time for preoperative BNP testing. In 
the majority of published studies, BNP samples were taken the evening prior to 
surgery. In this study this was the case for logistic reasons alone. Only 2 
published studies took samples >3 weeks prior to surgical intervention.
112,120 
Revised ACC/AHA guidelines advise preoperative BNP testing some 4-5 weeks 
prior to elective surgery to allow initiation and benefit of medical therapy, 
should this be the chosen intervention.
69 However it has been agreed that this is 
speculative, and needs evaluated in well-designed trials.  
Finally, a significant rise in postoperative NT-proBNP has been identified in 
patients who suffered a cardiac event compared to those that did not (609 vs 
183 pg/ml; p<0.001).
122 This has raised the possibility that postoperative BNP 
may identify patients who are unable to cope with the myocardial strain 
imposed on them and are undergoing a degree of myocardial decompensation. 
This holds the promise of postoperative secondary risk stratification, similar to 
that seen in postoperative elevation of cTnI. It may therefore be of interest to 
study postoperative discrimination levels of BNP that require altered 
postoperative management, and to determine what management options these 
may be. 
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8.6 Conclusion 
The ability to accurately predict cardiovascular morbidity and mortality in 
patients undergoing elective open AAA repair remains an elusive goal. Whilst 
preoperative cTnI may have a role in high risk patients undergoing major 
vascular surgery (when it might change management), its use in AAA repair is 
limited by its infrequent incidence. The prognostic performance of preoperative 
BNP, however, is at least equivalent to, if not better than, most traditional 
preoperative tests, including the varied risk scores. Its ability to predict in both 
the perioperative, intermediate and long-term periods make it a unique test. In 
addition, its ability to predict all-cause mortality over the same time periods 
makes it a potentially useful risk stratifier when considering the small AAA.  
When considering EVAR, BNP seems to have no clear role. It is of use in selecting 
patients that would be better considered for EVAR rather than open surgery, but 
does not appear to predict outcome within this group. When EVAR is not 
considered an appropriate option, there is some uncertainty as to what is the 
acceptable next step in those deemed high risk. Immediate and obvious choices 
include further noninvasive cardiac investigation followed by best medical 
therapy, or coronary revascularisation. Exactly what medical therapy, or 
coronary revascularisation technique is chosen, remains controversial. It also 
remains unknown how to monitor therapy prior to a decision to reconsider 
surgery. Other possibilities include change in anaesthetic technique, use of 
epidural anaesthesia, intensified intra and postoperative monitoring, and a 
longer stay in ICU.  
Regardless of the above uncertainties, BNP offers a test that gives an immediate 
result and that helps in the decision making process for a prophylactic 
operation. The test gives prognostic information that is superior to any current 
non-invasive cardiac investigation, or currently considered risk index, and on 
that basis should be considered a routine part of the work up in any patient 
being considered for open repair of their AAA.     
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Appendix 1: Information sheet/consent form for cTnI study 
 
THIS SHEET HAS BEEN APPROVED BY THE WEST ETHICS COMMITTEE 
INFORMATION SHEET FOR PATIENTS/VOLUNTEERS IN CLINICAL 
RESEARCH PROJECT 
 
Brief Title of Project 
Can B-type natriuretic peptide measurement aid risk assessment in 
general/vascular surgical patients? 
 
PARTICIPANT INFORMATION SHEET 
We invite you to take part in a research project. 
 
BACKGROUND 
Surgery is associated with a risk of problems that may arise during or after the 
procedure. Normally, a patient will be assessed for their risk of developing a 
problem, such as a heart attack or stroke. This assessment may include clinical 
examination a chest x-ray, and sometimes, an ultrasound scan of the heart. 
Despite these measures, heart attacks and strokes still occur. B-type natriuretic 
peptide, or BNP, is a chemical produced by the heart. The amount of BNP in the 
blood is increased in patients with a heart problem. We are interested to know 
whether a BNP blood test could help identify patients who are at risk of having a 
heart problem around the time of vascular and general surgery. 
 
WHAT WILL HAPPEN TO YOU? 
If you decide to go ahead, your participation will involve one extra blood test at the 
time of your admission for surgery. The blood sample will be taken from a forearm 
vein and will be 30mls in volume (i.e. three tablespoons). This blood sample will be 
tested for BNP, for troponin and CRP, which are chemicals produced in the body 
when the heart is under strain. This blood test will be repeated at 48 hours (on the 
ward), before discharge and at the outpatient clinic after your operation. 
 
CAN YOU CHANGE YOUR MIND? WHAT WILL HAPPEN IF YOU SAY NO? 
Participation in this study may not be of direct benefit to you but information from 
this study could help in the development of treatment for patients in the future. You 
should not take part if you are pregnant, or could become pregnant. If you wish to 
take part in the study, your General Practitioner will be advised of your 
participation and the clinical management that you will undergo. Participation in 
this study would be strictly confidential. If the results show new and important 
findings the results may be published in a scientific journal in order that other 
doctors may learn of this new information. The results would be published in a way 
that you cannot be identified. No payment will be made for your participation in this 
project. You may not wish to participate in this study, or may wish to withdraw at 
any time after commencing the trial. In this circumstance your care will in no way 
be affected. Should you come to any harm as a result of taking part in this study 
you may be entitled to compensation. Taking part in this study will not affect your 
ability to drive. 
 
DO YOU HAVE TO DECIDE AT ONCE? 
Please feel free to discuss this with your relatives and then let us know your 
decision either way. If you have any questions about the study at any time please 
telephone Dr SC Gibson at 0141 211 3000 (during or out with working hours). 
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WEST ETHICS COMMITTEE 
FORM OF CONSENT FOR PATIENTS/VOLUNTEERS IN CLINICAL 
RESEARCH PROJECT 
 
Title of Project 
Can B-type natriuretic peptide measurement aid risk assessment in surgical 
patients? By signing this form you give consent to your participation in the project 
whose title is at the top of this page. You should have been given a complete 
explanation of the project to your satisfaction and been given the opportunity to 
ask questions. You should have been given a copy of the patient information sheet 
approved by the West Ethics Committee to read and to keep. Even though you 
have agreed to take part in the research procedures you may withdraw this 
consent at any time without the need to explain why and without prejudice to your 
care. 
 
 
 
Consent: 
 
I,……………………………………………………………………………. (PRINT) 
 
 
 
of…………………………………………………………………………… 
 
give my consent to the research project above, the nature, purpose and 
possible consequences of which have been described to me 
 
 
 
by…………………………………………………………………………. 
 
 
 
Patient’s signature……………………………………………………  
 
 
 
Date …………………………………. 
 
 
 
Doctor’s signature…………………………………………………….... 
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Appendix 2: Information sheet/consent form for BNP AAA study 
 
Patient  Information  Sheet:  The  Role  Of  BNP  In  Cardiac  Risk 
Stratification In Patients Undergoing Aortic Aneurysm Repair 
 
We invite you to take part in a research project:  
 
Background 
All major surgery has a risk of problems with the heart that may arise during or 
after surgery. All patients going to get an operation have the risk of surgery 
estimated using clinical examination, a heart tracing, chest X ray, and 
sometimes, an ultrasound scan of the heart. Despite these measures, heart 
attacks still occur. Brain natriuretic peptide, or BNP, is a chemical produced by 
the heart. The amount of BNP in the blood is increased in patients with a heart 
problem. We are interested to know whether a BNP blood test could help 
identify patients who are at risk of having a heart problem around the time of 
surgery, or who may have heart problems in the next few years. You have been 
asked to be part of this study because you are going to undergo surgery. 
 
What Will Happen To You? 
If you decide to go ahead, your participation will involve one extra blood test 
before surgery. The blood sample will be taken from a forearm vein and will be 
30ml in volume (i.e. three tablespoons). You may experience some discomfort 
and have a bruise as a result of this blood test. This blood sample will be tested 
for BNP and troponin levels, chemicals produced in the body when the heart is 
under strain. This blood test will be repeated at 48 hours (on the ward), and at 
discharge.  An  ECG  (heart  tracing)  will  be  performed  before  and  after  the 
operation. We will also be asking your GP how you are getting on for three years 
after your operation. 
 
Can You Change Your Mind? What Will Happen If You Say No? 
Participation in this study may not be of direct benefit to you but information 
from this study could help in the development of treatment for patients in the 
future. Participation in this study would be strictly confidential. If the results 
show new  and important  findings the  results may be published in a  scientific 
journal in order that other doctors may learn of this new information. The results 
would be published in a way that you cannot be identified. No payment will be 
made for your participation in this project. You may withdraw from the project 
at any point without needing to give a reason. If you do not wish to participate in 
this study, or wish to withdraw at any time, your care will in no way be affected. 
Should you come to any harm as a result of taking part in this study you may be 
entitled to compensation. Taking part in this study will not affect your ability to 
drive. 
 
Do You Have To Decide At Once? 
Please feel free to discuss this with your relatives and then let us know your 
decision  either  way.  If  you  have  any  questions  about  the  study  at  any  time 
please telephone Dr G Bryce at 0141 211 2000 page 4045 or 07973 48 22 06. 
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WEST ETHICS COMMITTEE 
 
CONSENT FOR PATIENTS IN CLINICAL RESEARCH PROJECT 
 
 
―The Role Of BNP In Cardiac Risk Stratification In Patients 
Undergoing Aortic Aneurysm Repair?‖ 
 
 
  By signing this form you give consent to your participation in the project 
whose title is at the top of this page. You should have been given a complete 
explanation of the project to your satisfaction and have been given the 
opportunity to ask questions. You should have been given a copy of the patient 
information sheet approved by the West Ethics Committee to read and to keep. 
Even though you have agreed to take part in the research procedures you may 
withdraw this consent at any time without the need to explain why and without 
any prejudice to your care. 
 
 
 
 
Consent: 
 
 
I,…………………………………………………………………………(Print Name) 
 
 
 
of………………………………………………………………………...(Address) 
 
 
give my consent to the research procedures above, the nature, the purpose and 
possible consequences of which have been described to me 
 
 
 
by………………………………………………………………………(Print Dr Name) 
 
 
 
Patient‘s signature………………………………………… Date……………………… 
 
 
 
Doctor’s Signature…………………………………………Date……………………… 
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Appendix 3: Data Sheet 
 
 
B.N.P. Study 
 
  Name 
  Hospital Number 
  Date of Birth 
  Phone no. 
 
Diagnosis- 
Operation- 
Operation date - 
 
Consultant- 
 
Male                          Female 
 
Smoker                       Yes     per day        No, never       Stopped        ago 
 
Diabetic                     Yes                              No 
Previous MI                 Yes                              No 
Hypertensive              Yes                              No 
 
Hyperlipidaemia        Yes                             No 
 
Angina                        Canadian classification   0           1           2        3          4  
      
Heart failure               NYHA                             0           1           2        3          4                                                                     
                                   
 LVH:                         none              
                                  diuretic/digoxin/Rx for angina/hypertension 
                                   periph. Oedema/warfarin/b-line cardiomyopathy 
                                   raised JVP/cardiomegaly 
                  
COPD:                         mild disease          
                                    dypsnoea on exertion 
                                    moderate, limiting dypsnoea 
                                    dypsnoea at rest, pulm. fibrosis 
                                                                                   
                                   
Renal disease:               Yes                              No 
 
Cerebrovascular:         CVA              TIA                    None 
 
 
     Relevant medications: 
 
 
 
 
Pulse                                         Blood pressure                                          GCS      
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Specialised investigation:                                           Result 
 
Echo 
 
Exercise testing 
 
Stress thallium 
 
Pulmonary function tests 
 
Coronary angiography 
 
 
 
Bloods:                       Taken                             Result 
 
CRP 
 
Hb 
WCC 
Platelets 
 
PT 
PTT 
pFib 
 
Na 
K 
Urea 
Creatinine 
 
Cr Clearance 
 
Lipids -    cholesterol                                           LDL 
                 Triglycerides                                       HDL 
                         
 
Magnesium 
 
Troponin 
 
 
ECG                   done                                         normal                           
abnormal 
 
Sats on air 
 
Weight  -         Height - 
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Intraoperatively: 
Operation type - 
CEPOD - 
No. of procedures - 
 
Blood loss - 
Peritoneal contamination  - 
 
Hypothermia ( 34.5 degrees) - 
 
Hypotension - 
 
Beta blockers - 
 
X-clamp time -                                        supra-renal X-clamp - 
 
Length of procedure 
 
ABGs -  pO2 
    pCO2 
    H
+ 
    BE 
    Lact. 
 
Post operatively: 
 
ITU                             days 
HDU                           days 
Ward                           days 
 
 
P-POSSUM 
 
Physiology score 
 
Operative severity score 
 
Morbidity 
 
Mortality 
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At 48 hours: 
 
Bloods              Taken                          Result 
 
Urea 
Creatinine 
 
Troponin 
 
CRP 
 
 
ECG              done                                normal                       abnormal          
 
5 days: 
 
Urea 
Creatinine 
 
Troponin 
ECG 
 
 
Complications 
 
 
 
 
After 6 weeks: 
 
Bloods                  Taken                             Result 
 
Urea 
Creatinine 
 
Troponin 
 
CRP 
 
 
ECG             done                                 normal                        abnormal 
 
Complications in interim: 
 
 
Respiratory status                                                                       
 
 
 
New meds 
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